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Abstract 
Introduction: The basal ganglia are components of neuronal circuits responsible for 
important functions, such as learning, memory, motor control and motivation. Disturbances 
of these functions are symptoms of neuropsychological diseases, including the Parkinson’s 
disease, attention deficit hyperactivity disorder, depression and addiction. Since a changed 
neuronal activity in the involved pathways has been observed in all these diseases, it is 
important to develop a sensitive tool for functional studies of the neuronal tracts in vivo. 
The present work proposes 52Mn for tracing neuronal pathways of the rat brain in an 
activity-dependent manner with positron emission tomography (PET). Several crucial 
aspects of this application, including the dosage, image quality and quantification, as well as 
pharmacological properties of the tracer, have been carefully evaluated. 
Methods: Firstly, the relationship between the dose of non-radioactive Mn2+ injected into 
the ventral tegmental area (VTA), the signal enhancement it provides in magnetic 
resonance (MR) images and the dopaminergic toxicity, was assessed. Secondly, a 52Mn 
phantom study was conducted to evaluate the quality of the obtained PET images.  
Next, a behavioral test and immunohistochemical staining techniques were used to evaluate 
the potentially harmful impact of the radioactivity doses in the range from 20 to 170 kBq on 
motor control system, dopaminergic neurons and the DNA damage. Having defined the non-
toxic dose, [11C]methylphenidate and [11C]flumazenil PET measurements were performed 
to assess the effect of a single intracerebral injection of Mn2+ and 52Mn on the dopaminergic 
and GABAergic systems, respectively. Finally, the activity-dependence of the 52Mn neuronal 
transport was studied with pharmacological agents which modulate the neuronal activity.  
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Additionally, an experimental setup for PET with an online measurement of the 
radioactivity blood level with a blood sampler (BS) was established. It was subsequently 
used to investigate the impact of different techniques of obtaining the arterial input 
function (AIF) on the kinetic parameters (KPs) of [18F]fluorodeoxyglucose ([18F]FDG). The 
KPs estimated using the AIF derived from the manually collected and dispersion-corrected 
blood samples served as the reference approach. 
Results: 45 nmol of Mn2+ provided a visible, although not statistically significant, change in 
the T1 maps 24 h after administration. However, it also caused a dopaminergic lesion at the 
injection site. The 0.5 nmol dose did not lead to the toxic effect, but it was not sufficient for 
MR imaging. Furthermore, 50 nmol of Mn2+ significantly reduced binding potential of 
[11C]flumazenil in the frontal cortex ipsilateral to the injected striatum at 2 days, but not at 
4 weeks post-injection. There was no impact of the metal on the binding potential of 
[11C]methylphenidate. 
24 h after the injection of 170 kBq of 52Mn into the VTA, the tracer was clearly visible along 
the mesolimbic and mesostriatal pathways in the PET images. The quantitative analysis 
confirmed its accumulation also in other expected brain areas. However, the dose led to an 
impaired rotation behavior and a dopaminergic lesion 4 weeks post-injection. These side 
effects were avoided by reducing the dose to 20 kBq. Moreover, 150 kBq of 52Mn, but not 
the 30 kBq dose, induced a substantial DNA damage. 
The neuronal transport of 52Mn was not affected by any of the tested pharmacological 
agents, except for the non-radioactive Mn2+ which substantially reduced 52Mn concentration 
in the analyzed brain regions. However, different transport rates and distribution patterns 
of the tracer were observed depending on the injected subnucleus of the VTA. 
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In the BS study, the sensitivity of the device was 23 %. Using a non-corrected image-derived 
AIF resulted in large differences of the KPs from the reference values. The deviations of the 
KPs estimated with the BS-based approach were 3-5 % if 10 min of the BS recording was 
combined with one manually collected blood sample to obtain the AIF. However, using the 
୮୪ୟୱ୫ୟ
୵୦୭୪ୣ ୠ୪୭୭ୢ
 activity ratio led to an 8 % overestimation of the k3. 
Conclusions: Imaging neuronal tracts of the rat brain with 52Mn PET is possible. In order to 
avoid harmful effects of the applied radioactivity, doses in the range of 20-30 kBq should be 
used. The activity-dependence of the 52Mn neuronal transport could not be confirmed and 
should be farther investigated. 
The online recording of the radioactivity level with the BS assures an accurate 
measurement of the peak activity after a bolus injection and prevents a blood loss. The 
obtained AIF allows reliable kinetic modeling if one manual blood sample is included. 
However, the differences in the estimated KPs lower than 10 % should be interpreted 
carefully provided the ୮୪ୟୱ୫ୟ
୵୦୭୪ୣ ୠ୪୭୭ୢ
 ratio was used. 
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Nomenclature and Acronyms 
Manganese occurs in the form of several isotopes and different ions. In the present work 
the following symbols are used to distinguish them: 
Mn – refers to the metal in general, without specifying the isotope and the ionic form, 
Mn2+ – refers to the divalent ion of the stable manganese isotope, 55Mn, 
Mn3+ – refers to the trivalent ion of the stable manganese isotope, 55Mn, 
52Mn – refers to the divalent ion of the radioactive manganese isotope, 52Mn. The most 
proper acronym would be 52Mn2+. However, for the sake of simplicity, 52Mn is used. 
Additionally, if any other symbol of an element is used (e.g. Na, Ca, Cr) without specifying 
the oxidation state, it simply denotes the name of the element.
AIF arterial input function 
AMG amygdala 
APD avalanche photodiode 
BOLD blood oxygenation level 
dependent 
BS blood sampler 
bw body weight 
CER cerebellum 
CLi caudal linear nucleus 
DA dopamine 
FDG fluorodeoxyglucose 
fMRI functional magnetic resonance 
imaging 
GABA γ-aminobutyric acid 
GP globus pallidus 
γH2AX γ-phosphorylated 2AX histone 
protein 
HIPP hippocampus 
IF interfascicular nucleus 
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i.p. intraperitoneal 
IPN interpeduncular nucleus 
i.v. intravenously 
MEMRI manganese-enhanced 
magnetic resonance imaging 
Mn manganese (regardless of its 
molecular form) 
Mn2+ divalent manganese ion of the 
non-radioactive isotope (55Mn) 
52Mn divalent ion of the radioactive 
manganese isotope (52Mn) 
MRI magnetic resonance imaging 
MS manual sampling 
NAc nucleus accumbens 
OB olfactory bulb 
OT olfactory tubercle 
PBP parabrachial nucleus  
PET positron emission tomography 
PD Parkinson’s disease 
PFC prefrontal cortex 
PIF paraintrafascicular nucleus 
PMT photomultiplier tube 
 
PN paranigral nucleus 
RLi rostral linear nucleus 
RN red nucleus 
RRF retrorubral field 
s.c. subcutaneously 
SNC substantia nigra pars compacta 
STR striatum 
TH tyrosine hydroxylase 
THL thalamus 
tVTA tail of the VTA 
VP ventral pallidum 
VTA ventral tegmental area 
VTAR rostral part of the VTA 
VTGX ventral tegmental decussation 
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1 Ventral Tegmental Area 
1.1 Anatomy 
The ventral tegmental area (VTA) is a symmetric brain structure located at the base of the 
midbrain and extending in the rostral-caudal direction from -4.68 mm to -6.84 mm from the 
bregma [16]. Although there is no common agreement on the subdivision of the VTA, 
several nuclei are usually assigned to compose the region. These include: parabrachial 
pigmented nucleus (PBP), paranigral nucleus (PN), rostral and caudal linear nuclei (RLi and 
CLi, respectively) and interfascicular nucleus (IF). In more recent publications the tail of the 
VTA (tVTA) is also included (Figure 1.1) [15, 17].  
This division is slightly different in the Paxinos Atlas, the most commonly used anatomical 
template of the rat brain. Firstly, the tVTA is not distinguished. Secondly, an additional 
small group of cells, the paraintrafascicular nucleus (PIF), is identified bilaterally to the IF, 
ventromedially to the PBP, and dorsally to the PN. Moreover, the very anterior part of the 
PBP is distinguished as the rostral part of the VTA (VTAR). Finally, the IF and the R/CLi are 
not directly adjacent to each other, but the area between them is referred to as the VTA 
decussation (VTGX) [16]. In order to be able to use the Paxinos Atlas for the data analysis 
and to reference to other works, which often utilized this template, the Paxinos 
nomenclature is used throughout this work, with an exception for the tVTA which will be 
sporadically mentioned in this chapter. 
Together with the neighboring substantia nigra pars compacta (SNC) and the retrorubral 
field (RRF), the VTA is considered the source of the dopaminergic cells in the brain. These 
26 |  
 
Figure 1.1. Location and subdivision 
of the VTA in the rat brain 
The VTA is located at the ventral surface 
of the midbrain. The nuclei that compose 
the VTA include: PBP, PN and tVTA. The 
IF, RCi and CLi are usually also assigned 
as parts of the region. Abbreviations: 
aopt – accessory optic tract, cp – cerebral 
peduncle, fr – fasiculus retroflexus, IP – 
interpeduncular nucleus, ml – medial 
leminiscus, MM – medial mammillary 
nucleus, mp – mammillary peduncle, pn 
– pontine nuclei,  RN – red nucleus, RRF – 
retrorubral field, SNR/SNC/SNL – 
substantia nigra reticulata/ compacta/ 
lateral, tth – trigeminothalamic tract. The 
numbers in the upper right corners 
indicate the distance from the bregma. 
Adapted from [13]. 
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nuclei are often referred to as the A10, A8, and A9 cell groups, respectively [18], and they 
are three out of seventeen dopaminergic cell groups identified in the brain [9]. The nine 
major ones are depicted in Figure 1.2. 
 
 
 
 
 
 
 
 
1.2 Diversity of cell types 
The dopaminergic cells are not the only type of neurons present in the VTA. In fact, they 
comprise only approximately 65 % of the VTA neurons. The remaining portion is composed 
of cells releasing γ-aminobutyric acid (GABA) (~ 30 %) and glutamate (~ 5 %). It is said 
that the dopaminergic neurons are most densely present in the PN and PBP, the GABAergic 
cells in the rostral cluster and in the tVTA, while the glutamatergic neurons in the 
rostromedial part [17]. However, it is important to notice that the classification of the VTA 
neurons based on the neurotransmitter they release might be a simplification. 
Figure 1.2. Dopaminergic nuclei in the rat brain 
Nine out of seventeen identified groups of dopaminergic cells are shown. They are mostly 
located in the midbrain. The A8, A9, and A10 groups are situated within the RRF, SNC, and 
VTA, respectively. The main projection pathways are also schematically depicted. The 
mesocorticolimbic and the mesostriatal pathways target forebrain areas, but the rubrospinal 
tract, which is more prominent in rodents than in primates, projects in the caudal direction. 
Adapted from [9]. 
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In fact, it has been recognized that some dopaminergic VTA neurons co-release glutamate 
[19, 20] or GABA [21, 22], and that the latter one can be also co-released by some 
glutamatergic VTA cells [23]. Interestingly, although it had been initially proposed that the 
co-release of dopamine (DA) and glutamate occurred from the same synaptic vesicles [24], 
more recent findings indicate that the two neurotransmitters are actually stored in separate 
vesicle pools within an axon, at least in the rat nucleus accumbens (NAc) [25]. In contrast,  a 
vesicular coexistence of DA and GABA has been shown [26]. 
Additionally to the three main neurotransmitters, different VTA neurons also express a 
diverse peptides and proteins, such as cholecystokinin, parvalbumin, calretinin, and 
neurotensin [15, 27], which have a modulatory effect on the neuronal activity. Moreover, 
opioid and cannabinoid receptors have been also found in the region and their agonists are 
known to exert a significant impact on the VTA cells [28-31]. This diversity in the chemical 
composition shows that the VTA is not a homogenous nucleus. Its complexity is also 
reflected in distinct patterns of the electrophysiological activity. 
Conventional dopaminergic VTA neurons (identified as tyrosine hydroxylase (TH)-positive) 
are characterized by phasic and tonic discharge patterns and these types of the neuronal 
activity play a role in so called reward-prediction error and uncertainty signaling [32-34]. 
However, a clearly different pattern has been identified in a substantial portion of the VTA 
neurons. Those cells “fired action potentials at a significantly higher frequencies in a 
sustained fashion” [35]. Therefore, the heterogeneity of the VTA neurons can be described 
at the level of expressed neurotransmitters and neuromodulators, as well as at the level of 
physiological properties. These differences also correlate with the differences in the cell 
morphology [35, 36]. Crucially, it has been recently recognized that neurons with similar 
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characteristics tend to be localized within specific subregions and project to particular 
brain areas [35, 37, 38].  
1.3 Projections and their functions 
Multiple brain regions provide neuronal input to the VTA and many are innervated by 
projections originating in the area. In rats, majority of the VTA neurons have been found to 
innervate only a single site [39], but in a more resent study in mice a separate population of 
the VTA cells which target forebrain as well as midbrain structures was distinguished [40]. 
The confirmed connections of the VTA are schematically depicted in Figure 1.3. Additionally 
to the long-range targets, there exists a dense net of local interconnections within the VTA 
[15]. 
Complexity of the entire system indicates that the VTA is involved in intense neuronal 
processing and that it plays a role in numerous functions. Among all the known neuronal 
tracts involving the VTA, the mesolimbic, mesocortical, and mesostriatal pathways have 
been studied most extensively and their biology as well as roles in behavior have been 
understood to some extent. 
1.3.1 Mesolimbic pathway 
The mesolimbic neuronal tract leads from the VTA to the ventral striatum, which is 
composed of the NAc and the olfactory tubercle (OT). The NAc, in turn, is composed of two 
subregions, the core and the shell. The VTA projections originating from different subnuclei 
show some preferences in respect to the targeted areas. Specifically, neurons in the 
posteromedial part of the VTA, including CLi, IF, PN, and medial PBP, project mostly to the 
medial OT and medial shell of the NAc, while neurons in the lateral VTA project 
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Figure 1.3. Neuronal input onto and output of the VTA 
A. Dopaminergic neurons receive projections from: bed nucleus of the stria terminalis (BNST), dorsal raphe 
nucleus (DRN), laterodorsal tegmental nucleus (LDTg), lateral habenula (LHb), lateral hypothalamus (LHT), 
medial prefrontal cortex (mPFC), periaqueductal grey (PAG), pedunculopontine tegmentum (PPTg), 
rostromedial mesopontine tegmental nucleus (RMTg), and ventral pallidum (VP). B. GABAergic neurons are 
innervated by some of the same regions: BNST, DRN, LHb, LHT,mPFC, PAG, and NAc. It is currently not 
known where the projections onto the glutamatergic cells derive from. C. The main output regions of the 
dopaminergic VTA neurons include: NAc, STR, mPFC, HIPP, and AMG, but many other targets have been also 
identified: OT, olfactory bulb (OB), PAG, and diagonal band (DB). D. The GABAergic and glutamatergic VTA 
neurons project onto the NAc and LHb. MSM – medium spiny neuron. Modified from [15].  
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preferentially to the lateral OT, lateral shell of the NAc and the NAc core [41]. 
The mesolimbic pathway is critically involved in reward and motivation systems of the 
brain which are closely linked to learning and aversive behavior. The roles of the 
mesolimbic pathway have been elucidated by numerous studies which found that the 
neurons increase their activity in response to an unpredicted rewarding stimulus. With 
training, the response of these neurons shifts to the stimuli that predict the reward and if 
the reward is not delivered within an expected time, their activity of the neurons drops to 
the below-baseline level [42].  
The activity of the VTA neurons is subsequently transmitted onto the NAc. Electrical as well 
as pharmacological stimulation of the VTA neurons results in DA release in the NAc [43-45]. 
DA is an endogenous agonist of the dopaminergic receptors and an increase in the DA level 
or activation of the receptors have been linked to motivational or rewarding effects of food 
intake after a food deprivation [46], sexual arousal [47], and intake of addictive drugs, such 
as amphetamine or cocaine [48].  
Nevertheless, although the DA release in the mesolimbic pathway is clearly the most 
important mediator in signaling the reward-related information, the entire neuronal circuit 
responsible for managing the motivational behavioral states is actually far more 
complicated [49]. In fact, the DA release in NAc is not only mediated by the VTA neurons, 
but also by the stimulation from the prefrontal cortex (PFC) [50]. Moreover, amygdala 
(AMG) and hippocampus (HIPP) also modulate activity of the NAc neurons by dopaminergic 
signaling, although the latter acts via the VTA [51, 52]. Furthermore, not only NAc, but also 
other regions innervated by the VTA are involved in reward processing. For instance, the 
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lateral habenula receives GABAergic projections from a subpopulation of the VTA neurons 
and this inhibitory pathway is activated under rewarding conditions [53]. 
1.3.2 Mesocortical pathway 
The mesocortical pathway leads from the VTA to the medial prefrontal, limbic and motor 
cortices and it is composed of dopaminergic fibers in only ~ 30 % [39, 54]. Activity of these 
dopaminergic neurons is under the glutamatergic control [55]. The remaining projections 
of the pathway are GABAergic, glutamatergic or mixed [54, 56]. The VTA neurons targeting 
cortical areas seem to be distributed across the entire region [57], although some studies 
have indicated that most of them originate from the rostromedial subregions, including 
VTAR, the rostromedial portions of the PBP and PN, the RLi, and the IF [39, 54, 58]. 
The mesocortical pathway is functionally linked to the mesolimbic pathway, as its 
involvement in reinforcement behaviors and emotional processing has been demonstrated. 
For instance, it has been shown that rats learn to self-administer addictive drugs, like 
cocaine, into the medial PFC (mPFC) [59, 60] and that a direct electrical stimulation of this 
site also acts as a reinforcement [61]. 
However, the PFC is probably responsible for processing different aspects of the reward-
related information. It might be specifically involved in reward-guided learning and 
decision making and it has been proposed that distinct areas of the PFC are preferentially 
responsible for “selecting reward goals, choosing actions to obtain reward, and monitoring 
the potential value of switching to alternative courses of action” [62]. Therefore, the PFC 
controls more cognitive aspects of the reward-related actions. 
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1.3.3 Mesostriatal pathway 
The mesostriatal pathway arises from the VTA-SNC complex and targets the dorsal striatum 
(STR). Since majority of the projections (~ 75 %) originate from the SNC [41], the pathway 
is also called nigrostriatal. Somas of the VTA-originating projections are located mostly 
within the PBP, but some also in the IF [41]. 
Interestingly, the VTA neurons projecting to the STR are very similar to those innervating 
the lateral shell of the NAc and to the SNC neurons which also target the STR. The 
similarities concern some aspects of molecular composition, electrophysiological activity, 
cell morphology, and site of origin in case of the VTA neurons. This set of characteristics is 
distinct from the characteristics of the VTA neurons projecting to the medial shell and core 
of the NAc, mPFC, and basolateral AMG and the differences between the two neuronal types 
may correspond to their involvement in different behavioral functions [35]. Therefore, in 
terms of the role of the VTA projections to the dorsal STR, it is difficult to differentiate it 
from the role of the SNC projections which target the same brain region. 
One of the most important behavioral contributions of the mesostriatal pathway lies in 
maintaining motor control, motor coordination and sensorimotor integration [63, 64]. The 
dorsal striatal regions, innervated by the mesostriatal pathway, are also crucially involved 
in expressing goal-directed actions and habitual behavior, which are two stages of an 
evolutionary adaptive process of associative learning [65-68].  
1.4 Disturbances in the neuronal circuits involving the VTA 
Based on the variety of the functions that the neuronal networks including the VTA are 
involved in, it can be easily predicted that disturbances in these networks may manifest 
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themselves with a wide spectrum of neurological and behavioral symptoms. Additionally, 
due to the mutual influences of different neuronal circuits on each other, a dysfunction of 
one pathway or a given cell type may affect the entire network. Consequently, the observed 
symptoms may be unspecific. Nevertheless, some neuropsychological diseases have been 
linked to particular pathological changes within the VTA networks.  
One example is the Parkinson’s disease (PD) which is caused by the degeneration of the 
nigrostriatal pathway. It affects approximately 7 mln people globally. The behavioral 
symptoms include: tremor, muscle rigidity, bradykinesia, and postural instability [64]. 
Additionally, PD patients may also suffer from disturbances in mood, sleep, cognitive 
functions, and others. The best currently available medication is the dopaminergic 
supplementation with L-DOPA, which however, is effective for only several years [69]. 
Another disorder that has been related to the malfunctioning of the mesostriatal, but also 
the mesolimbic, pathway is addiction. It has been proposed that the psychological 
component of addiction may be associated with disturbances in the gradual shift of the 
neuronal activity from the medial to lateral components of the thalamo-cortico-striatal 
circuits that normally occurs during associative learning and allows adaptive habit 
formation [70, 71]. Interestingly, some similarities in the brain activation patterns, 
including mesolimbic and prefrontal areas innervated by the VTA, have been found 
between drug and food addicts, imposing that similar treatment strategies might be 
efficient in both conditions [72]. 
Abnormalities in functioning of the mesolimbic and mesocortical pathways have been also 
found in other psychiatric disorders, including schizophrenia and depression [73, 74]. 
Regarding the former one, it has been proposed that the observed hyper-responsiveness of 
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the dopaminergic system [75-77] might be triggered by the neuronal hyperactivity in the 
anterior HIPP which projects to and overstimulates the VTA [78]. In case of depression, an 
opposite effect, i.e. an insufficient activity of the VTA neurons, was observed in animal 
models [79, 80]. The VTA hypoactivity may be presumably driven by the hyperactivity in 
the PFC [81] which stimulates the amygdala to activate the VP. The VP, in turn, exerts an 
inhibitory effect on the VTA [78]. 
The list of the neuropsychological disorders, briefly presented above, is certainly not 
complete. Post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity 
disorder (ADHD) are yet another conditions which should be mentioned to demonstrate the 
wide range of diseases in which the VTA and the related neuronal circuits are disturbed [82, 
83]. Interestingly, although the symptoms of the diseases are very diverse, and range from 
anhedonia and lack of motivation in depression, through abnormal anxiety reactions in 
PTSD and difficulties in focusing attention in ADHD, to hyperactivity or even hallucinations 
in schizophrenia – to name just a few – the dysregulation of the neuronal activity patterns is 
a common feature. 
Therefore, monitoring neuronal activity of the VTA, its projections and the target areas, 
which together constitute complex neuronal networks, is an important element of studying 
brain connectivity in health and disease. It is also the key step in the development of 
efficient therapies for the diseases which currently affect millions of people worldwide, 
impairing every-day lives of the patients and their families and producing significant costs 
for the health-care systems [84]. In this regard, the development of adequate methods is 
crucial. 
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1.5 Methods for in vivo studies of functional neuronal 
connectivity in experimental animals 
Currently available techniques for functional studies of the neuronal networks in vivo 
include relatively invasive electrophysiological recordings as well as minimally or non-
invasive imaging methods. The first approach allows the most direct measure of the 
electrical activity of the neurons. It also provides the opportunity to correlate the neuronal 
activity with an unrestrained behavior of the experimental animal. Additionally, if the 
electrodes are inserted into two anatomically connected brain regions, one of them can be 
used for stimulation, while the other one for recording of the induced change in the activity. 
In this way, the strength of the neuronal connection between the brain regions can be 
measured [85-87]. 
However, not only is the electrophysiological recording an invasive technique, but also the 
neuronal connections of interest have to be known in advance in order to correctly implant 
the electrodes. Finally, recording the activity of several neuronal pathways spreading in 
different directions across the brain would require inserting multiple electrodes which 
would likely result in a significant brain damage. 
A non-invasive approach, which allows recording of the neuronal activity also in humans, is 
electroencephalography (EEG). Besides its non-invasiveness, advantages of the technique 
include coverage of the entire brain and a high temporal resolution. However, EEG is also 
characterized by a relatively low spatial resolution or regional specificity. These 
characteristics could also describe magnetoencephalography (MEG), another brain imaging 
technique. One of the main problems associated with the functional brain mapping using 
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either of the methods is the volume conduction effect of the head [88]. Despite significant 
advancement in the technology as well as in data analysis procedures, the spatial resolution 
of EEG/MEG of the human brain remains in the cm range [89]. Additionally, detection and 
discrimination of the signals from deep brain structures are not straightforward [90]. 
Alternatively, a few functional magnetic resonance imaging (fMRI) methods, which are 
usually characterized by a superior spatial resolution, have been developed. The most 
commonly used in functional brain connectivity studies is the blood oxygenation level-
dependent (BOLD) fMRI. 
The technique is based on the relationship between the neuronal activity and the 
hemodynamic response of the blood vessels. It is quite well understood that an increase in 
the neuronal activity imposes an increased need of oxygen and other substrates, which 
results in a rise of the blood supply, mostly in the form of a higher cerebral blood flow. The 
increment actually exceeds the needs of the tissue resulting in the increase in the ratio of 
the oxygenated to deoxygenated hemoglobin. This, in turn, translates into an increased MR 
signal [91]. 
Although BOLD fMRI has significantly contributed to the better understanding of the human 
brain function, the fact that it is an indirect and relative measure of the neuronal activity is a 
drawback of the method. Additionally, the BOLD signal depends on several factors which 
are difficult to control. These factors include the local capillary density, the temperature 
and pH, as well as the so called draining vein problem which may lead to a misregistration 
of the true signal location [92]. 
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Moreover, it is quite difficult to use fMRI in animal experiments. Despite being a completely 
non-invasive technique, which is a great advantage, MRI requires anesthetizing the animal 
in order to reduce its mobility in the scanner. This is a serious limitation due to the known 
impact of anesthetics on the neuronal activity, as well as on the hemodynamic parameters 
[93-96]. Although MRI studies in awake rodents have been conducted, the animals in those 
experiments were usually physically restrained [97, 98]. The restraining may not only 
impose a substantial stress, which in turn may affect the measurement, but it also precludes 
performing many behavioral tasks, which are often used in animal studies as measures of 
neurological functions. 
One another MRI method which aims to measure the neuronal activity is manganese-
enhanced MRI (MEMRI). The technique is based on a unique combination of biological and 
magnetic properties of the divalent manganese ion (Mn2+) and can be also used with the 
awake animal protocol. It is described in detail in the following chapters. 
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2 Manganese 
2.1 Biological relevance 
Manganese (Mn) belongs to trace elements essential for human health. The adequate intake 
for an adult man is 2.3 mg/day and for a woman it is 1.8 mg/day [99]. Manganese is a 
cofactor of many enzymes involved in tissue development and metabolism as well as in 
antioxidant processes. Its enzymatic activity is based on the cation forms, predominantly 
Mn2+ [100]. 
One of the best described roles of Mn is its participation in dismutation of the superoxide 
radical (O2-) in mitochondria. The process is catalyzed by superoxide dismutase (SOD2) and 
it relies on the conversion of the free radical into hydrogen peroxide and oxygen [101].  
Another enzyme, for which Mn acts as a cofactor, is glutamine synthetase. In fact, the 
enzyme contains approximately 80 % of Mn2+ in the brain [102]. It catalyzes the conversion 
of glutamate into glutamine in astrocytes [103]. Glutamine, in turn, is further converted into 
γ-aminobutyric acid (GABA) which is the key inhibitory neurotransmitter of the central 
nervous system (CNS).  
Considering the importance of glutamate and GABA in the CNS, it is not surprising that Mn 
dietary deficiency may lead to disturbances in the brain function. For instance, higher 
susceptibility to seizure has been found in experimental Mn-deficient rats [104] and the Mn 
level in the blood was lower in epileptic patients than in healthy people [105, 106]. 
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Further disturbances that have been associated with Mn deficiency include poor skeletal 
development and growth as well as impaired reproduction in animals [107]. However, Mn 
deficiency in humans is very rare [108]. 
2.2 Uptake mechanisms 
Mn can enter the CNS from the blood either across the capillary endothelium or via the 
choroid plexus. The first mechanism dominates at the normal plasma level of the metal, 
while the second one plays a bigger role when the Mn concentration in the plasma is 
elevated [109, 110]. Crossing the blood brain barrier (BBB) by Mn2+ is restricted by the 
extensive binding (≥ 70 % in the rat) of the ion to plasma proteins. However, Mn2+ would 
enter the CNS readily from protein-free saline and the free ion is the most probable form 
which is actually taken up. Complexes with HCO3-, citrate, phosphate and other solutes 
constitute less than 40 % of the Mn2+ uptake [110]. 
The relatively high uptake level of Mn ions suggests an existence of mechanisms that 
facilitate the transport. In fact, it has been shown in vivo that Mn crosses the BBB in a  
transferrin-dependent manner and that the protein binds the trivalent ion, Mn3+ [111]. 
Furthermore, divalent metal transporter 1 (DMT1) and ZIP8 protein are also involved in 
Mn2+ transport across cell membranes [112, 113], although their roles in facilitating the 
transport through the BBB have not been demonstrated. 
Moreover, Mn2+ can also enter excitable cells through non-specific mechanisms. The most 
important one being via voltage gated calcium channels (VGCC) [114, 115]. Additionally, it 
can cross the cell membrane of erythrocytes through Na/Ca exchanger [116] and Na/Mg 
antiporter [117]. Finally, the intracellular Mn2+ uses the Ca uniporter mechanism to enter 
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mitochondria [118]. Most importantly, however, it has been recently demonstrated that the 
Mn2+ uptake into neurons correlates with the neuronal activity. This was measured using 
electrophysiological recording and Ca imaging and it provided the first direct evidence that  
the Mn2+ neuronal uptake may be used as a tool to monitor the neuronal function [119].  
2.3 Neuronal transport 
Interestingly, Mn ions which have been taken up by neurons are subjected to axonal 
transport. Although the involvement of microtubules and, more specifically kinesins, in this 
process has been demonstrated [120, 121], more detailed mechanisms are not fully 
understood. Nevertheless, Mn2+ transport along different neuronal tracts has been studied 
in experimental animals. For instance, one day after a direct administration into the rat 
striatum, 54Mn2+ was transported to the ipsilateral thalamus, hypothalamus, medial 
forebrain bundle (MFB) and substantia nigra, as visualized in autoradiograms. Some 
portion of the tracer was also found in the cortical areas and the amygdala [120]. 
Many other neuronal pathways, including the olfactory and visual tracts [120, 122-124], as 
well as pathways connecting deep brain nuclei and the cortex [125, 126], have been also 
investigated. Interestingly, different transport rates of Mn2+ have been estimated for the 
olfactory neurons (2-5 mm/h) [123] and for the neurons of the visual pathway (1 mm/h) 
[122], which may suggest that different molecular mechanisms of the transport are 
available in different types of neurons. 
Majority of the studies utilizing Mn neuronal transport were conducted with manganese 
enhanced magnetic resonance imaging (MEMRI) which will be described in detail in the 
next chapter. However, it is important to mention herein that Mn2+ does not only enter 
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neurons and is transported by the neuronal projections, but it also crosses synapses. This 
unique characteristic allows using the ion for tracing multi-synaptic neuronal circuits, 
which is not possible with other divalent metal ions [124]. 
For example, 54Mn2+ administration to the olfactory epithelium resulted in the tracer uptake 
in the olfactory bulbs and its further migration via the secondary and tertiary olfactory 
pathways. Six weeks after the application, the metal was detected in many other brain areas 
as well as in the spinal cord [127]. Similarly, Mn2+ injected into the eye could be detected in 
the retinal ganglion cells, their projections to the midbrain and projections of the next order 
leading up to the primary and secondary visual cortices [123, 128-130]. 
A crucial characteristic of the Mn2+ transport along axons is its partial dependence on the 
neuronal activity. A rigorous study has demonstrated that following an intravitreous 
injection of Mn2+ in mice genetically deprived of photoreceptors, which resulted in no 
electrical response of the neurons to the light stimulation, the contrast agent reached the 
midbrain area slower than in the wild type controls [131]. In another study, a 
pharmacological blockade of neuronal activity with tetradotoxin (TTX), or with a 
combination of TTX and Ni2+, attenuated an AMPA-induced increase in the Mn2+ transport 
along the habenulo-mesencephalic pathway, although it did not abolish the basal transport 
level [132]. 
However, in the visual pathway of the mice with the retinal blindness mentioned above, 
Mn2+ was not able to cross synapses. Therefore, while the axonal transport of the tracers is 
only partially dependent on the neuronal activity, the transsynaptic transport depends on 
the activity completely [131]. 
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2.4 Manganese neurotoxicity 
Despite the interesting electrophysiological properties of the divalent Mn ion, which could 
drive novel applications in the field of biomedical research, toxicity of the metal imposes a 
serious limitation. Although it is not common, Mn intoxication may occur as a consequence 
of an environmental overexposure to the element, liver cirrhosis, or an abuse of a not 
purified psychostimulant drug, ephedron. The resultant condition, called manganism, is 
characterized by neurological and behavioral symptoms which resemble, but are not 
exactly the same as, the symptoms of the Parkinson’s disease (PD) [133].  
Specifically, the affected patients suffer from muscle weakness and rigidity which result in 
disturbed gait, mask-like facial expression and drooling. Moreover, emotional and mood 
changes have been reported. One of the features that differentiate Mn intoxication from the 
PD is the lack of resting tremor, although action or postural tremors may occur. 
Additionally, conversely to the PD, there is no responsiveness to the L-DOPA treatment in 
manganism [133]. 
The similarity of the symptoms of the two conditions is not surprising taken into account 
that similar brain regions are affected in both diseases. In humans, Mn accumulates mostly 
in the basal ganglia, including globus pallidus, caudate, putamen, and substantia nigra and 
the accumulation can be readily visualized with MRI [133]. The basal ganglia, and the 
previously described mesostriatal pathway, are DA-rich areas involved in motor control 
and movement coordination [134]. Neurodegeneration of the neurons in the substantia 
nigra pars compacta and their striatal projections is the source of the PD.  
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The briefly described behavioral symptoms of manganism observed in human patients have 
been replicated in studies with non-human primates exposed to Mn overdoses [135-138]. 
Importantly, the animal experiments have provided additional information about molecular 
effects of the intoxication. The studies often focused on the dopaminergic system and, in 
fact, a decrease in the striatal and/or midbrain DA, as well as its metabolite, 
dihydroxyphenylacetic acid (DOPAC), levels have been reported following an exposure to 
the total Mn doses of hundreds of mg [135, 136, 139, 140]. However, the DA concentrations 
were not affected in other studies, some of which used lower Mn doses (below 100 mg) 
[138, 141, 142]. 
Also concentrations of DA transporter (DAT) and DA receptors in the caudate or putamen 
were reduced in monkeys, as measured with neurochemistry or neuroimaging techniques 
[137, 143]. Nevertheless, other studies reported no changes in the DAT and DA receptor 
levels [133, 141, 144]. The reasons for the discrepancy in the results are not fully 
understood. Potentially, the total accumulated dose and the differences between the 
monkey species may be relevant.  
The impact of Mn intoxication on other neurotransmitter systems has been studied to a 
lesser extent. However, a decrease in GABA and 5-hydroxyindoleacetic acid, the main 
metabolite of serotonin, have been observed in the pallidum, and a decrease in the 
norepinephrine concentration in the caudate of monkeys subchronically treated with 
MnSO4 or MnO4 [135, 142]. Moreover, enzymatic activity of DOPA decarboxylase in the 
putamen and acetyltransferase in the globus pallidus were reduced upon a longitudinal 
exposure to the metal [136]. 
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It is, therefore, clear that substantial amounts of Mn accumulated in the brain after a long-
term exposure may interact with several neurotransmitter systems. The neurotransmitters, 
their receptors and transporters, as well as the enzymes involved in their synthesis or 
breakdown assure proper brain functioning. Consequently, if the biological properties of 
Mn2+ shall be used as an experimental tool, it is crucial to ensure that Mn doses do not lead 
to the toxic effects. 
It is worth noting that the toxic effects may be different, or may not occur at all, following a 
single administration. Although this aspect has been studied to a limited extent only, it is 
known that a systemic administration of 16-80 mg/kg of MnCl2 induced a reduction in the 
motor activity in rats [145], while a 50 nmol dose injected directly into the vitreous body of 
a mouse eye disturbed electrical activity measured in the visual cortex [121]. Additionally, 
40 nmol of Mn2+ unilaterally administered into the rat VTA significantly affected the 
morphology of the cells [146]. Finally, an intracerebral application of the 8 nmol dose did 
not cause neuronal toxicity, although this was verified in the cortex, and not in the basal 
ganglia which are most vulnerable to Mn [147].  
In summary, Mn toxicity is a crucial aspect of any application involving systemic as well as 
local administration. Thus, before Mn ions are used for a biological experiment, the 
potential toxic effects should be carefully evaluated. 
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3 Magnetic Resonance Imaging 
MRI is one of the most widely used biomedical imaging modalities whose development was 
initiated in the 1970s. It provides images of high special resolution and with a very good 
soft tissue contrast. These features make the technique a very useful diagnostic and 
research tool. 
3.1 MRI principles 
The method is based on magnetic properties of hydrogen atoms which constitute almost 
50 % of biological tissues [148]. Other isotopes, including 13C, 19F and 17O, can also be 
imaged, although this is not commonly done. Due to the imbalanced number of protons and 
neutrons, the nuclei of these isotopes are characterized by a non-zero angular momentum, 
i.e. a spin. When a spinning nucleus is placed in an external magnetic field, its axis of 
rotation tends to be aligned with the direction of the field [5]. 
The alignment of the hydrogen spins can be parallel or antiparallel to the lines of the 
applied magnetic field (Figure 3.1.A-B). The former orientation requires less energy than 
the latter one and thus, more nuclei are positioned in this way. The difference in the 
number of the parallel and antiparallel-oriented spins provides the net magnetic moment 
which depends on the strength of the magnetic field. In a high field more nuclei join the 
anti-parallel population [5]. 
Whether the nucleus is in the parallel or antiparallel orientation, it precesses around the 
direction of the applied magnetic field with a characteristic frequency. This frequency (also 
called the Larmor frequency) depends on the strength of the magnetic field and on the 
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gyromagnetic ratio which is characteristic for a given nucleus (Figure 3.1.C). The Larmor 
frequency of hydrogen nuclei at the magnetic field strengths used in clinical MRI systems 
corresponds to the radio frequency (RF) range. Therefore, in order to provide energy to the 
hydrogen nuclei by means of the nuclear magnetic resonance, an RF pulse is applied. This is 
done with a transmitter coil of the MRI scanner. As a result, some low-energy nuclei join the 
Figure 3.1. Physics principles of MRI 
A. Without an external magnetic field nuclear spins are oriented in random directions. B.
When the external field is applied, the spins become aligned with its direction (B0). C. An 
individual nucleus rotates around its own axis and it precesses around the direction of the 
B0 at a specific frequency (the precession pathway is depicted by the dashed line). D.
Following an application of an energy pulse, the net magnetization vector (NMV) is flipped 
into a direction which depends on the magnitude and duration of the pulse. Here, the NMV 
was flipped by 90 ° (B1). After the energy pulse is removed, the NMV gradually returns to its 
original orientation (T1 relaxation). At the same time, the precessional movements of 
individual spins become desynchronized (T2 decay), which is depicted by different shades 
of grey of the arrows.  Adapted from [12]. 
A       B 
 
 
 
C       D 
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high-energy population which is associated with a change in the direction of the net 
magnetization vector (NMV). Simultaneously, the precessional movement of the individual 
spins becomes synchronized [5]. 
After the RF pulse is removed, the NMV gradually returns to its original orientation (Figure 
3.1.D), so the longitudinal (or T1) magnetization will be recovered. This process is 
associated with giving up the energy, which the nuclei had gained, to their surrounding and 
it is called spin-lattice relaxation. The rate of the T1 relaxation has an exponential course 
and the time required for the recovery of 63 % of the original longitudinal magnetization is 
referred to as the T1 relaxation time [5]. 
Simultaneously with the longitudinal relaxation, the precession of individual spins 
gradually becomes incoherent due to the interactions of the nuclei with each other. This 
process is called spin-spin relaxation and results in a decay of the transverse magnetization 
(or T2 decay) (Figure 3.1.D). The time after which 37 % of the transverse magnetization has 
been lost is called the T2 relaxation time [5]. 
According to the Faraday’s law of electromagnetic induction, the moving nuclear spins will 
induce a voltage in a conductive loop if such a loop is placed nearby. This phenomenon is 
exactly the mechanism by which the signal is recorded by a receiver coil in the MRI scanner.  
3.2 Image weighting 
The excellent contrast of soft tissues that is achieved in MRI results from different magnetic 
properties of the tissue molecules. For instance, water molecules are characterized by a 
long T1 time, while the T1 time of fats is short. This is a consequence of different bonds of 
hydrogen atoms with other atoms in the molecules. The T2 times of the two substances 
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differ as well - the T2 time of water is long, while the T2 time of fats is short. By an 
appropriate adjustment of parameters of MR sequences, these differences can be visualized 
in the images. 
The most important parameters include the time between the consecutive applications of 
the RF pulses (i.e. the repetition time, TR) and the time when the MR signal is read out 
following the RF pulse (i.e. the echo time, TE). In order to expose the differences in the T1, 
i.e. to obtain a T1-weighted (T1W) image, typically a short TR and a short TE are set. If a T2-
weighted (T2W) image is desired, the TR and the TE should be long (Figure 3.2) [5]. 
Figure 3.2. Differences in the relaxation times between fat and water 
A. T1 relaxation of fat and water. B. T2 relaxation of fat and water. Image weighting depends on the 
duration of TR and TE. Adapted from [5]. 
A 
B 
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3.3 Signal location and image formation 
The previously mentioned receiver coil registers the signal, but it cannot localize its origin. 
Therefore, an additional mechanism is necessary to obtain three-dimensional images. In 
fact, every MRI scanner is equipped with a set of gradient coils which are positioned in 
three dimensions. Their task is to temporarily modify the uniform magnetic field along all 
the axes in a controlled manner.  
The first gradient is applied in the z dimension of the scanner to provide slice selection. The 
second and the third gradients are consecutively applied to modify the frequency and phase 
of the spinning hydrogen protons. Thus, the nuclei from a given slice will be characterized 
by a specific frequency and phase depending on their position along the x and y directions. 
This information is later used during the process of image formation [5]. 
The signal recorded by the receiver coil after an application of each RF pulse, which is 
followed by the application of the three gradients, is saved as one data point in a spatial 
frequency domain, called K-space. During the entire scanning time, the polarity and the 
slope of the gradients change resulting in the gradual filling of the entire K-space. Finally, a 
mathematical operation called fast Fourier transform is used to convert the information of 
the K-space into an image [5]. 
3.4 MRI contrast agents 
Although MRI provides a very good contrast for most of the soft tissue types, there are 
cases, e.g. certain pathologies, when the intrinsic contrast is not sufficient. In order to 
increase the contrast, substances with specific magnetic properties can be used. These are 
usually compounds whose molecules contain atoms with unpaired electrons. The unpaired 
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electrons are responsible for a positive susceptibility of the substances (paramagnetism). 
When placed in an external magnetic field, spins of these electrons align parallel with the 
field, which results in its local enhancement. As the T1 and T2 times of the tissue depend on 
the magnetic field in which the tissue is situated, the relaxation parameters will be affected 
in the presence of the contrast medium [5]. 
For instance, the long T1 of water molecules is related to the fact that their tumbling rate is 
much faster than the Larmor frequency of the hydrogen protons. However, if the magnetic 
field is enhanced by the presence of the contrast agent, the tumbling rate of the molecules 
becomes closer to the Larmor frequency and the T1 relaxation is more efficient. The 
shortened T1 time will result in higher signal intensity in the T1W image [5]. 
The most commonly used contrast media are gadolinium (Gd)-based. Although, the Gd ion 
alone is nephron- and hepatotoxic, it can be chelated with other molecules which assure a 
safe use. In this form the contrast agent can be administered to a patient via an intravenous 
injection [149]. 
3.5 Manganese-enhanced MRI 
Mn divalent ion also poses paramagnetic properties. It strongly reduces the T1 and T2 
times of water and hence, can serve as an MRI contrast agent. Although, Mn-based contrast 
media are not commonly used, several compounds have been tested, including Mn bicine 
complex [150], Mn citrate, Mn N-(2-hydroxyethyl)iminodiacetic acid (HIDA) [151], and 
N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP). The latter one 
is used for pancreas imaging in animal models [152] as well as in patients [153-155]. 
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Figure 3.3. T1W MEMR images 
A. An image of a rat brain. Arrows indicate cortical 
layers. B. An image of a marmoset brain. The scale 
bars correspond to 5 mm. OB – olfactory bulb, Hab –
habenula, Str – striatum, Hip – hippocampus, Col –
colliculus, Ceb – cerebellum, V1 – primary visual 
cortex. Reproduced from [7]. 
A   B 
The free Mn2+, administered in the form of MnCl2, has been also used in animal research. 
The studies utilized it to image myocardial infarction [156-158], as well as brain structure 
and function. In those studies MnCl2 was administered systemically as a bolus injection or 
as an infusion, resulting in excellent contrast enhancement (example is shown in Figure 
3.3). 
However, due to the poor penetration through the BBB, relatively high doses of Mn2+ are 
required to achieve the desired contrast enhancement in the brain. For instance, to obtain 
the enhancement effect shown in Figure 3.3, the animals were injected with 90-180 mg/kg. 
The high doses may potentially lead to toxic effects, as previously described (section 2.4). 
Unfortunately, the toxicity aspect has not been carefully investigated in many MEMRI 
studies. Nevertheless, a robust dose-dependent decrease in motor activity, resembling the 
typical symptoms of Mn intoxication, has been observed following a single subcutaneous 
(s.c.) injection of 16-80 mg/kg in rats. Although the lowest dose resulted in minimal adverse 
effects, it was not sufficient for brain mapping [145]. 
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Alternatively, a cumulative dose of 80 mg/kg, which is adequate for imaging purposes, 
could be delivered by means of a continuous infusion using an intraperitoneally (i.p.) 
implanted osmotic pump. This procedure did not produce any behavioral side effects, but 
the required administration time was 7 days [145]. This may be not optimal for some 
studies. 
Besides imaging the brain anatomy, yet another interesting application of MEMRI has been 
developed in the field of neuroscience. Starting from 1998 [123], the technique has been 
widely used for tracing neuronal connections. The olfactory and visual pathways of the rat 
brain were imaged in the first place [123], but the focus of the studies rapidly spread onto 
other neuronal tracts, including cortical as well as deep brain circuits [126, 146, 159, 160]. 
The intense studies have been driven by the unique properties of Mn2+ as an MRI contrast 
agent, which allow visualization of multi-synaptic neuronal connections in a living brain. 
As previously described, the Mn2+ neuronal uptake and crossing the synapses dependent on 
the neuronal activity completely, while the axonal transport is partially activity-dependent. 
These mechanisms are associated with increased opening of Ca channels during electrical 
activity of the neurons which results in more Mn ions entering the cells [119]. 
Consequently, the active brain areas exhibit increased signal intensity in T1W MR images 
[132]. This unique property of Mn2+ has been widely used for studying brain function and 
plasticity in rodents [125, 161-163], birds [164, 165] and monkeys [166]. 
For example, activation of the pain pathway after application of an electrical stimulus and a 
subsequent reduction in the activation following an administration of morphine could be 
visualized using MEMRI in rats [167]. In another interesting experiment, the technique was 
used to study seasonal plasticity of the neuronal pathway between two song-control brain 
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nuclei in songbirds. The study revealed structural as well as functional differences between 
male and female birds [164]. Further functional MEMRI studies in the field of neuroscience 
included investigations of auditory pathway in mice [168], brain circuitry involved in novel 
stress response [169] and the conditioned taste aversion in rats [125], as well as many 
others.  
Besides investigations of the normal brain function, the technique has been also used to 
study brain dysfunctions in various disease models. Animal models of neurodegenerative 
diseases, like the Alzheimer’s disease (AD) and PD, were widely investigated [119, 170-
172], but usefulness of MEMRI for studying disturbances in different neurotransmitter 
systems, including specifically the DA, norepinephrine and serotonin transporters, has been 
also proved [163, 173, 174]. In summary, the diversity of the topics that have been studied 
with MEMRI illustrates how universal the method is.  
One of the biggest advantages of using MEMRI for tracing neuronal pathways relies on the 
possibility to image the brain function without affecting it with anesthesia. Although 
currently it is not a typical approach, Mn2+ can be injected into a specific brain region of an 
awake experimental animal via a guide cannula previously fixed on the skull. The freely 
moving animal can then undergo a behavioral procedure, while the tracer will be gradually 
transported along the neuronal tracts being involved in the activity.  
The fact that the animal can be unrestrained and freely perform the task, being it an 
exploration of a new territory or pressing a lever, is crucial for many experimental 
paradigms used in neurological and neuroscientific studies. Moreover, the relatively low 
neuronal transport rate of Mn2+ allows sufficient time for the experimental procedure.  
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Once the task has been completed, the animal is anesthetized and placed in the MRI scanner 
to read out the tracer distribution in the brain. Therefore, not only the influence of the 
anesthetics on the neuronal activity, but also the distress of the animal associated with 
being in the scanner, is avoided during the behavioral performance. In fact, this procedure 
has been successfully used in one study in rats [125]. 
The only limiting factor for MEMRI procedures is Mn toxicity. Especially if dopaminergic 
neurons, like the basal ganglia, or longitudinal studies involving multiple administrations of 
the tracer are of interest, this aspect should be carefully evaluated. As previously 
mentioned, tens of nmol of Mn2+ are commonly used for tracing neuronal pathways which 
may lead to toxic effects. Doses lower than 10 nmol have been reported not to cause toxicity 
after a single administration into the cortex, but the results could be different in the more 
vulnerable dopaminergic areas. Additionally, the low doses impose that the scanning 
procedure is either performed directly after the injection [131, 147], or it takes several 
hours [175]. Therefore, sensitivity of the MRI systems is a serious limitation for MEMRI 
experiments in which avoiding the toxicity effects is desired [8]. 
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4 Positron Emission Tomography 
The development of positron emission tomography (PET) was initiated in the 50s and 60s 
of the XX century. Further works led to an introduction of first tomographs in the mid-70s 
[176, 177]. Since then, a tremendous progress has been achieved in the concepts of PET 
data acquisition and processing, image reconstruction algorithms, as well as in the design 
and synthesis of various radioligands. Consequently, PET has become a powerful molecular 
imaging modality characterized by a very high sensitivity [178]. It is currently widely used 
for research as well as for clinical purposes in several biomedical disciplines. 
4.1 PET physics  
4.1.1 Beta decay 
A nucleus of an atom consists of positively charged protons and not charged neutrons 
which are held together by the nuclear force. The nucleus is stable if the numbers of 
protons and neutrons are balanced. If there is an excess of one of the nucleons, the nucleus 
becomes unstable and tends to convert the excessive nucleon into the other one in the 
process called beta (β) decay. A conversion of a neutron into a proton is associated with an 
emission of an electron, and hence it is called β- decay. However, PET imaging is based on 
the opposite transition, i.e. a conversion of a proton into a neutron, called β+ decay. This 
process is associated with an emission of a positron and an electron neutrino. As a result,    
a different chemical element, with the number of protons reduced by one, is formed [179]. 
For example, 11C decays to 11B through β+ decay: 
𝐶 →  𝐵 + 𝛽ା +  𝜈௘  ହଵଵ଺ଵଵ  
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During β+ decay, the mass-energy of the system, i.e. of the parent and daughter nuclei, the 
positron, and the neutrino, has to be conserved. Therefore, the reaction is only possible if 
the energy difference between the initial and the resultant nuclei is at least twice the 
equivalent of the electron mass, i.e. 1.022 MeV. The exact energy of the emitted positron 
depends on the parent and the daughter nuclei. Consequently, different PET isotopes are 
characterized by different positron energy which, in turn, influences the distance the 
positrons can penetrate the tissue, called the positron range  [1, 180]. 
Alternatively to β+ decay, proton-rich nuclei may also decay through another process which 
results in the reduction in the number of protons, namely electron capture (EC). Electron 
capture relies on absorbing an orbital electron by the nucleus which allows the conversion 
of a proton into a neutron. This is also associated with a release of a neutrino [179]. As an 
example, 125I decays to 125Te via the EC: 
𝐼 →  𝑇𝑒 +  𝜈௘  ହଶଵଶହହଷଵଶହ  
Importantly, the process does not necessarily lead to a stable nuclide. An outer electron 
may fill the vacancy that was left after the absorbed electron, resulting in an emission of X-
rays, or if the nucleus is in an excited state, it may further decay to the ground state by 
emitting γ-rays [179].  
Whether a radionuclide decays through positron emission or electron capture depends on 
the energy difference between the parent and the daughter nuclei. In general, the higher the 
difference, the higher the probability of β+ decay. However, for larger nuclei with a very 
high energy difference, more decay pathways are possible and the β+ branching fraction 
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may be quite low [180]. Table 4.1 summarizes physical properties of the positron emitters 
most commonly used in PET. 
4.1.2 Annihilation 
After a positron is emitted from the nucleus, it penetrates the surrounding tissue for a 
distance dependent on its energy. However, due to numerous interactions with the 
surrounding matter, the positron’s path is very tortuous [1]. As it passes through the tissue, 
the positron also loses its kinetic energy and finally, when it is already almost at rest, it 
combines with an electron creating a positronium. All this happens very rapidly and the 
positronium exists for only about 10-10 s before annihilation occurs [179]. 
Annihilation is a process in which the masses of the interacting positron and electron are 
converted into energy according to the Einstein’s mass-energy equivalence. It results in an 
emission of electromagnetic radiation and the most probable form of it is an emission of 
two 511 keV γ-rays (Figure 4.1). Because not only the energy, but also momentum has to be 
conserved, the photons are emitted in an opposite direction [1]. 
Isotope Emean (MeV) 
Emax 
(MeV) 
Range in water (mm) β+ branching 
(%) 
Half-life 
(min) mean max 
11C 0.386 0.960 1.2 4.2 99.8 20.4 
18F 0.250 0.634 0.6 2.4 96.9 109.8 
15O 0.735 1.738 3.0 8.4 99.9 2.0 
13N 0.492 1.732 1.8 5.5 99.8 10.0 
64Cu 0.278 0.653 0.7 2.5 17.5 762.1 
89Zr 0.396 0.902 1.3 3.8 22.7 4704.6 
68Ga 0.890 1.899 2.9 8.9 87.7 67.8 
 
Table 4.1. Properties of selected PET isotopes 
Adapted from [1-3]. 
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The properties of the emitted photons are crucial for PET. The energy of 511 keV is high 
enough to allow the γ-rays to leave the body and be detected outside. Moreover, the fact 
that they are always emitted with the 180 ° angle allows for a precise localization of the 
annihilation event [179]. 
4.2 Pure and non-pure positron emitters 
As these are the annihilation photons, and not the ejected positron, that are detected in PET, 
any other photons with similar energy that simultaneously hit the detectors during the 
measurement may induce artificial signals. Thus, isotopes which decay without emission of 
additional γ-rays (i.e. “pure” positron emitters) are traditionally preferred for PET imaging. 
11C, 15O, 13N and 18F are all examples of pure emitters (Table 4.1). The small fraction of the 
decays of these isotopes that occurs via EC lead to stable isotopes and thus, no additional 
photons are emitted. Also 64Cu is considered a pure positron emitter, even though its β+ 
Figure 4.1.Positron emission and annihilation 
A positron is ejected from a 18F nucleus resulting in its transition into an 18O 
nucleus. The emitted proton passes through the surrounding tissue losing its 
kinetic energy until it combines with an electron in the process of annihilation. 
This results in two 511 keV photons being emitted in an opposite direction. 
Adapted from [1]. 
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branching fraction is only 17.5 %. Neither the relatively high β-, nor the EC branching 
fractions (38.5 % and 44 %, respectively) have a significant impact on PET data acquisition. 
Only about 0.5 % of the decays is associated with an emission of γ-rays, which may be 
neglected [3].  
However, non-pure positron emitters can be also used in PET. For instance, 3.2 % of the 
68Ga decays are associated with an emission of 1.077 MeV γ photons, some of which may 
scatter generating γ-rays of lower energy, detectable by the PET scanner [3]. Nevertheless, 
the isotope is widely used in research, as well as in clinical applications, for imaging 
different types of cancer [2]. Another example is 124I which decays through the β+ emission 
in only 22.4 % and through γ radiation in 74.1 % [3]. 124I is used for imaging of thyroid 
diseases [181].  
4.3 Interactions of photons with matter 
There are three main mechanisms by which photons interact with matter and their 
probability depends on the photon’s energy. Radiation with the energy lower than 
approximately 100 keV predominantly interacts via the photoelectric effect and radiation 
with the energy between 100 keV and 2 MeV via Compton scattering. Additionally, if the 
photon carries at least 1.022 keV, it may spontaneously convert into a positron and an 
electron, which is called pair production. In respect to the annihilation photons, the 
Compton scattering is the most relevant type of the interactions [1]. 
This effect relies on the energy transfer from a photon to a free or loosely bound electron 
which results in ejecting the electron from its original position and in scattering the photon 
off from its original path. After the interaction, the energy of the photon is reduced by the 
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binding energy of the electron and its acquired kinetic energy [179]. The consequences of 
these events for PET are twofold. Firstly, the annihilation event is detected at a wrong 
location, and secondly, the detected signal is attenuated. 
The decay γ rays of non-pure positron emitters interact with matter in the same way as the 
511 keV photons. Therefore, not only may they induce spurious signal by directly hitting a 
detector, but also they contribute to the scattering effect. Moreover, if the energy is high 
enough and the pair production occurs, the created positron will undergo annihilation 
resulting in an emission of two detectable photons. This will add on to the artificial signal. 
Also a combination of different types of the γ radiation interaction with matter is possible 
depending on the energy of the photons [3]. 
4.4 PET instrumentation and data acquisition 
The 511 keV photons generated in the annihilation process travel through the surrounding 
until they reach a detector. The detector converts the amount of the energy deposited by 
the photon into an electrical signal. This is usually achieved based on the process called 
scintillation. It relies on absorbing the energy of the photons by electrons in the detector 
crystal, which brings them to an excited state, and subsequent returning to the ground state 
by releasing the energy in the form of light. The scintillation light is emitted isotropically 
and its amount is proportional to the amount of the energy absorbed in the first place. 
Therefore, the energy of the annihilation photons deposited in the detector can be 
measured [1, 179].  
In order to provide a high signal to noise ratio (SNR), the detector should absorb as much of 
the incident photons as possible. Therefore, dense materials, like bismuth germanate or 
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lutetium oxyorthosilicate (LSO) are used. Furthermore, the brightness of the scintillator (i.e. 
the number of the photons produced following an absorption of one 511 keV photon), as 
well as its timing and energy resolution, are important factors [1]. 
The next step of the PET signal detection involves converting the scintillation light into an 
electrical signal. This is usually achieved with photomultiplier tubes (PMTs). The PMTs not 
only release photoelectrons upon a deposition of the energy of the scintillation photons on 
a photocathode, but also amplify the signal of the released electrons. The PMTs are typically 
arranged in 4 × 4 blocks coupled with 8 × 8 arrays of the scintillation crystals which is           
a cost-effective design [179].  
In order to detect an annihilation event, both the emitted photons have to be detected. 
Therefore, in PET scanners the detector blocks are arranged in a ring (or rings). If the 
photons are registered by any two detector elements of the ring within a designated timing 
window, a coincidence is detected (Figure 4.2). The path between the two activated 
detectors is called a line of response (LOR) and a set of all parallel LORs in one angle is 
called a projection. During PET data acquisition the signal from the projections in all 
possible angles is recorded to form a sinogram (Figure 4.3) [10]. The sinogram is the basis 
Figure 4.2. Coincidence detection. 
As a result of the annihilation process, two γ photons are emitted in opposite directions. If the photons are 
registered by two detectors within the timing window (2τ), a coincidence is recorded. Modified from [1, 14]. 
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Figure 4.3. Sinogram formation 
A set of LORs in a given angle θ is depicted with solid lines (left). Similar projections are acquired in all other 
angles and the complete set of all the projections makes a sinogram (middle, “r” denotes the distance of the 
LOR from the center of the field of view). In the sinogram, the signal integrated from one LOR in a given angle 
is represented by the brightness of the corresponding pixel. A PET image (right) is reconstructed from the 
sinogram. Modified from [10].  
for the image reconstruction. 
4.5 Corrections 
Before a PET image is reconstructed from the sinogram, several data preprocessing steps 
are usually applied. The steps include: normalization, attenuation correction, dead time 
correction, scatter correction, and correction for random coincidences. If these are not 
applied, the pixel values in the reconstructed image may not reflect the tracer concentration 
accurately. 
Normalization is necessary because the detector elements are not perfect in terms of their 
dimensions, geometry and the associated electronics. This results in variability in the 
responses of individual detectors to the same excitation. Normalization relies on applying 
appropriate multiplication factors on each pair of the detectors to correct for the 
nonuniformities [179].  
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As previously mentioned, due to the interactions of the photons with the surrounding 
matter, some portion of the signal that should be recorded by the detectors is lost. 
Attenuation correction is applied in order to take this effect into account. It relies on 
multiplying the signal from each LOR by a factor that depends on the thickness and density 
of the material along the LOR. These factors can be obtained by calculating the reduction of 
the signal originating in an external rotating source that occurs when an object (or a 
subject) is place in the field of view (FOV) of the scanner. This approach has been used in 
the present work. 
Besides signal attenuation, interactions of photons with matter also lead to scattering them 
off from the original trajectory. Consequently, the annihilation event may be attributed to 
an incorrect location. Unfortunately, correcting for this effect is not straightforward. One 
approach which reduces the problem relies on limiting the energy window. Scattering a 
photon by a large angle is associated with a large reduction in its energy. Therefore, only 
photons that have been scattered by a relatively small angle will be accepted in the narrow 
energy window [179]. 
Another type of events that contribute to the inaccuracy in the detected signal is a random 
coincidence. This is a coincidental detection of two photons that do not originate from the 
same annihilation. Events of this type occur with a uniform probability across the scanned 
object and their contribution to the recorded signal can be estimated. This is done either 
based on the number of singles recorded by each detector, or by including an additional 
coincidence circuit in which the logic pulse from one of the two detectors in each pair is 
delayed. Then, none true coincidence can fit within the timing window and if an event is 
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detected it must be accidental. The estimated amount of randoms is subsequently 
subtracted from the measured data [179]. 
Finally, the dead time correction needs to be applied to account for the time the scintillation 
crystals decay after an excitation. The correction can be done by modelling the dead time 
behavior of the system at different activity concentration levels [179]. 
4.6 Image reconstruction 
There are two main approaches to the reconstruction of PET images from the sinogram 
data. In the first of them, called backprojection, an image matrix is defined in the first place. 
Then, a value is attributed to each pixel of the matrix based on the corresponding data from 
the sinogram. This, however, may sometimes result in attributing values outside of the 
scanned object, which is a drawback of the simple backprojection algorithm. 
Implementation of the projection slice theorem allows for taking this inaccuracy into 
account. Based on the theorem, the Fourier transform and the inverse Fourier transform 
operations can be used to accurately calculate the radioactivity distribution within the 
image [179]. 
A further improvement in the PET image reconstruction has been achieved by 
implementation of a filtering step. The filter function is applied on the Fourier transform of 
the sinogram data and the inverse Fourier transform is taken from the output. Depending 
on the filter, the final image is characterized by a trade-off between a higher spatial 
resolution and an improved SNR. A big advantage of the filtered-backprojection algorithm 
(FBP) is its low computational demand. The fact that the real geometry of the detectors is 
not accounted for and neglecting the noise belong to the disadvantages of the method [179].  
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The FBP algorithm was used to reconstruct the images in the blood sampler study, as will 
be described in section 18.4. 
The second of the two approaches covers a number of iterative methods of the PET image 
reconstruction. The general idea behind all of them is to produce an “initial guess” of the 
image, calculate the projections of the assumed image, and finally compare them to the true 
projections. The two sets will differ in the first comparison, but based on the obtained 
differences, the “initial guess” will be modified and the entire process repeated. With an 
increasing number of such cycles, the predicted projection set will become more similar to 
the true one. The iterative process will stop when no further improvement can be achieved 
[182]. 
A verity of techniques has been developed to implement this idea. One of the currently 
widespread methods is the ordered subsets expectation maximization (OSEM) algorithm. It 
was developed as an improvement of the expectation maximization algorithm. The 
improvement has been achieved by using only a subset of the entire dataset for each 
iteration, which allows reducing the computational time significantly. In order to further 
amend the reconstructed image, a maximum a posteriori (MAP) function can be used. As the 
name suggests, the function uses a priori information to enforce certain desired conditions 
(e.g. that the tracer concentration is non-negative) [183].  
The biggest drawback of the iterative methods is the relatively high computational demand, 
especially in regard to 3-dimensional images, which translates into the long reconstruction 
time. This is the price that has to be paid for the improved SNR and higher spatial 
resolution. The OSEM3D-MAP algorithm was used in the present work for the 
reconstruction of almost all the 52Mn PET images, as will be described in section 8.2. 
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5 Manganese-52 as a PET Tracer 
5.1 Characteristics of 52Mn 
 Among over twenty characterized isotopes of Mn, three positron-emitters, 52Mn, 52mMn, 
and 51Mn, are potentially suitable for PET. The isotopes differ in regard to their half-lives 
(5.591 days for 52Mn, 21.1 min for 52mMn, and 46.2 min for 51Mn) and positron energy. 
Although the half-lives of 51Mn and 52mMn are closer to the half-lives of commonly used PET 
isotopes, the high positron energies of these isotopes (970.2 keV and 1179 keV, 
respectively) translate into long distances the positrons may penetrate the tissue 
(4.275 mm and 5.288 mm, respectively). Consequently, a worse image quality can be 
expected. 
In contrast, the positron energy and range in tissue of 52Mn are much more favorable. The 
mean and maximal energies are 244.6 keV and 575.8 keV, and the corresponding ranges in 
water are 0.63 mm and 2.461 mm, respectively [184]. The relatively long half-life allows 
more time for radiochemistry, transportation of the tracer and performance of the 
experiment. Moreover, a long-term monitoring is possible after a single tracer 
administration. 
Nevertheless, PET imaging with 52Mn is also associated with some disadvantages. Not only 
is the β+ branching fraction (29.6 %) relatively low compared to traditional PET isotopes, 
but also the decay scheme includes multiple γ rays (Figure 5.1), some of which may 
interfere with PET data acquisition. Specifically, γ rays with the energies of 744.2 keV, 
935.5 keV, and 1434.0 keV occur with high probability (90.0, 94.5, and 100.0 % per decay, 
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Figure 5.1. Scheme of the decay of 52Mn 
Source: [4]. 
respectively) and may be recorded by the detectors. Although narrowing the energy 
window during the measurement should eliminate a direct detection, these γ rays may 
interact with the surrounding matter losing some of their energy. The scattered γ rays may 
be potentially captured by the PET system [185].  
The undesired γ radiation, along with the relatively long half-life of 52Mn, also contributes to 
the increased radiation exposure for all the persons involved in the study. Finally, for safety 
reasons, a prolonged time of waste storage is required [180].  
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5.2 Production and separation methods 
In order to use 52Mn for any PET application, the production method has to be well 
established. In fact, a tremendous improvement has been achieved in the production as well 
as the separation techniques over the past several years [186-191].  
52Mn can be obtained from chromium (Cr) of high chemical purity (99.95-99.99 %) by 
proton irradiation, according to the nuclear reaction: 52Cr(p,n)52Mn. Due to the small 
amounts of 53Cr in Cr, the reaction may also proceed with the production of 2 neutrons: 
53Cr(p,2n)52Mn. Finally, a bombardment of 54Cr, which is also present in the substrate, will 
result in the production of 54Mn: 54Cr(p,n)54Mn [191]. Due to its long half-life (312 days), 
54Mn will contaminate the obtained product. Contribution of the different reaction channels 
depends on the energy of the applied proton beam [186]. It has been shown that using 
16 MeV protons allows achieving at least 99.55 % purity of 52Mn [188, 189]. 
The nuclear reaction described above can be conducted on a small medical cyclotron. The 
target is usually pressed onto a silver disk with a mechanical press and, subsequently, 
irradiated at the proton beam current of 20-60 µA for 1-5 h. The silver disc is cooled with 
water from the backside [8, 188, 189, 191]. After the irradiation, several hours should be 
allowed for the decay of 52mMn (half-life 21 min) [8]. 
The most difficult part of the tracer preparation is separation of 52Mn from the Cr matrix. 
This step is necessary for any biomedical application due to the toxicity of Cr [192]. 
However, the separation process may be challenging because both, Mn and Cr, can be 
present at many oxidation states. Moreover, Mn2+ and Cr3+ are difficult to separate by 
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chromatographic methods [189]. Nevertheless, a few techniques have been recently 
proposed. 
The currently preferable method was introduced by Graves and colleagues [188] and it 
relies on so called “trap-and-release” mechanism. After irradiation, the target is first 
dissolved in HCl and subsequently diluted with ethanol. The produced ionic complexes of 
52Mn chlorides can be extracted by an anion-exchange resin. In the same conditions Cr3+ is 
hydrated and passes through the column. Subsequently, the eluent is changed to a fully 
aqueous HCl solution which elutes 52Mn from the resin bed. The entire cycle is repeated 
three times [188]. 
This separation technique can been further improved by using pure ethanol and by 
conducting an additional rising on a small column, which allows a removal of metallic 
impurities, such as Zn, Fr, Co and Cu, and consequently, improves the specific activity (SA) 
of the final product [191]. 
5.3 Current applications of 52Mn PET 
Although 52Mn was used in autoradiography or γ-counting biodistribution studies already 
in the 1960s [193, 194], only very recently has it entered the field of preclinical PET 
imaging. The first trial was reported in 2013 [185]. In that study, one rat was injected with 
approximately 600 kBq of the tracer i.p. and scanned 1 and 2 days afterwards, 
demonstrating that 52Mn PET is feasible. The second rat was injected i.v. and with a higher 
dose which resulted in a better penetration of the tracer throughout the body and an 
improved image quality. 5 min after the administration, the tracer was detected in the liver, 
kidneys, throat, bladder and testicles. However, the penetration through the BBB was very 
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poor. Finally, a long-term distribution was monitored in the third rat. Except for the 
abdominal organs, the tracer accumulation in the bones and spinal cord was also observed.  
After this first proof-of-principle work, only four other application studies involving in vivo 
52Mn PET were conducted, have been reported until now. In the first of them, the tracer was 
used to track DMT1 – overexpressing human stem cells which had been transplanted into 
the striatum of two rats [189]. Although penetration of 52Mn via the BBB was very poor 
following the systemic administration, the tracer could be detected in the brain in an ex vivo 
PET measurement, as well as in autoradiography. 
In the second study, two mice were injected i.v. with 52Mn and the distribution pattern of 
the tracer known from the previous reports was replicated [195]. 
A very interesting application of 52Mn, with a potential to be translated into the clinical 
level, has been described in the third article. In that work the tracer was used for functional 
imaging of pancreatic β cells in mice. Importantly, not only an uptake by the pancreas in 
healthy animals was shown once again, but also a pharmacological manipulation of the 
uptake could be demonstrated. Namely, the pancreas standardized uptake value (SUV) of 
52Mn was reduced following an administration of nifedipine or diazoxide, both of which 
block the ability of Ca to stimulate insulin release. Conversely, the SUVs were increased 
after an administration of glibenclamide which increases the level of intracellular Ca [196]. 
Therefore, the known mechanism of the intracellular 52Mn uptake, i.e. via the VGCCs, was 
once again confirmed. 
Finally, based on a part of the data from the present doctoral thesis, 52Mn was used for 
tracing neuronal pathways in rats [8].  
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In summary, 52Mn PET is a very novel tool in the field of preclinical imaging. It allows 
longitudinal monitoring of the Mn biodistribution, as well as imaging of specific targets that 
the tracer has an affinity to. Due to the unique biological properties of the divalent Mn ion, 
as well as the physical properties of the isotope, many other applications are potentially 
possible. However, since only a handful of studies utilizing 52Mn have been reported, many 
aspects require further investigations. Among those are dosimetry issues and a description 
of the tracer’s behavior in the CNS. 
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6 Motivation and Objectives 
As it has been discussed in the previous sections, Mn2+ is characterized by unique biological 
properties which make it a very interesting tool for tracing neuronal pathways. If it was 
possible to avoid the toxicity effects associated with the doses required for MEMRI, the 
technique could be safely applied in many studies focusing on the relationship between the 
brain function and behavior in experimental animals. Since PET is a much more sensitive 
imaging method than MRI, and using Mn doses of 2-3 orders of magnitude lower should be 
possible, the main goal of this work was to introduce 52Mn as a PET tracer for functional 
imaging of neuronal tracts in preclinical studies. This objective was divided into several 
steps which were realized in separate studies. 
In the first study (Study 1), the relationship between the doses of Mn2+, the changes in the 
T1 relaxation time the doses provide, and the dopaminergic toxicity they may induce, was 
investigated. The goal was to verify whether the dose which does not lead to a 
dopaminergic lesion following a direct administration into the VTA would suffice for MRI. 
The second study (Study 2) focused on the image quality that can be achieved with 52Mn 
PET. The goals of the performed phantom measurements were to select the most optimal 
image reconstruction algorithm, which would be subsequently used in in vivo experiments, 
and to assess a potential influence of prompt γ rays emitted during the 52Mn decay process 
on the obtained image. 
Subsequently (Study 3), the effect of different radioactivity doses of 52Mn on motor control, 
on the VTA dopaminergic neurons, and on the DNA integrity in this nucleus was evaluated. 
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This was accomplished by means of a behavioral test as well as immunohistochemical 
staining methods in total of three experiments. The primary goal was to define the 
radioactivity dose of the tracer which could be safely administered into the rat brain. 
The aim of the next study (Study 4) was to investigate the possible impact of 52Mn on the 
dopaminergic and GABAergic neurotransmitter systems. Specifically, the short- and long-
term effects of the intrastriatal administration of the PET tracer on the non-displaceable 
binding potential (BPnd) of [11C]methylphenidate and [11C]flumazenil were to be assessed. 
For comparison, a similar assessment of potential effects of non-radioactive Mn2+, at the 
dose relevant for MEMRI, was also carried out.  
This study was important because DA, as well as GABA, may affect neuronal activity [197, 
198]. If Mn ions change the DA or GABA neurotransmission, they may indirectly modify the 
neuronal activity, which would be highly undesired.  
Finally (Study 5), in order to demonstrate the activity-dependence of the 52Mn neuronal 
transport,  several pharmacological agents, known to influence the neuronal activity, were 
co-injected with the PET tracer into the VTA. It was expected to detect an increased or 
reduced 52Mn concentration in the VTA output regions depending on whether a stimulant 
or an inhibitor of the neuronal activity was used. A positive result of this study would 
strongly support the idea of using 52Mn for functional imaging of the neuronal activity. 
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7 Small Animal PET with Online Blood Sampling  
Although this work focuses predominantly on tracing neuronal pathways following a direct 
injection of 52Mn into the brain, this is not a standard route of administration of a PET 
tracer. In human patients, as well as in experimental animals, PET tracers are normally 
injected intravenously (i.v.) and they reach the target organ with the blood stream. The 
subject undergoes a PET scan after a defined uptake time which should be sufficient for the 
tracer to reach a constant level in the region of interest (ROI). Subsequently, the tracer 
concentration can be extracted from the PET image (Cimg) to quantify the result. This is 
commonly done using the standardized uptake value (SUV) which is the Cimg normalized by 
the injected dose (ID) and the body weight of the subject (BW): 
𝑆𝑈𝑉 = 𝐶௜௠௚ ∗
𝐵𝑊
𝐼𝐷
 
Using the SUV is a convenient approach but it has some limitations. Specifically, the SUV 
may substantially depend on the image resolution, noise level, and the method of ROI 
definition [199].  
An alternative quantification method, kinetic modeling, can be used if dynamic data are 
available. In this approach, PET is conducted directly after the tracer administration and 
gradual accumulation of the tracer in the ROI is recorded. The time activity curve (TAC) 
from the ROI is then used to estimate rate constants of the processes predefined by the 
applied model. Consequently, the very general concept of the tracer “uptake” is 
decomposed into several steps, which provides more precise characterization of the tracer 
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pharmacokinetics and, ultimately, of the biological processes under investigation [200, 
201]. This is especially important when a novel PET tracer is developed. 
However, in order to use a full, and not a simplified, kinetic model, it is necessary to know 
the distribution of the tracer in the arterial blood and in the plasma over time, i.e. the 
arterial input function (AIF). The AIF may be obtained from blood samples collected during 
the PET measurement, which is relatively easy to perform in humans. However, manual 
blood sampling (MS) in small animals is much more challenging due to the limited blood 
volume. In order to avoid the blood loss, the blood radioactivity level can be recorded with 
a blood sampler (BS) in an arterial-venous shunt. This procedure also assures an accurate 
capturing of the peak activity after a bolus injection [202].  
An interesting design of an MR-compatible BS was proposed several years ago [203] but, 
despite its excellent performance, the device has been never used in a routine small animal 
PET study. Therefore, an additional goal of the present work was to establish an 
experimental protocol for PET with online blood sampling using a very similar BS in rats. 
The established procedure should be applicable for experiments with any PET tracer, 
including potential 52Mn-labeled compounds. The specific aim of this study was to evaluate 
the impact of the technique of the AIF recording on the kinetic parameters (KPs) of 
[18F]fluorodeoxyglucose ([18F]FDG).  
  
MATERIALS AND METHODS 
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8 Description of the Studies 
Total of five studies were carried out in order to evaluate different aspects of using non-
radioactive Mn2+ and the positron-emitting 52Mn, for tracing neuronal pathways in rats. 
Most of them were in vivo studies and only Study 2 was a phantom measurement. 
8.1 Study 1: Relationship between Mn2+ doses, signal 
enhancement in MRI and dopaminergic toxicity 
Twelve rats underwent a baseline MRI scan, in which T1W images and T1 maps were 
acquired. 2-3 days later, they were stereotactically injected into the right VTA with Mn-
bicine chelate solution. The Mn-bicine complex is a low affinity chelate and at the pH of 7.4, 
which was used, 10 % of the metal is present as free ions [150]. The amount of MnCl2 to be 
dissolved in the bicine solution was calculated to provide 0.5 nmol (n = 4) or 45 nmol 
(n = 4) of free Mn2+ ions in the injected volume. The control group (n = 4) was treated with 
the bicine solution alone. 
The second MRI measurement was carried out at 24 h post-injection. The obtained T1W 
images allowed verification of the injection site and visualization of the distribution of the 
contrast agent. The T1 maps were used for a quantitative VOI-based analysis. 
The rats were sacrificed 4 weeks after the injection and their brains were used for the TH-
staining. 
8.2 Study 2: 52Mn phantom measurements 
Three phantoms were used in this study. The first one was an Ultra Micro Hot Spot 
Phantom (Data Spectrum Corporation, Durham, NC, USA) which contains 6 sets of rod 
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Figure 8.1. Resolution phantom 
A. Elements of the resolution phantom. B. A schematic cross-section through the phantom 
showing the arrangement and diameters of the rod volumes. Adapted from [6]. 
 
volumes with different diameters ranging from 0.75 mm to 2.40 mm. Its geometry is 
depicted in Figure 8.1. 
The phantom was filled with 52Mn solution (2.92 MBq in approximately 6 mL) and 
positioned in the center of the FOV of the PET scanner. The acquisition was performed with 
the energy window of 350-650 keV and it lasted 20 min. The images were reconstructed 
with different algorithms and matrix sizes. Those were: the FBP algorithm and the matrix 
size of 128 × 128 (i), the OSEM2D algorithm (4 iterations)  and the matrix size of 128 × 128 
(ii), the OSEM3D (2 iterations) – MAP (18 iterations) algorithm and the matrix size of 128 × 
128 (iii), and the OSEM3D-MAP algorithm but the 256 × 256 matrix size (iv). The obtained 
images were visually compared. 
The second phantom was a 1.5 mL Eppendorf tube completely filled with 52Mn solution 
(0.8 MBq). It was placed in the centre of the FOV of the PET scanner and the acquisition was 
performed 4 times without moving the phantom. Each time one of the following energy 
windows was used: 350-650 keV, 400-650 keV, 450-650 keV, or 450-600 keV. Each 
acquisition lasted 20 min and was reconstructed as a single frame using the OSEM3D-MAP 
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algorithm and the 256 × 256 matrix size. 
The third phantom was a 1 mL plastic syringe partially filled with 52Mn solution (23 kBq) 
and with the opening closed with plasticine. The entire syringe was closed in a water-filled 
15 mL Falcon tube. The water surrounding was meant to imitate a biological tissue. The 
phantom was positioned in the centre of the FOV of the PET scanner and 4 acquisitions 
were performed using the same energy windows as for the previous phantom. Due to the 
little activity available, each acquisition lasted 30 min.  
8.3 Study 3: Impact of different radioactivity doses of 52Mn on 
the dopaminergic system 
8.3.1 Experiment 1: Impact of the 170 kBq dose on the dopaminergic 
system  
Twelve rats were used in this experiment. Eight of them were stereotactically injected with 
169 ± 24 kBq (mean ± sd, further denoted as 170 kBq) of 52Mn into the right VTA (VTA 
group, n = 4) or right STR (STR group, n = 4). The remaining four rats were injected also 
into the right VTA but approximately 3 months later. The time delay assured full decay of 
the injection solution (VTA decayed group). 
Static PET (20 min acquisition) and MRI measurements were carried out on the animals 
from the VTA and STR groups 24 h post-injection in order to evaluate the tracer distribution 
in the brain. 4 weeks post-injection all the animals underwent the rotameter test. 1 day 
later, the rats were sacrificed and the brains were removed for the TH-staining.  
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8.3.2 Experiment 2: Impact of the 30 kBq and 150 kBq doses on the DNA 
strand breaks 
Since a dopaminergic lesion, not likely caused by the metal, was observed in some animals 
in Experiment 1, Experiment 2 aimed at assessing a possible contribution of the ionizing 
radiation to the observed toxic effect. Thus, eight rats were unilaterally injected into the 
VTA with either 149 ± 10 kBq (further denoted as 150 kBq, n = 4) or 28 ± 6 kBq (further 
denoted as 30 kBq, n = 4) of 52Mn. The control group (n = 4) was injected with saline 
solution. Two animals from each group were sacrificed at 90 min and two at 24 h post-
injection. The brain tissues from all the rats were used for immunohistochemical staining 
against γ-phosphorylated histone protein H2AX (γH2AX-staining) which detects DNA 
breaks. 
8.3.3 Experiment 3: Impact of the 20 kBq dose on the dopaminergic system 
Total of twenty four rats were used in this experiment. Eighteen of them were 
stereotactically injected with the reduced dose of 52Mn (20 ± 5 kBq) into the right VTA. Six 
rats were injected with a buffered saline solution to serve as a control group. 24 h after the 
injection, the 52Mn-treated rats underwent static PET (60 min acquisition) and MRI. All the 
animals underwent the rotameter test at the following time points: 3 days post-injection 
(six 52Mn-injected rats), 14 days post-injection (another six 52Mn-treated rats), and 28 days 
post-injection (six 52Mn-treated rats and six control animals). 1 day after the rotameter test, 
the animals were sacrificed and the brains were removed. Three brains from each group 
were used for the TH-staining. 
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8.4 Study 4: Interactions of Mn2+ with the dopaminergic and 
GABAergic neurotransmitter systems 
Three groups of rats were stereotactically injected into the right STR with 1 µL of non-
radioactive MnCl2 solution containing 50 nmol of Mn2+ (Cold Mn group, n = 8), the solution 
containing 29 ± 13 kBq of 52Mn (Hot Mn group, n = 8), or 0.9% NaCl solution (Control group, 
n = 8). On the following day, the rats underwent anatomical MRI and [11C]methylphenidate 
PET. At 48 h post-injection the [11C]flumazenil PET was performed. After 4 weeks, the MRI, 
as well as the [11C]methylphenidate and [11C]flumazenil PET measurements were repeated 
on 2 consecutive days to evaluate the long-term effects. The study design is depicted in 
Figure 8.2. 
In case of the Hot Mn group, the systemic injections of the [11C]-tracers were preceded by 
60 min static scans in order to acquire the signal from the 52Mn still present in the brain. 
The [11C]-tracer was administered directly afterwards without changing the animal’s 
position on the bed. With the assumption that during the time of these PET acquisitions, the 
52Mn distribution in the brain does not change, it was planned to subtract the static 52Mn 
images from the subsequently acquired dynamic images containing the mixed signal of 
Figure 8.2. Time line of Study 4 
     Day 0       Day 1            Day 2        Day 29             Day 30 
Short-term effects      Long-term effects 
Stereotactic 
Injection 
MRI + 
[11C]methyl-
phenidate PET 
[11C]flumazenil 
PET 
MRI + 
[11C]methyl-
phenidate PET 
[11C]flumazenil 
PET 
M a t e r i a l s  &  M e t h o d s   | 83 
 
52Mn and the [11C]-tracer. The following framing was used to reconstruct the dynamic 
images: 12 × 5 s, 6 × 10 s, 6 ×30 s, 5 × 60 s, 10 × 300 s.  
Unfortunately, due to the difficulties associated with the subtraction procedure in the Hot 
Mn group, the images containing the 11C signal alone could not be recovered. Therefore, the 
data of this group could not be analyzed.  
8.5 Study 5: Activity-dependence of 52Mn neuronal transport 
and dosimetry 
Six groups of rats were treated with different pharmacological agents known to stimulate or 
inhibit the neuronal activity. These agents were stereotactically co-injected with 27 ± 8 kBq 
(mean ± sd) of 52Mn solution in 2 µL, directly into the right VTA. The following 
pharmacological agents were used: 
 100 µM 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-epropionic acid (AMPA, Alomone 
Labs Ltd., Jerusalem, Israel) – AMPA group, n = 7; 
 tetrodotoxin (TTX, Alomone Labs Ltd.) – TTX group, n = 10; 
 N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA, Alomone Labs Ltd.) – NMDA 
group, n = 10; 
 2-amino-5-phosphonopentanoic acid (AP-5, Alomone Labs Ltd.) – AP5 group, n = 5; 
 Manganese (II) chloride tetrahydrate (MnCl2 × 4H2O, Sigma-Aldrich Chemie GmbH, 
Munich, Germany) – Cold Mn group, n = 4; 
 The control group (CTRL) was injected with 52Mn solution alone; n = 9. 
After the stereotactic injection and suturing of the wound, the animal was transferred to the 
PET scanner and the acquisition started 26 ± 3 min (mean ± sd) after the end of the 
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injection. It lasted 6 h and the images were reconstructed as 12 × 30 min frames which 
allowed visualization of the gradual transport of 52Mn from the injection site to different 
brain regions. The injection location was verified based on the T2W MR images. 
The PET data from the CTRL rats were additionally used for dosimetry estimates, which will 
be described in details later.  
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9 PET tracers 
52Mn was produced by Dr Gregory Severin and Dr Jesper Fonslet at The Hevesy Laboratory, 
Technical University of Denmark. Since the present work focuses on potential applications 
of this PET tracer, its production and separation methods are described in detail. 
 [11C]methylphenidate and [11C]flumazenil were used in Study 4. These tracers were 
synthesized by Ramona Stumm and Dr Andreas Maurer at the Werner Siemens Imaging 
Center. The radiosynthesis procedures of these substances are also described. 
9.1 Production of 52Mn 
52Mn was produced from Cr powder (200 mg, 99.99%, 100-325 mesh, Alfa Aesar, Thermo 
Fisher GmbH, Karlsruhe, Germany). Cr was mechanically pressed onto a silver disc (0.5 cm 
thick × 2.7 cm diameter) and covered with an Al foil. The irradiation of the target (20 µA 
protons at 15.4 MeV, degraded by the foil from the nominal 16.0 MeV, for 4.8 h) was 
performed on a PETtrace cyclotron (General Electric, Boston, Massachusetts, USA). During 
this process, the silver disc was being cooled with water from the backside. 
Following the irradiation, several hours were allowed for a decay of 52mMn (T0.5 = 21 min) 
contaminating the product. Subsequently, the silver disk was immersed in 12 M HCl 
overnight. The obtained mixture was directed for a chemical separation [191]. 
9.2 Separation of 52Mn 
Two different methods were used. Method 1 (used only for Experiment 1 in Study 3) was 
adapted from Lahiri et al. [204]. Method 2, adapted after Graves et al. [188], was used for all 
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the other studies. Method 2 was preferred as it resulted in a reduced content of metallic 
impurities and in an improved specific activity (SA). 
Method 1 
The obtained solution was first diluted with water to the approximate HCl concentration of 
7.6 M, and subsequently separated into two falcon tubes. 0.5 M trioctylamine in 
cyclohexane (Sigma Aldrich Chemie GmbH, Copenhagen, Denmark) was added to each of 
them. The vials were shaken for 5 min and then spun in a centrifuge (4400 rpm, 5 min, 
radius of approximately 20 cm). As a result, three phases were formed in the tubes with the 
green Cr being mostly present in the bottom one. The two upper phases from both tubes 
were pooled and the centrifugation was repeated. A small amount of the aqueous Cr phase 
formed once again at the bottom of the tube. The upper phases were decanted and 
centrifuged for the final 10 min. The separated Cr phase was removed with a syringe. 
Afterwards, the 52Mn phase was back-extracted into 2 mL of aqueous 0.1 mM NH4OH 
solution (Sigma Aldrich Chemie GmbH) by vigorous shaking and centrifugation (5 min). The 
formed aqueous phase was pipetted out into a glass vial for drying (130 oC under Ar flow). 
The obtained purple residue was dissolved in 12 M HCl and then diluted with neat ethanol. 
The solution was passed over a 400 mg AG 1 × 4 anion exchange resin (Bio-Rad 
Laboratories, Copenhagen, Denmark). The following solutions were sequentially used in the 
resin: 6 M HCl (5 mL), 2 M HCl (5 mL), water (5 mL), 6 M HCl (5 mL), and 2 M HCl (5 mL). 
12 M HCl in ethanol (5 mL) was used as the mobile phase. This was followed by passing the 
mobile phase, repassing the active sample and final washing with the mobile phase. 4 mL of 
0.1 M HCl were used to elute 52Mn from the column.  
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The solution was subsequently dried at 130oC under Ar. Then, 1 mL of 0.1 M HCl was added 
to the vial to redissolve the activity. 350 µL of the solution was again taken to be dried 
under Ar at 130 oC. Finally, 50 µL of 10 mM Na (L+) ascorbate in normal saline (0.9 % NaCl) 
was passed through a sterile filter into the vial. 10 mM Na (L+) ascorbate in normal saline 
was used as a buffer also in all future preparations of 52Mn used in this work. 
Method 2 
The obtained solution was first dried at 130 oC, then reconstituted in 3.0 mL of 12 M HCl, 
and finally diluted with neat ethanol to 60 mL. This was passed over a 725 mg AG 1 × 8 
column and 2 M HCl, 6 M HCl and ethanol were sequentially used for rinsing. This was 
followed by 97:3 ethanol:aq. 12 M HCl which trapped 52Mn. 
The column was subsequently washed with 97:3 ethanol:12 M HCl (22 mL) and 52Mn was 
eluted in 1 mL of 0.1 M HCl. The obtained solution was dried at 130 oC. The dried substance 
was redissolved in 0.5 mL of HCl, then diluted with ethanol to 10 mL, and subsequently 
passed over a second AG 1 × 8 column (697 mg). The washing and eluting steps, as well as 
the following drying and redissolving, were exactly the same as in the first run. Finally, the 
entire column procedure was conducted for the third time on a small 89 mg AG 1 × 8 anion 
exchange resin. 52Mn was eluted in 0.1 M HCl, dried under Ar, and redissolved in 10 mM 
Na (L+) ascorbate in normal saline. 
Regardless of the 52Mn separation method, a sample of the final solution was evaluated with 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES, Thermo Fischer 
Scientific, Waltham, MA, USA) versus Ag, Cr, Ni, Cu, Fe, Mn, Ca and Zn standards. 
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9.3 Production of 11C 
11C was produced on a PETtrace cyclotron (GE Healthcare, Munich, Germany) from 14N, 
according to the nuclear reaction: 14N(p,α)11C. For this purpose, N2 gas with 1 % O2 was 
irradiated with 70 µA protons at 16.5 MeV for 30 min. [11C]CO2 was created as the reaction 
product. Subsequently, the product weas catalytically reduced to [11C]methane, which was 
then reacted with iodine to obtain [11C]iodomethane. [11C]iodomethane was used to 
synthetized  the tracers. 
9.4 Synthesis of [11C]methylphenidate  
The synthesis occurs in two steps, as depicted in Figure 9.1. Its precursor is D-threo-N-NPS-
ritalinic acid, 2 mg of which are dissolved in a mixture of 500 µL dimethylformamide (DMF) 
with 2 µL NaOH 2 M. In the first step of the synthesis, [11C]iodomethane is dissolved in the 
mixture. The methylation reaction is performed at 83 °C for 8 min. After cooling to 30 °C, 
hydrolysis of the NPS protecting group is performed as the second step. It relies on adding 
150 µL of HCl 1M and 2.5 µL of thioglycolic acid to the reaction mixture with a subsequent 
incubation at 30 °C for 3.5 min. 
Separation of the final product is conducted with high performance liquid chromatography 
(HPLC). The purified [11C]methylphenidate is trapped on a solid-phase extraction cartridge 
(Strata-X, Phenomenex), eluted with ethanol and subsequently diluted with phosphate-
buffered saline and sterile filtered (0.22 µm).  
In Study 4, 24 ±3 MBq (mean ± sd) of the tracer was administered i.v. as a bolus injection. 
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9.5 Synthesis of [11C]flumazenil 
[11C]iodomethane is combined with 2 mg of the precursor, desmethylflumazenil, in 300 µL 
of dimethylformamide and 3 µL of 0.5 M NaOH. The reaction is performed at 70 °C for 5 min 
(Figure 9.2). After cooling to 30 °C, the mixture is diluted with 1.5 mL of the HPLC eluent 
and directed to the HPLC for the separation of the final product. [11C]flumazenil is trapped 
on a solid-phase extraction cartridge (Strata-X, Phenomenex), eluted with ethanol and 
subsequently prepared for injections by dilution with phosphate-buffered saline and by 
sterile filtration (0.22 µm). 
In Study 4, 26 ±2 MBq (mean ± sd) of [11C]flumazenil was administered i.v. as a bolus 
injection. 
 
Figure 9.2. Synthesis of [11C]flumazenil 
Figure 9.1. Synthesis of [11C]methylphenidate 
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10 Animals and Stereotactic Injection 
10.1 Animals 
All the animal procedures were performed in accordance with international standards for 
the care and use of laboratory animals and were approved by the local Animal Welfare and 
Ethics Committee of the Country Commission Tübingen, Germany (Animal Licenses No 
R05/2013, R02/16 and R01/2017). In all the in vivo studies, male Lister Hooded rats were 
used. They were housed in individually ventilated cages in groups of up to 4 per cage. Food 
and tap water were provided ad libitum. The temperature and humidity in the animal 
facility were 22 ± 1°C and 55 ± 2 % RH, respectively. The light was always turned on at 7 am 
and turned off at 7 pm. 
The number of animals used for each study is provided in the respective section. 
10.2 Stereotactic injection  
Prior to the surgery, the rats were anesthetized by one of the following methods: 
 Medetomidine (Domitor, Orion Corporation, Espoo, Finland) / midazolam 
(Midazolam-hameln, Hameln Pharma Plus GmbH, Hamelin, Germany) / fentanyl 
(Fentadon, Albrecht GmbH, Aulendorf, Germany) mixture in saline (0.15/2.0/0.005 
mg/kg bw, i.p.) – used in Studies 1 and 3. After the surgery, the flumazenil (Fresenius 
Kabi, Bad Homburg, Germany) / atipamezole mixture (0.75/0.20 mg/kg bw, s.c.) was 
administered as an antidote. 
 Isoflurane (Isoflurane CP, CP-Pharma Handelsgesellschaft mbH, Burgdorf, Germany) 
– oxygen (Hans Mast GmbH, Tuebingen, Germany) mixture (2.5 % for induction and 
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app. 1.7 % for maintenance) – used in Studies 4 and 5. In this case, fentanyl was 
additionally administered for analgesia (5 µg/kg bw, i.p.)  
The intracerebral injections were performed on a stereotactic frame (Stoelting Europe, 
Dublin, Irland), where the animal’s head was fixed with ear and tooth bars. The body 
temperature was maintained by a heating mat. In order to expose the skull surface, the skin 
was incised with a scalpel. Subsequently, a small hole was drilled in the skull at the location 
determined based on the rat brain atlas [16] (Figure 10.1). The following coordinates were 
used: 
 for the VTA injections in small rats (200-250g, Studies 1 and 3): 5.20 mm posterior, 
2.00 mm lateral to the bregma, and -8.00 ventral mm from the skull surface; 
 for the VTA injections in bigger rats (350-450g, Studies 4 and 5): 5.40 mm posterior, 
2.05 mm lateral to the bregma, and 8.05 mm ventral from the skull surface; 
 for the intrastriatal injections (Studies 3 and 5): 0.7 mm anterior, 3.2 mm lateral to 
the bregma, and -5.15 mm ventral from the skull surface. 
A B 
Figure 10.1. Stereotactic injection 
A. The stereotactic frame connected to the automatic infusion pump allows for a direct and precise 
administration of the tracer solution into the designated brain location. B. A small hole in the skull is drilled 
before insertion of the needle. 
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*Throughout this table, “buffer” refers to 10 mM Na (L+) ascorbate-buffered normal saline, even though the 
bicine solution used in Study 1 also served as a buffering agent. 
**Reduced concentration of the NaCl was used in order to achieve the final osmolality of 304 mOsm/L, which 
is close to the physiological value.  
Study Group N Injection solution 
Target region; 
inj. vol (µL); 
inj. rate (µL/min) 
1 
0 nmol 4 100 mM bicine 
Right VTA; 
0.05; 0.05 
0.5 nmol 4 5 nmol of MnCl2 in 100 mM bicine 
45 nmol 4 50 nmol of MnCl2 in 100 mM bicine 
3 
Exp. I 
VTA 4 
169 ± 24 kBq of 52Mn in buffer* Right VTA or STR; 
1.00; 0.25 STR 4 
VTA decayed 4 the same, but decayed solution 
3 
Exp. II 
Control – 90 min 2 
0.9 % NaCl 
Right VTA; 
1.50; 0.25 
Control – 24 h 2 
30 kBq – 90 min 2 
28 ± 6 kBq of 52Mn in buffer 
30 kBq – 24 h 2 
150 kBq – 90 min 2 
149 ± 10 kBq of 52Mn in buffer 
150 kBq – 24 h 2 
3 
Exp. III 
3 days 6 
20 ± 5 kBq of 52Mn in buffer Right VTA; 
1.50; 0.25 
14 days 6 
28 days 6 
Control 6 buffer 
4 
Control 8 0.9 % NaCl 
Right STR; 
1.00; 0.25 Cold Mn 8 50 mM MnCl2 in 0.45% NaCl**
 
Hot Mn 8 52Mn in buffer 
5 
CTRL 9 52Mn in buffer 
Right VTA; 
2.00; 0.25 
AMPA 7 52Mn in buffer with 100µM AMPA 
NMDA 10 52Mn in buffer with 1 mM NMDA 
AP-5 5 52Mn in buffer with 1mM AP-5 
TTX 10 52Mn in buffer with 5 µM TTX 
Cold Mn 4 52Mn in buffer with 25 mM Mn2+ 
 
Table 10.1. Summary of the injection procedures used in the in vivo studies 
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The injections were done using a 5 µL syringe with a 26 G needle (Hamilton Robotics, 
Bonaduz, Switzerland). The needle was inserted into the rat brain at an angle of 8 ° for the 
VTA injections, or at 0 ° for the intrastriatal injection. An automated pump (Stoelting) was 
used to deliver the solution into the target location. The injected volumes and infusion rates 
differed between the studies and are specified in Table 10.1. The table also summarizes all 
the pharmacological agents used for the stereotactic injections.  
After the end of the injection, the solution was allowed to diffuse over 7-8 min to prevent its 
backflow into the needle. Then, the needle was withdrawn at the approximate rate of 
1 mm/min. Finally, the hole in the skull was sealed with wax and the skin was sewn.  
In case of 52Mn administration, the radioactivity in the syringe was measured in a well 
counter (CRC-25R Dose Calibrator, Capintec Inc., Pittsburgh, PA, USA) before and after the 
injection.  
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11 Imaging Procedures 
11.1 PET measurements 
All the PET measurements were performed on µPET scanners (Inveon dedicated PET, 
Siemens Healthineers, Knoxville, TN, USA) which are characterized by the 10 × 10 × 12 cm3 
FOV. The Inveon Acquisition Workplace software (v.1.5.0.28, Siemens) was used for data 
acquisition which was performed with the energy window of 360-650 keV. Only in the 
phantom measurements different energy windows were used, as described in section 8.2. 
During the in vivo measurements, the rats were anaesthetized with the isoflurane (CP-
Pharma Handelsgesellschaft mbH) – oxygen (Hans Mast GmbH) mixture (2.5 % isoflurane 
for induction and 1.7 % for maintenance) and the body temperature was kept at 37 ± 0.5 °C 
by a rectal probe and a heating mat with a feedback loop control system. If the heating 
system was insufficient, a red light lamp was used in addition. 
The rats were scanned on individual MR-compatible beds (Bruker BioSpin) with the head 
fixed by tooth and ear bars. Additionally, a thin tube filled with a diluted 52Mn solution was 
put around the neck of the rat for later coregistration of the PET and MR images. Directly 
after the PET acquisition, the animal was transferred to the MRI scanner on the same bed. 
Only in Study 4, two rats were positioned head-to-head on the same bed for PET, while MRI 
was conducted individually for each animal. 
The durations of the PET acquisitions varied and are specified for each study in chapter 8. 
Each acquisition, with an exception for two volume phantom measurements, was followed 
by a 10 min transmission scan performed with a rotating 57Co source which was later used 
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for attenuation correction. All the PET data were also normalized and corrected for the 
tracer decay and the dead time of the detectors. 
All the PET images from the in vivo studies were reconstructed with OSEM3D (2 iterations)-
MAP (18 iterations) algorithm and the 256 × 256 matrix size. Different algorithms and 
matrix sizes were used in one phantom experiment, as described in section 8.2. 
11.2 MRI measurements 
In Studies 1 and 3, MRI was performed on a 7 T small animal MRI scanner (ClinScan, Bruker 
BioSpin, Ettlingen, Germany). Image acquisition was performed with Syngo MRI software 
(Siemens Medical Solutions, Erlangen, Germany). T2W and T1W images, as well as T1 maps, 
were obtained using the parameters presented in Table 11.1. 
 
Obtained image T2W T1W T1 map 
Sequence type Spin Echo         (SE) 
Gradient Echo 
(GE) 
Fast Low-Angle 
Shot (FLASH) 
TR 3000 ms 50 ms 10 ms 
TE 205 ms 3.65 ms 1.12 ms 
FOVr 57 mm 40 mm 34 mm 
FOVph 35.625 mm 40 mm 34 mm 
slice thickness 0.22 mm 0.31 mm 1 mm 
Matrix size 256 × 256 128 × 128 128 × 128 
Flip angles --------- --------- 6° and 34° 
Number of 
excitations (NEX) 1 1 2 
 
Table 11.1. Parameters of the MRI sequences used in Studies 1 and 3 
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Obtained image T2W T1W 
Sequence type 
Rapid Imaging 
with Refocused 
Echoes (RARE) 
FLASH 
TR 4264.78 ms 40 ms 
TE 11 ms 3.65 ms 
FOVr 32 mm 30 mm 
FOVph 35 mm 40 mm 
slice thickness 0.8 mm 0.3125 mm 
Matrix size 256 × 256 128 × 128 
RARE factor 8 --------- 
NEX 1 1 
 
Table 11.2. Parameters of the MRI sequences used in Study 4 and 5 
Another small animal 7 T MRI scanner (BioSpec, Bruker BioSpin) was used in Studies 4 
and 5. It was equipped with the ParaVision 6 acquisition software (Bruker Biospin). T2W 
and T1W images were acquired using the sequence parameters presented in Table 11.2. 
Both the scanners were equipped with a rat brain receiver coil (Bruker BioSpin).   
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12 Image Coregistration and VOIs 
PET and MR image analysis was performed with Pmod software v.3.2 (PMOD Technologies 
LCC, Zurich, Switzerland). For image analysis in Studies 1 and 3 (where smaller rats were used), 
the T1W (Study 1) and T2W (Study 3) images were first registered to the anatomical template. 
The template had been obtained by averaging T2W images of 5 rats of the same strain and similar 
body weight, not included in the present work. Subsequently, the T1 maps (Study 1) and the PET 
images (Study 3) were registered to their corresponding MR images. 
Volumes of interest (VOIs), ipsilateral and contralateral to the injection side, were drawn on the 
template in the coronal plane according to the rat brain atlas [16] and, subsequently, copied onto 
the coregistered T1 maps (Study 1) or PET images (Study 3). The following VOIs were included 
in the analysis of the images of the VTA-injected rats: NAc, STR, PFC, OT, AMG, and 
cerebellum (CER). In Study 1, only the first 3 of them were used. For the intrastriatally injected 
rats the following VOIs were included: GP, thalamus (THL), SN, and CER. The latter one served 
as a control region. The anatomical template and the VOIs are shown in Figure 12.1. 
Larger rats were used in Study 4 and their brain size matched the anatomical template and the 
VOIs provided in the Pmod software. Therefore, the MR images were firstly coregistered to that 
template and the PET images were subsequently coregistered to their respective MR images. 
Then, TACs were obtained from: the ipsilateral STR, the contralateral STR and the CER for the 
[11C]methylphenidate images, and from: the ipsilateral PFC, contralateral PFC and the pons 
(PON) for the [11C]flumazenil images. The TACs were used for kinetic modelling which was also 
performed with Pmod using the simplified reference tissue model (SRTM) [205]. 
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The [11C]methylphenidate data were modelled using the CER as the reference region and the 
[11C]flumazenil data were modelled using the PON as the reference region [206]. The estimated 
BPnd values were analyzed statistically, as will be described in the following chapter. 
Figure 12.1. VOIs used in Studies 1 and 3 
A. VOIs used for the image analysis of the rats injected into the VTA: PFC (blue), STR (red), NAc
(turquoise), OT (yellow), AMG (pink), and CER (green). B. VOIs used for the image analysis of the rats 
injected into the striatum: GP (violet), THL (yellow), SN (red), CER (green). Numbers in the upper right 
corners indicate the distance from the bregma in mm. C. 3D rendering of the VOIs shown in A. D. 3D 
rendering of the VOIs shown in B. Adapted from [8]. 
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Identification of the exact injection location was crucial in Study 5. Hence, the T2W MR images 
were coregistered to the rat brain atlas [16] which had been implemented in Pmod. This allowed 
identification of the injection location down to the subregion of the VTA. Subsequently, each of 
the 12 frames of the PET image was coregistered to its corresponding MR image. Before the 
coregistration, the MR and PET images were scaled by a factor of 0.05 in order to match the atlas 
dimensions. 
The VOIs used in Study 5 were drawn based on the atlas and they are depicted in Figure 12.2. 
They included: ipsilateral and contralateral OB, anterior olfactory nucleus (AON), prelimbic 
cortex (PLC), STR, NAc, horizontal limb of the diagonal band and the magnocellular nucleus 
(HLDB&MCN), VP, OT, and medulla oblongata (MO). TACs from these regions were used for 
the data analysis.  
Figure 12.2. VOIs used in Study 5 
 A. The VOIs were drawn in the coronal plane of the rat brain atlas. They included: OB (white), AON (orange), 
PLC (violet), STR (navy blue), NAc (light blue), HLDB&MCN (light green), VP (red), OT (yellow), and MO 
(purple). The numbers in the right upper corners indicate the distance from the bregma in mm. B. 3D 
renderings of the VOIs viewed from the caudal side (left) and from the rostral side (right). In the latter image, 
only the right VOIs are shown. 
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13 Quantitative Image Analysis 
Statistical analysis was carried out using SPSS Statistics 2.2 software (IBM Corporation, 
Armonk, NY, USA). Normal distribution of the data was always verified with the Shapiro-
Wilk test, homogeneity of variances with the Levene’s test, and sphericity with the 
Mauchly’s test.  
In Study 1, the group mean T1 values of the ipsilateral NA, STR and PFC at the baseline 
measurement were compared to their corresponding mean T1 values at the 24 h-time point 
measurement using a post-hoc Tukey’s test with the Bonferroni correction. The differences 
were considered significant for p < 0.05. 
In Study 2, the images of the resolution phantom reconstructed with different algorithms 
were compared visually. In the analysis of the images of the volume phantoms, the profile 
values obtained in the coronal plane were compared visually. 
In Study 3, the average concentration of the tracer in a given VOI in the PET image and the 
injected dose (ID) were used to express the results as [% ID]. The group means ± standard 
deviations (sd) are presented graphically.  
Additionally, the data from Experiment 3 were analyzed statistically. They were first log-
transformed to achieve normal distribution, and then analyzed with a mixed-design 
ANOVA. “Brain side” (ipsilateral or contralateral) was considered a between-subject factor 
(BSF) and “brain region” (NAc, OT, AMG, STR, PFC, and CER) – a within-subject factor (WSF). 
The omnibus test was followed by the Tukey’s post-hoc test. The differences were 
considered significant for p < 0.05. 
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In Study 4, the BPnd of the ipsilateral VOI (BPndR) was subtracted from the BPnd of the 
contralateral VOI (BPndL) for each individual animal. Then, the BPndL – BPndR differences 
of the Cold Mn group were compared to the BPndL – BPndR differences of the Control group 
using a 2-samples t-test. This was done separately for each tracer and each time point. In 
order to correct for these 4 comparisons, the p value of 0.0125 was used as the significance 
threshold. 
Additionally, the possible effect of the injection procedure alone was verified with a 
1-sample t-test performed on the BPndL – BPndR difference of the 24 h 
[11C]methylphenidate data and 48 h [11C]flumazenil data of the Control group. The p value 
of 0.05 was used for these tests. 
In Study 5, an additional VOI, covering the entire brain, was drawn for the dosimetry 
calculations, which will be described in the following chapter. The concentration of the 
tracer in all the other VOIs was expressed as the % of the activity in the whole brain 
[% WB]. The gradual changes in these concentrations over the 6 h of the PET scanning are 
graphically presented for individual rats and the characteristic patterns of the changes are 
compared beaten the groups. 
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14 Dosimetry 
OLINDA/EXM software (v.1.0, Vanderbilt University, Nashville, TN, USA) was used to 
estimate the absorbed dose (D) of the whole rat brain following the 52Mn injection into the 
VTA. In the first step, the absorbed doses for the masses range from 0.01 g to 20 g were 
computed using the OLINDA "sphere model" and the physical half-life of 52Mn. The natural 
logarithms of the doses and masses were fitted with a third order polynomial function for 
the interpolation of the absorbed doses corresponding to the measured data. 
The obtained coefficients were subsequently used to calculate the absorbed dose of the 
whole brain VOI (Figure 14.1.A) using its volume (1.98 cm3) as its mass (1.98 g) and the 
mean activity measured in the first frame of the PET images of three rats from the Control 
group, injected with 29.9, 30.6 and 31.8 kBq of 52Mn. The same was calculated for the 
injected VTAR-PBP region with 1 mm3 volume (Figure 14.1.B). 
No biological clearance of the tracer was assumed.  
Figure 14.1. VOIs used for dosimetry 
A. Whole brain. B. Right VTAR-PBP region shown from the rostral side. 
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15 Rotameter Test 
This behavioral test was based on the original work of Ungerstedt and Arbuthnott [207]. It 
was conducted using an automated rotameter system, composed of four hemi-spheres (TSE 
Systems GmBH, Bad Homburg, Germany), as shown in Figure 15.1.  The system records the 
number of clockwise and counterclockwise rotations the animal performs, registering a 
difference of 30° in its position.  
During the test, a rat was placed in the hemi-sphere and wore a corral which was connected 
to the recording unit by a wire. Its length was adjusted such that the animal could reach the 
edge of the hemi-sphere but could not go beyond it. After the first 10 min (which was 
considered the baseline), the recording was paused for 1-2 min in order to administer 
apomorphine (apomorphine hydrochloride, 0.25 mg/kg bw, s.c., Sigma Aldrich Chemie 
GmbH). Subsequently, it continued for 30 min, but the first 10 min recorded after the 
injection were considered the apomorphine uptake time and were not included in the 
analysis [208]. The remaining 20 min were divided into two 10 min bins and the number of 
the rotations performed during the two bins was averaged. This was considered the test 
measurement. The results are expressed as the ratio of the number of ipsilateral over 
contralateral rotations per 10 min (further referred to as “ipsilateral/contralateral 
rotations”).  
In Experiment 1 of Study 3, individual baseline and test results are presented graphically. 
The data of the rats from Experiment 3 in that study were analyzed statistically with SPSS 
Software 2.2 (IBM Corporation), employing a mixed-design ANOVA. For the analysis, 
“group” (3 days, 14 days, 28 days, or 28 days-control) was considered a BSF and the 
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Figure 15.1. Rotameter test – experimental setup 
“measurement” (baseline or test) a WSF. The assumptions of normal distribution and 
homogeneity of variances were tested with the Shapiro-Wilk test and the Levene’s test, 
respectively. The results were considered significant for p ≤ 0.05. 
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16 TH-Staining 
After dissection, brains were kept in 4 % paraformaldehyde solution (PFA) at 4 °C for 24 h, 
and then in 30 % glucose solution at 4 °C for at least 3 days. Subsequently, they were 
covered with TissueTek (VWR, Radnor, PA, USA) and stored at -20 °C until cutting on a 
cryotome (Leica Biosystems GmbH, Nussloch, Germany). From each brain, 20 µm sections 
were obtained in the coronal plane at the level of the injection (VTA-injected rats) or at the 
midbrain level (intrastriatally injected rats).  
The sections were directly immersed in tris-buffered saline (TBS) and this washing step 
was repeated three times for 10 min. Subsequently, the solution was changed to TBS with 
0.2 % triton and normal horse serum (NHS, Vector Laboratories Ltd., Peterborough, UK) 
and the preparation was placed on a shaker for 20 min. After this, the sections were 
incubated overnight in a bath composed of TBS, 0.2 % triton, NHS, and the primary 
monoclonal TH antibody (ImmunoStar, Inc., Hudson, NY, USA) which was used with the 
dilution of 1:1000. 
The next steps consisted of: washing three times for 10 min in the TBS with 0.2 % triton 
solution and incubating with the secondary antibody (biotinylated anti-mouse IgG antibody, 
Vector Laboratories Ltd.), used with the dilution of 1:1000, in TBS with 0.2% triton and 
NHS solution over 90 min on the shaker. After another series of washing (3 × 10 min in TBS 
with 0.2% triton), the sections were incubated with an avidin-biotin complex (Vectastain 
Elite ABC-Kit, Vector Laboratories Ltd.) for 60 min. Subsequently, the slices were washed 
again (3 × 10 min in TBS) and stained with 3,3'-diaminobenzidine (DAB, DAB Substrate Kit, 
Vector Laboratories Ltd.). The reaction was stopped by adding 2 drops of 30 % H2O2 
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solution. Following the final washing in TBS, they were placed on microscopic glass slides 
and left overnight to dry. 
NanoZoomer 2.0HT (Hamamatsu Photonics K.K., Hamamatsu, Japan) was used to analyze 
the stained tissue slices. Intensity of the staining of the injected VTA region (or the SN 
region in the STR-injected brains) was visually compared to the contralateral VTA (or SN). 
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17 γH2AX-Staining 
The dissected brains were immersed in 4% PFA and kept at 4 °C for 24 h. Then, ethanol 
solutions of increasing concentration (50 %, 70 %, 90 %, 100 %) were used for dehydration 
and xylene solution for washing (3 × 20 min). Wet brains were embedded in paraffin. 3 µm 
sections were cut in the coronal plane at the level of the injection using a Leica RM2235 
microtome (Leica Biosystems GmbH). They were placed on glass microscopic slides and left 
at 37 °C for 48 h to dry. The following steps preceded the staining: deparafinization 
(xylene), rehydration (ethanol solutions of decreasing concentration: 100 %, 96 %, 70 %, 
40 %), washing (phosphate-buffered saline, PBS), epitope retrieval (microwaving in a 
citrate buffer solution for 30 min), cooling, and final washing (PBS). 
The following agents were used in the staining procedure according to manufacturer’s 
instruction: anti-phospho-histone H2AX (Ser139) clone JBW301 antibody (Merck Millipore, 
Darmstadt, Germany), Tyramide Signal Amplification Kit (Alexa Fluor 488, Life 
Technologies GmbH, Darmstadt, Germany), and 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) (Sigma Aldrich Chemie GmbH).  
One section from each brain was used for a semi-quantitative analysis of the γH2AX foci, 
which was performed with a Zeiss Axio Imager MI fluorescence microscope (Carl Zeiss AG, 
Oberkochen, Germany). The microscope was equipped with a AxioCam MRm monochrome 
digital camera (Carl Zeiss AG) and controlled by AxioVision 4.8 software (Carl Zeiss AG).  
Three 230 µm × 170 µm “stack-images” were obtained from within the injected VTA region 
and three from the contralateral VTA. Each “stack-image” was composed of seven layers 
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acquired in different microscopic focus planes which were 0.25 µm away from each other. 
This is depicted in Figure 17.1. The seven layers were merged into a single 2D stack-image. 
The semi-quantitative analysis relied on counting all the nuclei visible in the image (further 
referred to as “cells total”) and the nuclei containing at least 3 γH2AX foci (“cells with foci”). 
The result was expressed as the “cells with foci/cells total” ratio, and the three numbers 
obtained at each brain side were averaged. Hence, for every brain there was one value for 
the ipsilateral VTA and one for the contralateral VTA. These were used to calculate group 
means and sd. 
 
  
Figure 17.1. Semi-quantitative analysis of the γH2AX-staining 
Three stack-images were acquired from the injected VTA and three from the contralateral VTA. The brain 
regions were identified based on the anatomical features visible in the DAPI-stained tissue. A disruption of 
the tissue at the brain surface additionally marked the injection position.  
Each stack-image was obtained by merging seven 2D images acquired at different microscopic focus planes. 
The results obtained from the three stack-images at each side were averaged and used to calculate the means 
and sd of the experimental groups. The scale bar in the lower left corner represents 1 mm. Adapted from[8].  
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18 PET with Online Recording of Blood 
Radioactivity 
18.1 Experimental setup 
The experimental setup (Figure 18.1) was composed of a µPET scanner (the same as 
previously described), a peristaltic pump (Ismatec REGLO Digital, Cole-Parmer GmbH, 
Wertheim, Germany), an infusion pump for a tracer administration (PHD 22/2000 Syringe 
Pump, Harvard Apparatus, Holliston, MA, USA), and a BS (Figure 18.2) which was build in-
house based on the previously proposed design [203]. Its detector system was based on the 
Cerium-doped lutetium oxyorthosilicate (Ce:LSO) and avalanche photodiodes (APDs). 
An arterial-venous shunt was surgically inserted into the left femoral artery and vein of a 
rat. It consisted of three pieces: the arterial piece (40 cm), the middle piece (30 cm), and the 
venous piece (25 cm). The former and the latter ones were made of a low density 
Figure 18.1. Experimental setup for PET with BS recording 
The experiment was carried out on the PET scanner. The rat was positioned on its back and 
the arterial-venous shunt was inserted on the left side. The catheter passed the BS and the 
peristaltic pump. The second catheter was inserted into the right femoral artery for MS. The 
tracer was administered with an infusion pump via the tail vein catheter. 
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polyethylene (LDPE) tube (ID = 0.4 mm, OD = 0.8 mm, Reichelt Chemietechnik GmbH, 
Heidelberg, Germany), while the middle piece was a Tygon tube (ID = 0.44 mm, 
OD = 2.26 mm, Ismatec). The three elements were connected with each other by steel 
connectors (1.5 cm long, ID = 0.3, OD = 0.63 mm, Ismatec). 
Additionally, a 25 cm long catheter for MS was inserted into the right femoral artery and 
a 20 cm long catheter for the tracer injection into the tail vein. Both the catheters were 
made of the LDPE tube described above. Importantly, the length of the MS catheter was the 
same as the length of the shunt from the animal to the centre of the FOV of the BS. 
The manual blood samples were collected to capillary tubes (Microvette CB 300 LH, 
Sarstedt, Nuembrecht, Germany).  
18.2 Experimental protocol 
Five rats were injected with approximately 60 MBq of [18F]FDG (0.5 mL over 25 s), which 
was directly followed by an injection of normal saline (0.1 mL over 5 s). The tracer 
Figure 18.2. Blood sampler 
The cassette with a groove for placing the 
catheter can be easily removed from and 
inserted in the BS. 
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administration, the PET acquisition, and the BS recording began simultaneously (0 s time 
point). The MS started 3 s earlier and continued until 75 s. The next blood samples were 
taken at 3, 6, 10, 15, 25, 40, and 60 min. Each sample was approximately 75 µL (3 drops) 
and this volume together with the number of samples collected during the first continuous 
sampling period were used to estimate the flow rate in the MS catheter.  
From each manual sample, 10 µL of the whole blood (wb) and 10 µL of the separated 
plasma (p) (centrifugation at 4000 rpm, 5 min, 5 °C, 25 cm diameter) were measured with a 
γ-counter (2480 WIZARD2, Perkin Elmer, Waltham, MA, USA). The temperature and the 
breathing rate of the rat were monitored during the experiment. 
The PET acquisition was followed by a 10 min transmission scan performed with a rotating 
57Co source which was later used for attenuation correction. After this, the venous piece of 
the shunt was cut and the coming out blood was collected to two Eppendorf tubes, each 
time for 30 s. The two volumes were measured by pipetting out and averaged. This was 
used to estimate the flow rate in the shunt. 
After each experiment, the BS was cross-calibrated with the well-counter. Moreover, the 
background activity was recorded and later subtracted from the BS dataset. The BS data 
were also decay-corrected before any further analysis. Additionally a set of nine 
independent measurements was carried out to estimate the sensitivity of the device. These 
measurements relied on a 5-6 min recording of the radioactivity whose level had been first 
defined in the well counter. 
 
 
112 |  
 
18.3 Dispersion  
The dispersion in the shunt was assessed in a separate measurement which was based on 
the previously proposed design [209]. The experimental setup (Figure 18.3) consisted of 
the BS, the peristaltic pump, and two cups filled with 16 mL of heparinized human venous 
blood. 0.45 mL of normal saline or of saline with 9.1 MBq of [18F]FDG was added to each of 
them. The cups were placed on magnetic stirrers which ensured proper mixing. All the 
components of the setup were connected by the same catheters which were used in the in 
vivo experiments. 
By turning the pump on, the blood from one cup (without the activity) was drawn in the 
catheter. Then, the pump was briefly paused and the end of the tube was moved to the 
second cup. By turning the pump on again, the blood with the radioactivity filled the 
catheter which was registered by the BS. The recording lasted approximately 1 min. 
Subsequently, the catheter end was placed back to the first cup. The entire procedure was 
repeated four times with cleaning the tube in between the trials. 
The decaying portions of the four recorded step functions were normalized to their 
Figure 18.3. Setup for dispersion measurement 
The setup consisted of two cups placed on magnetic stirrers, 
the BS, and the peristaltic pump (PP). The arrows indicate 
the direction of the blood flow in the catheter. 
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maximum values, and, as previously described [210], fitted with a monoexponential 
function: 𝑦 = exp ቀି௧
ఛ
ቁ, where τ is the dispersion factor and t is the time. The average τ 
value was used to model the impulse response function (IRF) of the setup according to the 
previously proposed method [210]. In this model the IRF is a monoexponential function: 
𝐼𝑅𝐹 = ଵ
த
exp ቀ− ௧
த
ቁ,  which can be used to deconvolve the recorded TAC. 
18.4 Data analysis 
The decay, dead time, and attenuation corrections, as well as normalization, were applied to 
the PET data. The images were reconstructed with the FBP algorithm using the following 
framing: 18 × 5 s, 1 × 30 s, 3 × 60 s, 1 × 180 s, 1 × 120 s, 1 × 300 s, 3 × 900 s. The two tissue 
compartment model (2TCM) assuming no dephosphorylation of FDG-6-phosphate (k4 = 0) 
[211], was used for the kinetic analysis of the right striatum. The analysis was performed 
nine times for ach rat. Each time the AIF was obtained in a different way: 
1. From the collected wb and p manual samples (“MS”). 
2. From the fitted manual samples (“MS-fit”) – The previously described fitting 
procedure [212] was used and the obtained data (𝑤𝑏ெௌି  and 𝑝ெௌ ) were used 
as the AIF. This was done to verify whether the fitting procedure would influence the 
KPs. 
3. From the fitted and dispersion-corrected manual samples (“MS-fit-dc”) – The IRF, 
normalized to the area under the curve equal 1, was used to deconvolve the 
𝑤𝑏ெௌି௙  and the 𝑝ெௌି௙  obtained previously. The outcome of the deconvolution 
was used as the AIF. This approach was considered the reference one throughout the 
study. 
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4. From the fitted and dispersion-corrected manual samples, with p values calculated 
using the population-based ௣
௪௕
 ratio (“MS-fit-dc-calc”) – A biexponential function has 
been shown to accurately describe the ௣
௪௕
 ratio for [18F]FDG in rats [202]. Hence, for 
each rat the ratio was first calculated using his original p and wb data:  
𝑝
𝑤𝑏
= 𝐴 ∗ 𝑒𝑥𝑝 ൬
−𝐵
𝑡
൰ + 𝐶 ∗ 𝑒𝑥𝑝 ൬
−𝐷
𝑡
൰ + 𝐸 
where t denotes time and A-E are the fit coefficients (Figure 18.4). To avoid a strong 
weighting by the many samples from the first 78 s, only the first-above-baseline 
(> 10 kBq/mL) and the last data point from this period were used. Next, the A-E 
coefficients obtained for each rat were averaged to provide group mean values (Am-
Em). These mean coefficients were used to compute the p values from the dispersion-
corrected 𝑤𝑏ெௌି௙௜௧: 
𝑝 = 𝑤𝑏ெௌି௙௜௧ିௗ ∗ (𝐴௠ ∗ 𝑒𝑥𝑝 ൬
−𝐵௠
𝑡
൰ + 𝐶௠ ∗ 𝑒𝑥𝑝 ൬
−𝐷௠
𝑡
൰ + 𝐸௠) 
This procedure served to evaluate the effect of using the population-based  ௣
௪௕
  ratio, 
rather than the true p data, to obtain the AIF on the KPs. 
5. From the BS data (“BS-calc”) – The original BS wb data and the p values calculated 
from that using the Am-Em coefficients, were used as the AIF. 
6. From the fitted BS data (“BS-fit-calc”) – The original BS data were fitted using the 
previously mentioned procedure. The p values were calculated from the 𝑤𝑏஻ௌି௙௜௧ 
using the Am-Em coefficients. 
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7. From the fitted and dispersion-corrected BS data (“BS-fit-dc-calc”) – The  𝑤𝑏஻ௌି௙௜௧ 
and  𝑝஻ௌି௙௜  obtained in the previous step were corrected for dispersion in the same 
way as described for the MS data. The resultant  𝑤𝑏஻ௌି௙௜௧ିௗ௖  and  𝑝஻ௌି௙௜௧ିௗ௖  were 
used as the AIF. 
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Figure 18.4. Plasma vs whole blood ratio 
A. Example wb and p TAC as measured with the γ-counter from the manually 
collected blood samples. B. The ቀ ௣
௪௕
ቁ ratio of the samples shown in A (black dots) 
and a biexponential fit to that data (red line). 
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8. From the PET image (“ID-calc”) – A VOI was drawn on the left ventricle of the heart 
in the PET image and the extracted TAC, together with the Am-Em coefficients were 
used to calculate the p values.  
9. From the fitted and dispersion-corrected combination of the BS and MS data (“BSMS-
fit-dc-calc”) – The first 10 min of the BS recording was combined with one blood 
sample manually collected at 60 min. The combined data were fitted as previously 
described and the obtained 𝑤𝑏஻ௌெௌି௙௜௧  was corrected for dispersion 
(𝑤𝑏஻ௌெௌି௙௜௧ିௗ௖). From this, the p values were calculated using the Am-Em coefficients. 
The mean KPs of the five rats, estimated with the approaches described above, were 
compared to the KPs obtained with the reference method (“MS-fit-dc”). 
 
 
 
 
  
RESULTS 
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19 Study 1 
The T1W MR images acquired 24 h after the stereotactic injections into the right VTA 
revealed a clear signal enhancement at the injection site in the brains treated with 45 nmol 
of Mn2+. This effect was hardly visible in the images of the animals injected with the 
0.5 nmol dose. No specific signal enhancement could be seen in the images of the Control 
group. Example images normalized to their maximum values are shown in Figure 19.1.A-B. 
After increasing the contrast in the images of the 45 nmol group, the mesolimbic pathway 
leading from the injected VTA to the ipsilateral nucleus accumbens could be recognized 
(Figure 19.1.C). 
Besides the visualization of the Mn2+ distribution, the T1W images allowed verification of 
Figure 19.1. Normalized T1W MR images 
24 h after the injection of 0, 0.5 or 45 nmol of Mn2+ into the right VTA, a relatively strong signal enhancement 
could be seen in the brains treated with the highest dose. This effect was very weak in the low-dose group. 
Typical images are shown in coronal (A) and sagittal (B) planes. An image of a rat injected with the 45 nmol 
dose is also shown in the horizontal plane in C. Increasing image contrast allowed visualization of the 
ipsilateral mesolimbic pathway leading from the VTA to the NAc (black arrow). Furthermore, a spot of an 
enhanced signal was noticed in the region corresponding to the right AMG (white arrow). 
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the injection location. In fact, a misinjection was recognized in one rat from each group. The 
data of these three animals were discarded from further analysis. 
The T1 maps obtained before and 24 h after the injection were used to quantitatively 
analyze the effect of Mn2+ on the T1 relaxation values in three ipsilateral brain regions 
known to receive the neuronal input from the VTA.  The results are graphically presented in 
Figure 19.2. 
The largest change was observed in the NAc of the rats treated with the 45 nmol dose – the 
T1 dropped from 2462 ± 137 ms to 2196 ± 160 ms (mean ± sd). A similar, although slightly 
weaker, effect was found in the STR of this group. Following the Mn2+ administration, the T1 
values changed from 2352 ± 110 ms to 2179 ± 179 ms. Contrary, hardly any difference was 
observed in the PFC – the T1 at the baseline and at the 24 h time point were 2077 ± 116 ms 
and 2089 ± 155 ms, respectively. 
In the 0.5 nmol group, much smaller and opposite changes were observed in the NAc and in 
Figure 19.2. Quantitative results of the T1 mapping 
Among the analyzed ipsilateral regions, the largest drop in the T1 value was observed in the NAc of the 
45 nmol group. There were no substantial changes in any of the region in the 0.5 nmol group. The bars 
represent group mean ± sd, n = 3 per group. 
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Figure 19.3. TH-stained brain tissue of rats treated with Mn2+ 
There was no sign of dopaminergic damage in the tissue slices from the Control group 
(A), neither from the 0.5 nmol group (B). In contrast, a clear reduction in the staining 
intensity was observed in the right VTA of the rats treated with the 45 nmol dose as 
compared to their contralateral VTA (C). 
the STR. The T1 rose from 2530 ± 75 ms to 2587 ± 259 ms and from 2324 ± 107 ms to 
2440 ± 211 ms, respectively. Similarly to the 45 nmol group, hardly any change was 
observed in the PFC. The T1 was 2144 ± 61 ms at the baseline and 2171 ± 171 ms at 24 h 
post-injection.  
The T1 values in the Control group also hardly changed in the ipsilateral PFC as well as in 
the STR. The respective results were 2191 ± 90 ms and 2427 ± 57 ms at the baseline, and 
2152 ± 93 ms and 2406 ± 103 ms at the 24 h time point. Somewhat surprisingly, a drop in 
the T1, from 2680 ± 132 ms at the baseline to 2454 ± 153 ms was found in the ipsilateral 
NAc. 
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ANOVA was conducted in order to evaluate the data statistically. Although it did indicate a 
significant interaction between the group, the region, and the time point (F(4,12) = 3.58, p = 
0.04), there was no significant difference between the groups at any time point and in any 
region in the post-hoc test. 
The TH-staining of the brain tissues obtained 4 weeks after the Mn2+ injections revealed 
a dopaminergic lesion in the VTA treated with the highest dose. This was visible as 
a reduced staining intensity of the neurons within the right as compared to the left VTA. 
This effect was not found in any of the animals from the 0 nmol or 0.5 nmol groups Figure 
19.3. 
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Figure 20.1. PET Images of the resolution phantom 
The images of the phantom filled with the 52Mn solution are shown in the coronal (A), 
sagittal (B), and axial (C) planes. The smallest rod volumes that could be resolved in any 
of the images were the 1.35 mm diameter rods (pointed by the arrows). They appeared 
clearest in the images reconstructed with the OSEM3D-MAP algorithm and the matrix size 
of 256 × 256 [8]. 
20 Study 2 
The PET images of a 52Mn-filled resolution phantom were acquired and reconstructed with 
different algorithms and matrix sizes to evaluate the appearance of small volumes. This was 
important because brain regions such as VTA or SN, whose volumes are in the range of 
1-2 mm3, would be possibly imaged in in vivo PET studies.  
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The 0.75 mm and 1.00 mm diameter rods of the phantom could not be resolved in any of 
the obtained images. However, the OSEM3D-MAP algorithm provided images in which the 
1.35 mm diameter rods could be distinguished (Figure 20.1). Moreover, the edges of these 
rods appeared sharper and the spaces between them clearer, when the 256 × 256 matrix 
size was applied. Therefore, the OSEM3D-MAP algorithm and the 256 × 256 matrix size 
were used for reconstructing all the in vivo PET data. 
Subsequently, two volume phantoms were used in order to verify the effect of the energy 
window used for the acquisition of the PET data. This was done by comparing the peak-
normalized profiles of the values measured in the coronal plane of the images. The exact 
positions of the evaluated image planes are presented in Figure 20.2 and the profiles in 
Figure 20.2. PET images of the volume phantoms 
A. 1.5 mL Eppendorf tube filled with 52Mn solution. The phantom 
was surrounded by the air. B. A plastic syringe filled with 52Mn 
solution was closed inside a falcon tube filled with water. The water 
surrounding was meant to imitate a biological tissue. Both the 
phantoms are shown in the coronal (left), sagittal (middle) and axial 
(right) planes. The color scales were adjusted to visualize higher 
activity present by the walls of the phantoms. The blue lines indicate 
the position at which the image profiles were obtained. The scale 
bars represent 1 cm. 
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Figure 20.3. Profiles of the volume phantoms PET images 
A. Profile of the Eppendorf tube phantom. B. Profile of the syringe phantom. 
For each phantom the image acquisition was performed with 4 different 
energy windows, as indicated in the legends. 
Figure 20.3. 
For both phantoms, the image profiles acquired with 4 different energy windows were very 
similar to each other. The right wall of the phantom was located in the very center of the 
FOV and the values of the profiles corresponding to this location were exactly overlain. 
Despite the slightly larger distance from the center of the FOV, the values of the profiles 
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corresponding to the other wall of the phantom were also close to each other. Therefore, it 
appeared that applying a narrower energy window than the standard 350-650 keV did not 
have a substantial effect, regardless of the surrounding environment (air or water). Thus, 
the standard energy window was used for all the in vivo studies. 
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21 Study 3 
21.1 Experiment 1 
21.1.1 Purity of the tracer solution 
The ICP-OES measurement of the metals in the tracer solution indicated presence of 
manganese, iron and chromium. The contents calculated per injected dose (1 µL) were as 
follows: 
 Mn: 2.1 ng (38.3 pmol) 
 Fe: 0.9 ng (16.9 pmol) 
 Cr: < 0.2 ng (< 3.8 pmol) 
No other metal contaminants were detected. The specific activity (SA) at the injection times 
was 3.18-3.30 GBq/µmol. 
21.1.2 PET 
24 h after the 52Mn injection into the right VTA, the mesolimbic and the mesostriatal 
pathways could be easily recognized in the acquired PET images (Figure 21.1.A). The 
highest content of the tracer was found in the ipsilateral NAc, confirming its transport along 
the mesolimbic tract. The second highest accumulation was detected in the ipsilateral STR 
consistently with the trace of 52Mn along the mesostriatal pathway observed in the images. 
A relatively high content was also found in the OT. The ipsilateral AMG and PFC 
accumulated lower amounts, and CER, used as a reference region, was characterized by the 
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lowest concentration. The exact quantitative results are presented in Figure 21.2.A and 
Table 21.1. 
Importantly, in all the analyzed brain areas but CER, there was more tracer detected on the 
ipsilateral than on the contralateral side. 
Figure 21.2. Quantification of the 52Mn distribution in PET images (Experiment 1). 
A. 24 h after 52Mn injection into the right VTA, the highest content of the tracer was found in the ipsilateral 
NAc, STR, and OT. A lower signal was detected in the AMG and PFC. In all the analyzed regions, except for the 
CER, there was higher 52Mn accumulation on the ipsilateral than the contralateral side. B. After injection into 
the right STR the tracer content in the adjacent GP, THL, and the ipsilateral SN was higher than in the 
respective contralateral areas. This was not the case for the CER. Bars represent mean + sd, n = 4, [8]. 
 
Figure 21.1. 52Mn  distribution in PET images (Experiment 1). 
A. Following injection into the VTA, 52Mn was transported along the mesolimbic and mesostriatal pathways. 
The arrow and arrowhead indicate the tracer accumulation in the NAc and the STR, respectively. B. After 
administration into the STR, 52Mn traced the striatonigral pathway, reaching the SN (arrow). Its accumulation 
in the THL was also prominent (arrowhead) [8]. 
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In the PET images of the rats injected into the STR, the striatonigral pathway, leading to the 
ipsilateral SN, was clearly delineated by 52Mn (Figure 21.1.B). The tracer accumulation was, 
once again, always higher in the ipsilateral than in the contralateral region for all the 
analyzed areas, except for the CER (Figure 21.2.B). As could be expected, the GP, situated 
adjacently to the injection site, was characterized by the highest content of the tracer, but a 
substantial amount of 52Mn accumulated also in the THL. Most importantly, SN, the target 
region of the direct striatonigral pathway, also contained a relatively high 52Mn amount.  
Similarly to the first group, the smallest fraction of the injected dose was found in the CER. 
The exact values are presented in Table 21.2. 
 
 
 
 
 
 
 
 
 
 
 
Region 
Ipsilateral 
(%ID/mm3) 
Contralateral 
(%ID/mm3) 
Nucleus accumbens 0.25 ± 0.04 0.04 ± 0.01 
Striatum 0.18 ± 0.05 0.02 ± 0.00 
Olfactory tubercle 0.12 ± 0.02 0.02 ± 0.01 
Amygdala 0.05 ± 0.01 0.01 ± 0.00 
Prefrontal cortex 0.04 ± 0.01 0.02 ± 0.00 
Cerebellum 0.02 ± 0.00 0.02 ± 0.00 
 
Table 21.1. 52Mn content in brain regions 24 h after injection into the VTA 
The values represent group means ± sd, n = 4.  
Region Ipsilateral [%ID/mm3] 
Contralateral  
[%ID/mm3] 
Globus pallidus 1.16 ± 0.14 0.01 ± 0.00 
Thalamus 0.31 ± 0.05 0.01 ± 0.00 
Substantia nigra 0.14 ± 0.06 0.01 ± 0.00 
Cerebellum 0.01 ± 0.01 0.01 ± 0.01 
 
Table 21.2. 52Mn content in brain regions 24 h after injection into the STR 
The values represent group means ± sd, n = 4. 
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Figure 21.3. Results of the rotameter test (Experiment 1) 
The ratio of the ipsilateral vs contralateral rotations was at least 2 times 
higher after the dopaminergic stimulation with apomorphine (test) than 
during the baseline measurement in two rats injected into the ventral VTA (A) 
and two rats injected into the STR (B). This effect was not present in any of the 
rats treated with the decayed solution (C). The average results of the three 
groups are compared in D. Bars represent mean + SD, n = 4, [8]. 
21.1.3 Rotameter test 
The animals’ performance in the rotameter test was examined 4 weeks after the 
intracerebral administration of 52Mn. All the rats rotated approximately equally to both 
directions during the baseline measurement, which resulted in the average 
“ipsilateral/contralateral rotation” of 0.9 ± 0.1 in the VTA group, 1.0 ± 0.2 in the STR group, 
and 1.2 ± 0.2 in the VTA decayed group. 
However, two animals from the VTA and two from the STR group exhibited 2-7 times 
increase in the measured parameter following dopaminergic stimulation with apomorphine 
(test). This indicated an imbalance of the dopaminergic system involved in the motor 
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Figure 21.4. Results of the TH-staining (Experiment 1) 
Example tissue sections of a rat from the VTA group (A), from the STR group (B), and from the VTA decayed
group (C) are shown in the middle. The small rectangles in each image indicate the locations of the higher 
magnification sections shown sidewise. Staining intensity of the neurons within the injected VTA and the SN 
ipsilateral to the injected STR were reduced in some rats as compared to the contralateral regions. This was 
not found in any of the brains treated with the decayed solution. The scale bar in A corresponds to 20 µm and 
applies to all the high magnification images [8]. 
control. Crucially, this effect was not present in any of the rats from the VTA decayed group 
(Figure 21.3). 
21.1.4 TH-staining 
The TH-staining was performed on the brain tissue from all the rats. In some animals from 
the VTA and STR groups, the staining intensity at the injection side was reduced as 
compared to the contralateral region (Figure 21.4.A-B). This indicated a lesion of the 
dopaminergic neurons. In contrast, both VTAs were stained approximately equally in the 
rats treated with the decayed solution (Figure 21.4.C). 
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This result was in line with the outcomes of the rotameter test and suggested that the 
observed dopaminergic lesion was not caused by the metal contaminants present in the 
solution, but rather by the radiation dose. Further investigation of the impact of the 
radioactivity doses was conducted in Experiment 2. 
21.2 Experiment 2 
γH2AX staining was performed on the brain tissue sections of the rats injected with either 
30 kBq or 150 kBq of 52Mn and sacrificed 90 min or 24 h after the injection. 
The results evaluated at the 90 min time point are presented in Figure 21.5. The increased 
number of foci, visible as green spots and clusters, is clear in the image of the VTA injected 
with the higher dose (Figure 21.5.E) as compared to the contralateral side (Figure 21.5.F) or 
to the VTA treated with the lower dose (Figure 21.5.C). Only sparse foci were present in the 
latter one, which was similar to the result in the control group (Figure 21.5.A). In the 
contralateral VTA of the 30 kBq and control groups, hardly any foci were found (Figure 
21.5.B and D). 
The semi-quantification of the images supported the qualitative results, showing an 
approximately 7 times higher fraction of cells with foci in the high dose group than in the 
low dose and Control groups. The number of the cells with foci vs the total number of cells 
in the contralateral VTA of the 150 kBq group was also elevated (Figure 21.7.A). 
In the tissue sections evaluated 24 h after the 52Mn injection, it appeared that the highest 
concentration of the foci was once again in the ipsilateral VTA of the 150 kBq group, 
although the foci were not as abundant as at 90 min post-injection (Figure 21.6.E and F). 
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                     Injected VTA          Non-injected VTA 
Figure 21.5. Results of the γH2AX staining – 90 min 
Example microscopic images of the brain tissue sections of: a rat from the Control group (A, B), from the 
30 kBq group (C, D), and from the 150 kBq group (E, F). An increased number of foci was apparent in 
the images of the VTA injected with the highest radioactivity dose. This was in contrast to the tissues 
treated with the 0 or 30 kBq doses. The scale bar in A represents 10 µm and applies to all the images, 
[8]. 
The images of the 30 kBq and the Control groups were similar to those from the first time 
point, although some more foci could be seen in the controls (Figure 21.6.A-D). 
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                     Injected VTA          Non-injected VTA 
Figure 21.6. Results of the γH2AX staining – 24 h 
Example microscopic images of the brain tissue sections of a rat from the Control group (A, B), from the 
30 kBq group (C, D), and from the 150 kBq group (E, F). An increased number of foci in the VTA injected 
with the highest dose was less apparent than at 90 min post-injection. Moreover, more foci were 
present in the contralateral VTA of this group as compared to the first time point. The number of foci in 
both the VTAs of the Control and 30 kBq groups appeared unchanged. The scale bar in A represents 
10 µm and applies to all the images, [8]. 
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This more homogenous distribution of the foci across the groups observed at the 24 h time 
point was reflected in the semi-quantitative results. They showed that the average “cells 
with foci/cells total” ratio in the VTAs treated with 150 kBq of 52Mn was only twice higher 
than in the VTAs of the control rats (Figure 21.7.B).  
21.3 Experiment 3 
21.3.1 Purity of the tracer solution 
Among the metals tested for with the ICP-OES, only Mn and Cr were detected.  There was 
0.1 ng (1.6 pmol) of the former element, and < 0.14 ng (< 2.7 pmol) of the latter one in the 
injection volume (1.5 µL). 
The SA at the injection times was 21.3-23.8 GBq/µmol, i.e. it was approximately 7 times 
higher than in Experiment 1. 
Figure 21.7. Semi-quantitative results of the γH2AX staining 
A. 90 min post-injection, the fraction of the cells with foci at the injection site was clearly highest in 
the 150 kBq group. It was also increased in the contralateral VTA of this group as compared to the 
Control and the 30 kBq groups. B. 24 h after the 52Mn administration, the fraction of the cells with foci 
was still highest in the 150 kBq group, although this effect was as strong as at the first time point. The 
bars represent mean + sd, n = 2/group/time point, [8]. 
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Figure 21.8. 52Mn distribution in PET images 
(Experiment 3) 
The tracer transport from the injected VTA to the 
ipsilateral NAc (arrow) and STR (arrowhead) was 
clearly visible in the PET images following 
administration of the reduced 52Mn dose. This
distribution pattern closely resembled the one 
observed in the PET images in Experiment 1, [8]. 
21.3.2 PET 
Following the outcomes of Experiments 1 and 2, the feasibility of imaging the neuronal 
pathways with a reduced dose of 52Mn (~20 kBq) was tested in 18 rats injected into the 
right VTA. The tracer distribution pattern in the PET images acquired 24 h post-injection 
closely resembled the one observed in Experiment 1. Once again, the ipsilateral mesolimbic 
and nigrostriatal pathways were clearly delineated (Figure 21.8). 
The results obtained by the VOI-based quantification of the images were also similar to 
those from Experiment 1. Namely, the highest 52Mn content was found in the ipsilateral NAc 
(0.17 ± 0.05 %ID/mm3). The OT and STR accumulated 0.11 ± 0.04 and 0.10 ± 0.03 
%ID/mm3, respectively, while the AMG and PFC accumulated lower amounts (0.05 ± 0.01 
and 0.03 ± 0.01 %ID/mm3, respectively). Similarly to Experiment 1, 52Mn content in the 
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contralateral regions was always lower compared to the ipsilateral ones. Only the CER, 
which served as a control region, accumulated the same amounts on both sides (0.01 ± 0.01 
%ID/mm3). This is shown in Figure 21.9.A. 
Statistical analysis of the PET data with ANOVA showed a significant interaction between 
the “region” and the “brain side” factors (F(2.93, 99.44) = 61.00, p < 0.001). The following 
Figure 21.9. Quantification of the 52Mn distribution 
(Experiment 3) 
A. The VOI-based analysis revealed a very similar pattern 
of the tracer distribution to the one observed in 
Experiment 1. The tracer concentration was always higher 
in the ipsilateral than in the contralateral region, and this 
difference was not found only in the reference VOI, the 
CER. B. Statistical analysis of the log-transformed data 
confirmed that the observed differences were significant. 
Bars represent mean ± sd, n = 18, *** p < 0.001, [8]. 
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post-hoc test revealed a highly significant difference (p < 0.001) between the ipsilateral and 
the contralateral side for all the regions but the CER (p > 0.05) (Figure 21.9). 
21.3.3 Rotameter test 
The test was performed at different time points after the 52Mn injections. Six rats were 
tested at 3 days, six at 14 days and six at 28 days post-injection. The Control group was 
examined only at the 28 days-time point. 
The average “ipsilateral/contralateral rotation” ratio was similar between the experimental 
groups during the baseline measurement. The exact scores were: 0.9 ± 0.1 in the 3 days 
group, 1.1 ± 0.4 in the 14 days group, 1.2 ± 0.4 in the 28 days group, and 1.0 ± 0.2 for the 
control animals. The results obtained during the test measurement (i.e. after the 
administration of apomorphine) remained in the same range, yielding: 1.0 ± 0.7 in the 
3 days group, 1.2 ± 0.5 in the 14 days group, 1.1 ± 0.8 in the 28 group, and 0.8 ± 0.6 in the 
controls. These results are shown in Figure 21.10. 
Figure 21.10. Results of the rotameter test 
(Experiment 3) 
There was no significant difference between 
the groups neither at the baseline, nor at the 
test measurement. Bars represent mean + sd, 
n = 6 per group, [8]. 
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Figure 21.11. Results of the TH-staining (Experiment 3) 
No differences in the staining intensity between the ipsilateral and contralateral VTAs were found at 
the examined time points: 3 days (A), 14 days (B), or 28 days (C) after the 52Mn injection. Similarly,, 
there was no effect in the Control group (D), [8]. 
When compared statistically with ANOVA, neither the main effects ((F(1, 20) = 0.05, p > 
0.05 for “measurement”, F(3, 20) = 0.62, p > 0.05 for “group”), nor the interaction between 
the two factors (F(3, 20) = 0.59, p > 0.05) were significant. 
21.3.4 TH-staining 
On the following day after the rotameter test, the rats were sacrificed and the brains were 
used for the TH-staining. There was no difference in the staining intensity between the 
injected and the contralateral VTA regions in any of the examined tissue sections (Figure 
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21.11). Therefore, the ability of the dopaminergic neurons to synthetize tyrosine 
hydroxylase despite the treatment with ~20 kBq of 52Mn was confirmed for up to 4 weeks 
post- injection.  
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22 Study 4 
This study aimed at verifying whether a single intrastriatal injection of non-radioactive 
Mn2+ or 52Mn could affect DAT or GABAA receptors (GABAAR), either shortly- (i.e. 24-48 h) 
or later (i.e. 4 weeks) after a direct intracerebral injection. Due to the difficulties associated 
with subtracting the 52Mn signal, still present at the injection site up to 1 month after the 
administration (Figure 22.1), from the image containing the “mixed” signal of 52Mn and the 
[11C]-tracer, the data of the Hot Mn group were not analyzed. 
The SA of [11C]methylphenidate as well as of [11C]flumazenil varied substantially across the 
measurements. It ranged from 9.2 to 74.6 GBq/µmol for the first tracer, and from 19.9 to 
66.8 GBq/µmol for the second one. The SA of [11C]flumazenil used for the measurement of 
the two rats from the Cold Mn group at 48 h  was even beyond this range (233.6 GBq/µmol). 
At the 24 h time point, the BPnd of [11C]methylphenidate in the right STR was 0.99 ± 0.09 
(mean ± sd) in the Control group and 1.01± 0.11 in the Cold Mn group, while the 
contralateral values were 0.95 ± 0.04 and 0.93 ± 0.08, respectively. 4 weeks later, the BPnd 
of the injected STR was 1.00 ± 0.09 in the control rats and 1.00 ± 0.15 in the treated 
Figure 22.1. 52Mn in the right STR 29 days after the administration 
The coronal (A), sagittal (B), and axial (C) views are shown. The blue lines in each image plane indicate the 
position of the two other planes. Due to this remaining 52Mn signal and the difficulties associated with 
subtracting it from the PET images of the [11C]-tracers, the data of the Hot Mn group were not evaluated. 
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animals, while the respective contralateral values were 1.07 ± 0.10 and 1.05 ± 0.15 (Figure 
22.2.A). 
The BPnd of [11C]flumazenil in the FC was estimated 2 and 30 days post-injection. In the 
Control group, it was 0.87 ± 0.10 in the ipsilateral region and 0.90 ± 0.08 on the 
contralateral side, while the corresponding values of the Cold Mn group were 0.69 ± 0.13 
and 0.83 ± 0.12. At the later time point, the BPnd in the control rats was 0.97 ± 0.13 on the 
ipsilateral and 0.97 ± 0.14 on the contralateral side, while in the rats treated with Mn2+, the 
corresponding values were 0.84 ± 0.10 and 0.89 ± 0.07 (Figure 22.2.B). 
In order to statistically analyze these results, the BPndL-BPndR differences were compared  
Figure 22.2. Results of the kinetic modelling of [11C]methylphenidate and 
[11C]flumazenil PET studies 
A. BPnd of [11C]methylphenidate in the STR evaluated 1 and 29 days after the injection of 
Mn2+ (Cold Mn group) or normal saline (CTRL) into the right STR. B. BPnd of [11C]flumazenil 
in the FC estimated in the same animals 2 and 30 days post-injection. Bars represent mean ± 
sd, n = 8 per group. 
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Figure 22.3. Left-right differences in the BPnd of [11C]methylphenidate and 
[11C]flumazenil after an intrastriatal Mn2+ injection 
A. The BPndL-BPndR of [11C]methylphenidate measured in the STR were not significantly 
different between the experimental groups at ta any of the evaluated time points. B. The 
BPndL-BPndR of [11C]flumazenil measured in the FC where significantly larger in the Cold 
Mn group than in the control rats 2 days after the administration of Mn2+. This difference 
was not significant anymore 30 days post-injection. N = 8 per group, *p < 0.0125. 
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between the Cold Mn group and the Control group. This was done separately for each tracer 
and each time point. The BPndL-BPndR differences of the [11C]methylphanidate data were 
not significantly different between the groups at any time point, indicating no effect of 
50 nmol of Mn2+ on the DAT in the rat striatum (Figure 22.3.A). However, the right-left 
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differences in the BPnd of [11C]flumazenil were significantly greater in the Cold Mn group 
than in the Control group at the first time point, indicating an impact of the intrastriatally 
administered Mn2+ on the GABAA receptors in the cortex. 30 days post-injection, this effect 
was not present anymore (Figure 22.3.B).  
Interestingly, Mn2+ presence in the ipsilateral FC was clearly visible in the T1W MR images 
of the Cold Mn group 24 h post-injection (Figure 22.4). 
In order to verify whether the intrastriatal sham injection had any effect on the DAT at 
1 day, or on GABAAR at day 2, the BPndL-BPndR differences of the Control group were 
analyzed with a 1-sample t-test. However, the tested mean differences were not 
significantly different from 0 (p > 0.05), indicating no impact of the injection procedure. 
Figure 22.4. Mn2+ neuronal transport 24 h after the intrastriatal injection 
A. An example T1W image of a rat from the Cold Mn group shown in the coronal 
(left), sagittal (middle) and axial (right) planes. Mn2+ transport to the SN (arrow) 
and THL (arrowhead) are clearly visible. The signal enhancement in the 
ipsilateral FC (cross-section of the blue lines) suggests that Mn2+ had reached 
also that area. B. An example T1W image of a Control rat at the same time point.  
A 
B 
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Figure 23.1. Identification of the injection location  
A. The injection location (arrow) could be easily recognized in the coronal (left) 
and sagittal (right) plane. In many cases the needle track was also visible 
(arrowhead). B. The injection location was marked (intersection of the blue lines) 
and its anatomical position was read out from the overlaid brain atlas. 
23 Study 5 
23.1 Dependence of the 52Mn distribution on the 
pharmacological treatment 
The goal of this study was to investigate whether the distribution of 52Mn unilaterally 
injected into the VTA would be affected by a co-injection of a pharmacological agent known 
to influence neuronal activity. However, due to the numerous neuronal projections of the 
VTA originating from its different subregions, the tracer distribution pattern may also 
depend on the exact location of the injection. Therefore, the injection location was carefully 
evaluated in the first place. This could be readily done based on the T2W MR images which 
were coregistered to the anatomical atlas of the rat brain. The example of one rat is 
presented in Figure 23.1. 
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Figure 23.2. Injection locations identified based on the MR images 
The identified locations are depicted on the rat brain atlas and the number on the left side indicates the 
distance from the bregma. The smaller images on the right side show a magnification of the injection area. 
Each dot in these images represents one animal. Injection locations identified within the VTAR or PBP are 
shown in green (n = 22), the locations within the PN or the PIF of the VTA are marked in yellow (n = 6), and 
the injection location within the RN are depicted in orange (n = 7). All the injection sites identified in other 
regions were considered incorrect and are represented by the red dots (n = 9).  
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In some images, the injection volume appeared relatively large and spread across a few 
slices. In those cases, the slice in which the needle track was visible was selected. In one 
animal from the NMDA group, a form of brain atrophy was identified. The data of that 
subject were rejected from further analysis. 
Evaluation of the injection locations revealed that 28 rats were injected into the VTA, 
7 were injected into the red nucleus (RN), which is located dorsally to the VTA, and the 
injection sites of the remaining 9 rats were identified in different locations around the VTA 
and RN. These 9 injection locations were considered incorrect and the data were excluded 
from further analysis. The incorrect injection sites are depicted as red dots in Figure 23.2.  
Since the target region of a VTA neuron may depend on the subnucleus of the VTA in which 
its soma is situated [41], the 28 animals injected into the VTA were further subdivided. 
Namely, the rats whose injection location was identified within the rostral VTAR or the PBP 
were grouped together, as these nuclei are anatomically very close to each other. The rats 
Table 23.1. The numbers of the rats injected into different subregions of the dopaminergic 
midbrain 
Based on the identified injection location, the animals were assigned to one out of three groups: VTAR-
PBP, PN-PIF, or RN. The remaining rats (Other) were rejected from further analysis. 
Experimental group 
Injection location 
VTAR-PBP PN-PIF RN Other 
CTRL 4 1 1 3 
AMPA 4 1 1 1 
TTX 4 3 1 2 
NMDA 4 1 3 1 
AP5 2 0 1 2 
Cold Mn 4 0 0 0 
Total 22 6 7 9 
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injected into the PN or the PIF of the VTA were considered the second group. These two 
small nuclei are also adjacent to each other. They are located medially and caudally to the 
VTAR-PBP. The 7 rats injected into the RN constituted the third group. This is summarized 
in Table 23.1. 
Only the data of the rats injected into the VTAR-PBP regions were included in the analysis 
of the effects of the pharmacological agents. There were 2-4 rats per a pharmacological 
agent in this group, which was sufficient for the comparison. Among the animals injected 
into the PN-PIF regions and into the RN, there were usually 0 or 1 rats per a 
pharmacological agent. 
Firstly, based on the qualitative evaluation, no differences in the 52Mn distribution pattern 
was noticed between the PET images of the rats treated with almost any of the 
pharmacological agent and the images of the control rats. The only group in which the 
tracer appeared to have a distinctive distribution was the Cold Mn group. Specifically, while 
the mesolimbic and the mesostriatal pathways were clearly delineated by 52Mn in the 
images of the control animals, it was difficult to identify these neuronal tracts in the images 
of the Cold Mn group (Figure 23.3).  
This blocking effect of non-radioactive Mn2+ could be clearly recognized also based on the 
image quantification. Among the three analyzed brain regions, the ipsilateral NAc and STR 
were characterized by a lower rate of increase in the 52Mn content over time in the rats 
from the Cold Mn group than in the control animals. This effect was not present in the 
ipsilateral PLC. In the contralateral NAc, STR, and PLC, the content of the tracer was not 
changing over time (Figure 23.4). 
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Figure 23.4. 52Mn transport to the main output regions of the VTA – Cold Mn group 
The transport rate of the tracer was clearly lower in the ipsilateral STR and NAc in the rats co-
injected with non-radioactive Mn2+ as compared to the control group. This effect was not visible in 
the PLC over the time of the measurement. Each line represents data of one animal. 
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Non-radioactive Mn2+ was the only tested pharmacological agent which had an impact on 
the spatial distribution of 52Mn in the rat brain. There were no obvious differences in the 
rate of the 52Mn accumulation and its distribution in any of the three analyzed VOIs 
between the AMPA group and the CTRL group (Figure 23.5), between the TTX group and the 
CTRL group (Figure 23.6), neither between the AP5 or NMDA groups and the controls 
(Figure 23.7). In all these animals, the pattern of the PET tracer distribution resembled the 
pattern seen in the previous studies. Namely, a substantial transport of the tracer could be 
recognized in the ipsilateral NAc and STR (but not the PLC), the main output regions of the 
VTA, while only marginal changes were observed in the contralateral regions. Only one 
NMDA rat was characterized by a clearly higher 52Mn concentration in all the analyzed 
ipsilateral regions.  
Since AMPA, NMDA, TTX, and AP5 appeared not to have an impact on the 52Mn distribution, 
all these rats (total of 18) could be grouped together based on the same injection location 
(VTAR-PBP) and compared to the six rats injected into the PN-PIF regions and to the seven 
rats injected into the RN. Two interesting observations were made in this comparison. 
Firstly, a strong signal was visible along the neuronal tract leading from the midbrain to the 
OB in the very first frame of the PET images of the PN-PIF group. This was much weaker in 
the images of the rats from the VTAR-PBP group (Figure 23.8). Based on the registered 
anatomical atlas, the high signal was identified in the following ipsilateral regions: VP, OT, 
OB, AON, HLDB, and MPN. 
The second characteristic pattern was noticed in the last frame of the PET images of the rats 
injected into the RN. The neuronal pathway delineated with 52Mn projected into the caudal 
direction crossing the midline of the brain. It extended along the contralateral MO. 
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Figure 23.5. 52Mn transport to the main output regions of the VTA – AMPA group 
The gradual changes in the concentration observed in the AMPA group were very similar to the 
changes in the corresponding regions of the control group. Each line represents data of one animal. 
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Figure 23.6. 52Mn transport to the main output regions of the VTA – TTX group 
The gradual changes in the concentration observed in the TTX group were very similar to the 
changes in the corresponding regions of the control group. Each line represents data of one animal. 
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Figure 23.7. 52Mn transport to the main output regions of the VTA – NMDA and AP5 groups 
The changes in the concentration observed in the AP5 group were similar to the changes in the 
corresponding regions of the control group. In the NMDA group, the data of two rats showed a 
different pattern in the ipsilateral STR and NAc . Each line represents data of one animal. 
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Figure 23.8. 52Mn distribution in the VTAR-PBP 
and PN-PIF – injected rats 
A pathway leading from the midbrain to the OB was 
clearly visible in the first frame of the images of the 
rats injected into the PN-PIF regions (right 
column). The signal along this pathway was much 
weaker in the rats injected into the VTAR-PBP 
regions (left column).  
The blue lines in the sagittal image at the top 
indicate the position of the coronal images shown 
sequentially below. The exact distance from the 
bregma is indicated by the numbers in the upper 
right corners. 
The color scale was adjusted to visualize the PET 
signal in the brain of the PN-PIF-injected rat, and
the color scale of the PET image of the VTAR-PBP-
injected rat was adapted to that based on the 
injected dose. 
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According to the overlaid rat brain atlas, this neuronal pathway could be the rubrospinal 
tract (Figure 23.9). 
In order to quantitatively compare the 52Mn distribution between the groups based on the 
injection location, the mean concentrations of each group were computed. This was done 
not only for the three VOIs analyzed before (Figure 23.10), but also for six additional 
regions in which the tracer was visually localized in the PET images (Figure 23.11 and 
Figure 23.12). Some interesting features have been observed.  
Firstly, a common characteristic observed across all the VOIs located rostrally to the VTA 
was that the mean 52Mn concentration of the PN-PIF group was always the highest among 
the three groups, and this was true for the ipsilateral as well as for the contralateral sides. 
Interestingly, this difference between the PN-PIF group and the other two groups was 
Figure 23.9. 52Mn distribution in the VTAR-PBP and RN – injected rats 
The last frames of the PET images are shown. Even at this stage, there was not much 
signal in the contralateral MO in the rats from the VTAR-PBP group (A). In contrast, a 
pathway along the contralateral MO was clearly delineated in the RN group (B). This 
pathway was potentially the rubrospinal tract. In A, the same image as in Figure 23.8 is 
shown and the color scale of the image in B was adapted to it, based on the injected doses. 
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3 kBq/cc 
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Figure 23.10. 52Mn transport to the VTA output regions in the rats grouped based on the 
injection location – part 1 
The thick lines represent the group means and the shaded areas are the standard deviations of the 
means.  
     Ipsilateral         Contralateral 
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Figure 23.11. 52Mn transport to the VTA output regions in the rats grouped based on the 
injection location – part 2 
The thick lines represent the group means and the shaded areas are the standard deviations of the 
means.  
 
     Ipsilateral         Contralateral 
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Figure 23.12. 52Mn transport to the VTA output regions in the rats grouped based on the 
injection location – part 3 
The thick lines represent the group means and the shaded areas are the standard deviations of the 
means.  
 
     Ipsilateral         Contralateral 
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present already in the first frame of the PET image, which was in line with the previously 
described qualitative evaluation of the PET images.  
In addition, the high 52Mn concentration observed in the beginning in virtually all the VOIs 
of the PN-PIF group, only slightly fluctuated over time (especially in the ipsilateral AON and 
OB). In contrast, a gradual increase in the tracer amount was observed in the VTAR-PBP and 
RN groups. This rise was more rapid in the VTAR-PBP group than in the RN group in the 
ipsilateral ventral structures: NAc, OT, VP, and HLDB & MPN. 
Finally, the only region with a lower content of 52Mn in the PN-PIF group than in the other 
two groups was the MO. In fact, the contralateral MO was also the only brain area 
characterized by a faster accumulation of the tracer in the RN group than in the VTAR-PBP 
group. This was a reflection of the 52Mn distribution visually identified in the PET images. 
23.2 Dosimetry 
The data from the first frames of the PET images of three CTRL rats injected into the VTAR-
PBP were used to estimate the absorbed dose of the injected region, as well as of the entire 
brain. The first step of the analysis relied on modelling the relationship between the 
logarithmic values of the absorbed dose (ln(D)) and the mass of the brain tissue (ln(m)). 
The used 3rd order polynomial function provided a very good fit (R2 = 0.998) (Figure 
23.13). The obtained equation was subsequently used to calculate the Ds for the masses of 
the two VOIs. 
Under the assumption of no biological clearance of the PET tracer, the average dose rate at 
the injection time was 0.141 Gy/h for the VTAR-PBP and 0.001 Gy/h for the whole brain. 
Using these dose rates, the doses accumulated over different time periods could be 
160 |  
 
computed. Hence, the doses accumulated over 24 h would be 3.17 Gy for the VTAR-PBP and 
0.03 Gy for the whole brain, while the respective doses accumulated over 4 weeks would be 
26.40 Gy and 0.20 Gy. The doses for the injected region were much larger than those for the 
entire brain because of the much higher average concentration of the tracer. 
Based on the above estimates, the doses absorbed over 4 weeks by the VTAR-PBP region in 
the rats in Study 3 injected with 170 kBq (Experiment 1) and 20 kBq (Experiment 3) of 
52Mn could be also computed. They were 144.6 Gy and 17.1 Gy, respectively. Similarly, the 
absorbed doses accumulated over 90 min in the rats treated with 28 kBq or 149 kBq 
(Study 3, Experiment 2) could be compared. Those were 0.2 Gy and 1.0 Gy, respectively. 
6
8
10
12
14
-5 -3 -1 1 3 5
ln
 (D
)
ln (m)
 ln(𝐷) = −0.0047 ∗ ln(𝑚)ଷ + 0.0074 ∗ ln(𝑚)ଶ − 0.7620 ∗ ln(𝑚) + 9.32 
Figure 23.13. First step of the dosimetry estimation 
The relationship between the ln(D) and the ln(m) for the mass range from 0.01 g to 
20 g was modeled with a third order polynomial function. 
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24 PET with Online Recording of Blood 
Radioactivity 
24.1 Evaluation of the experimental protocol 
The sensitivity of the BS was exceptionally high, 23 ± 1 % (mean ± sd, n = 9). The energy 
resolution was 19 % for the 511 keV photo peak with a timing resolution of 11.2 ns. 
The physiological parameters of the animals were quite stable over the time of the 
experiment. A drop in the body temperature was observed in two rats when the flow in the 
shunt was initiated, but that was by only ~ 1 °C (Figure 24.1). The estimated flow rate in the 
shunt was 1.2 ± 0.1 mL/min and in the MS catheter 1.2 ± 0.4 mL/min. 
The wb TACs recorded by MS, by the BS and derived from the PET images were, overall, in a 
20
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Figure 24.1. Physiological parameters of a rat during the PET 
experiment with the BS measurement 
The body temperature and the breathing rate were monitored from the 
moment of anaesthetizing the animal until the end of the experiment. “0 
min” indicates the time point of the tracer injection. 
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good agreement (Figure 24.2). However, the PET-TAC was always the lowest during the 
first 30 s of the experiment. From approximately 10 min time point, it rose above the other 
two TACs. Additionally, the BS TAC tended to overestimate the MS TAC in the second half of 
the experiment.  
This comparison was made after the MS and the BS TACs had been shifted on the time axis 
to match the first-above-baseline data point of the PET TAC. In this way, the delay in the 
shunt could be estimated. It was 1.7 ± 0.6 s (mean ± sd, n = 5). 
The dispersion factor, τ, estimated in the step function measurements, was 1.94 ± 0.38 
(mean ± sd, n = 4). The mean value was used to model the IRF of the shunt system, which 
was required for the dispersion correction. However, in order to apply the correction by 
deconvolving the TACs by the IRF, the TACs had to be fitted in the first place. This 
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Figure 24.2. Wb TACs recorded by the BS, MS, and PET in one rat 
The insert shows the first 90 s of the measurement. In order to correct for the 
delay, the MS- and BS-TACs were shifted on the time axis to match the first-above-
baseline data point of the PET TAC (arrow). 
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Figure 24.3. The TACs fitting procedure and the dispersion correction  
A. An exemplar wb MS TAC, a fit to that data (MS-fit) and the dispersion- 
corrected fit (MS-fit-dc). B. The wb BS TAC from the same rat, a fit to that data 
(BS-fit) and the dispersion-corrected fit (BS-fit-dc). C. The combination of the 
BS recording with 1 manual sample, a fit to that data and the dispersion-
corrected fit (BSMS-fit-dc). The inserts show the first 90 s of the measurement. 
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Method of 
obtaining the AIF 
K1 (mL/ 
min/ccm) 
% diff. 
from ref. k2 (1/min) 
% diff. 
from ref. k3 (1/min) 
% diff. 
from ref. 
MS 0.19 ± 0.04 7.1 0.37 ± 0.09 8.0 0.048 ± 0.009 0.5 
MS-fit 0.18 ± 0.04 2.7 0.36 ± 0.08 4.5 0.049 ± 0.009 2.1 
MS-fit-dc (ref.) 0.17 ± 0.04 0.0 0.34 ± 0.08 0.0 0.048 ± 0.009 0.0 
MS-fit-dc-calc 0.18 ± 0.03 1.6 0.35 ± 0.07 2.0 0.052 ± 0.010 8.3 
BS-calc 0.19 ± 0.03 8.9 0.35 ± 0.06 2.3 0.041 ± 0.010 -13.4 
BS-fit-calc 0.19 ± 0.03 8.4 0.34 ± 0.05 0.6 0.042 ± 0.007 -12.4 
BS-fit-dc-calc 0.18 ± 0.03 5.4 0.32 ± 0.04 -5.3 0.039 ± 0.008 -18.9 
ID-calc 0.22 ± 0.06 24.1 0.40 ± 0.09 16.7 0.025 ± 0.006 -47.6 
BSMS-fit-dc-calc 0.18 ± 0.03 5.4 0.33 ± 0.05 -4.8 0.046 ± 0.008 -3.3 
Table 24.1. KPs of the 2TCM  
estimated using the AIF obtained in nine different ways. The AIF obtained from the fitted and dispersion-
corrected manual samples (MS-fit-dc) was considered the reference approach. The mean ± sd of 5 rats are 
shown for K1, k2 and k3. For each parameter, the % difference from the reference is shown in the 
neighboring column. Please refer to the text for explanation of the abbreviations. 
 
procedure allowed removing the noise from the data and it performed very well based on 
the visual inspection (Figure 24.3). 
24.2 Impact of the technique of obtaining the AIF on 2TCM-KPs 
The AIF includes the wb TAC as well as the p TAC of the PET tracer. In this study, the AIF 
was obtained in nine different ways from the same measurements. The effect of the 
technique used for deriving the AIF on the KPs estimated with the 2TCM is shown in Table 
24.1 and Figure 24.4. 
The true wb and p data, manually collected during the experiment, subsequently fitted and 
corrected for dispersion (MN-fit-dc) were used as the reference approach. The K1, k2, and k3 
estimated using this AIF were: 0.17 ± 0.04 mL/min/ccm (mean ± sd, n = 5), 0.34 ± 0.08 
1/min, and 0.048 ± 0.009 1/min, respectively. Comparing these values to the KPs estimated 
with the MS-fit approach, allows an estimation of the effect of the dispersion correction. 
When the correction was not applied, the KPs were almost 2-5 % overestimated, with the k2 
being most affected.  
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Figure 24.4. KPs of the 2TCM  
The K1, k2, and k3 were estimated using the AIF obtained in nine 
different ways. The AIF from the fitted and dispersion-corrected 
manual samples (MS-fit-dc) was the reference approach (dashed 
line). Using the AIF derived from the PET images (ID-calc) 
resulted in the highest deviations from the reference values. The 
BS-based approaches led to a reduced k3. This could be recovered 
by combing the BS data with 1 manual sample (BSMS-fit-dc-calc).  
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When these overestimated values are compared to the KPs obtained with the original wb 
and p data, before the fitting step (MS), the impact of the fitting procedure can be assessed.   
The procedure led to the change in the K1 from 0.19 ± 0.04 to 0.18 ± 0.04 mL/ min/ccm, in 
the k2 from 0.37 ± 0.09 to 0.36 ± 0.08 1/min, and in the k3 from 0.048 ± 0.009 to 0.049 ± 
0.009 1/min. Therefore, the effect was only minimal.  
In the next step, the impact of using the ௣
௪௕
 ratio to extract the p values from the wb 
recording was assessed. Applying this approach to the MS data (MS-fit-dc-calc), resulted in 
only a small effect on the K1 and k2 values (they were overestimated by only approximately 
2 %), but there was above 8 % overestimation of the k3. Since using the  ௣௪௕  ratio is 
unavoidable for deriving the AIF from the BS as well as from PET images, a similar effect is 
expected when these approaches are used. 
In fact, when the BS-based techniques were applied the KPs were quite different from the 
references. When the original, i.e. not fitted and not corrected for the dispersion, BS data 
(BS-calc) were used, the K1 and k2 were overestimated by almost 9 % and more than 2 %, 
respectively. As discussed above, approximately 2 % of these errors could be attributed to 
the necessity of using the  ௣
௪௕
  ratio. However, even taking this into account, the K1 would be 
still overestimated by almost 7 %. The deviation in the k3 was even higher; this KP was 
underestimated by more than 13 %. 
When the fitted BS data (BS-fit-calc) were used to obtain the AIF, the differences in all three 
KPs were reduced by 0.5-2 %. This small change also indicates that the fitting procedure 
itself did not have a strong effect, similarly to the effect on the MS data.  
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Next, applying the dispersion correction to the fitted BS TAC (BS-fit-dc-calc) led to a further 
reduction in the deviation of the K1 from the reference value. It was now overestimated by 
slightly more than 5 %, which still incorporated 2 % resulting from using the  ௣
௪௕
  ratio. 
However, the k2, and especially the k3, deviated more. They were underestimated by 5 and 
almost 19 %, respectively. This could be corrected for by combing the first 10 min of the BS 
recording with 1 manual sample collected at 60 min. When this combination was fitted and 
dispersion-corrected (BSMS-fit-dc-calc), the estimated K1 was 0.18 ± 0.03 mL/min/ccm, the 
k2 was 0.33 ± 0.05 1/min, and the k3 was 0.046 ± 0.008 1/min. Therefore, the deviations 
from the respective reference values where within 5 % range. 
For a comparison, the KPs were also estimated with the AIF derived from the PET images 
(ID-calc). This approach resulted in very high differences of the obtained values from the 
references. The K1 and k2 were overestimated by 24 and 17 %, respectively, while the k3 
was almost 48 % underestimated. 
  
DISCUSSION 
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25 Mn2+ for Tracing Neuronal Pathways with 
MEMRI vs Toxicity of the Metal 
The first study conducted within the present work aimed to assess whether Mn2+ doses 
required for MEMRI are safe for an intracerebral administration in rats. The results showed 
that 45 nmol of Mn2+ applied directly into the VTA caused a dopaminergic lesion 4 weeks 
after the injection (Study 1). Furthermore, the 50 nmol dose administered into the STR 
affected GABAA receptors in the FC which was manifested as a reduction in the BPnd of 
[11C]flumazenil 2 days post-injection (Study 4).  
The STR receives neuronal projections from most of the cortical areas, including the 
prefrontal and limbic cortices [213], and one day after the intrastrital injections of Mn2+, an 
increased signal intensity was observed in the FC in the T1W MR images. Therefore, the Mn 
ions were most probably transported from the STR to the FC where they interacted with the 
GABAA receptors. Although this would reflect the retrograde, rather than the most 
commonly observed with MEMRI anterograde transport, this direction of the intracellular 
movement of the Mn2+ is also possible [214].  
Interactions of Mn with the GABAergic system have been previously reported. Specifically, 
an increased accumulation of Mn in several brain regions, including the STR, GP, and HIPP, 
in the iron-deficient rats was significantly correlated with reduced GABA levels [215]. 
However, an opposite effect, i.e. an increased GABA concentration, has been found in the 
CER of the rats exposed to a daily Mn dose of 20 mg/kg administered over 30 days [216]. 
Interestingly, in non-human primate studies, there was no impact of a 5-26 months long s.c. 
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treatment with manganese (IV) oxide (MnO2) on GABA, neither on glutamic acid 
decarboxylase (GAD), which converts glutamate to GABA [136, 143]. Therefore, the 
available literature is not fully consistent, although the observed discrepancies could be 
potentially attributed to the interspecies differences, as well as to the different 
experimental protocols used. 
In Study 4, the BPnd of [11 C]flumazenil was not significantly changed 30 days after the Mn2+ 
injection. Therefore, it is possible that following a single application of the metal in rats, the 
impact on the GABAA receptors is only transient. This transient reduction in the availability 
of the receptors could potentially reflect an increased level of the endogenous GABA. In fact, 
it has been shown that Mn may increase the GABA concentration by interacting with GABA 
transporter (GAT) [217]. Nevertheless, this interpretation should be treated carefully, since 
GABA levels were not directly measured in Study 4.  
Most importantly, regardless of the molecular mechanism underlying the observed effect of 
Mn2+ on the GABAA receptors, this effect is highly undesired if Mn2+ shall be used as a tool 
for measuring neuronal activity. GABA is the main inhibitory neurotransmitter of the CNS 
and any change in its level may induce a direct impact on the neuronal activity. 
In contrast to the results of [11C]flumazenil PET, neither short- nor long-term impact of 
Mn2+ on the BPnd of [11C]methylphenidate was observed in Study 4. Thus, a single 
intrastriatal administration of 50 nmol of the metal does not affect DAT in the STR. This is in 
contrast to the effects observed following a prolonged Mn exposure. For instance, a dose-
dependent reduction in the striatal binding potential of [11C]nomifensine, which is another 
marker of the presynaptic DA reuptake, was observed in monkeys following a 16 months 
treatment with MnO2 [137]. Additionally, a transient decrease in the binding potential of 
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[11C]raclopride, a D2 receptor antagonist, was also reported in that study. Furthermore, 
decreased levels of DA and its metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), have 
been found in the GP following a 5 months exposure to the total of 8 g of MnO2 in monkeys 
[136], and an effect on the D1 receptors has been also reported [143]. 
In a more recent study, in which lower doses of Mn (i.e. total of 0.15-0.20 g) were applied, 
there was no effect of the metal on DAT and on D2 receptors despite the prolonged 
exposure time, although the amphetamine-induced DA release was affected [218]. Hence, 
the Mn effect on the dopaminergic system most probably depends on the total accumulated 
dose [133]. While the 50 nmol of Mn2+ used in Study 4 led to a reduction in the availability 
of the cortical GABAA receptors, it was apparently too low to exert a significant effect on the 
striatal DAT. 
It is important to recognize that the 45-50 nmol doses used in Studies 1 and 4, are a 
reasonable representation of the doses commonly used in MEMRI investigations focusing 
on tracing neuronal pathways. In the studies of this type conducted over the recent years, 
between 1 and 400 nmol have been applied in rodents [125, 131, 146, 171, 219], birds 
[164], and monkeys [126, 166, 220]. However, the toxicity aspect was not always evaluated. 
Due to the differences between the species and the neuronal systems under investigation, 
as well as between the MRI scanners used in different studies, it is not easy to define an 
exact dose of Mn2+ which is sufficient for MEMRI and at the same time does not have a 
pharmacological or toxic effect. In rats, it has been shown that a direct injection of 40 nmol 
of Mn2+ into the VTA significantly reduced the number of “normal-appearing neurons”. The 
20 nmol dose also reduced this number, although the difference from the controls did not 
reach statistical significance [146].  
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However, in another study, performed in mice, even a lower dose led to functional 
disturbances in the neuronal activity. Specifically, 4 h after an intravitreous injection of 
12.5 nmol of Mn2+, reduced visual evoked potentials were recorded in the visual pathway. 
Although this effect was not present anymore at 24 h post-injection, the applied dose was 
anyway not detectable by the 11.7 T MR scanner [131], demonstrating that the potentially 
useful dose of Mn2+ was beyond the sensitivity of the MRI system. 
Nevertheless, a detection of even lower doses of Mn2+ has been reported by other 
investigators. In monkeys, an 8 nmol dose was sufficient for MRI and did not cause a 
neuronal death. However, it resulted in astrogliosis in the surrounding tissue [147]. It is 
known that astrogliosis significantly affects neuronal activity and may even induce epileptic 
seizures [221]. Therefore, the 8 nmol dose would still be too high for functional 
neuroimaging with MEMRI. Moreover, the toxicity of this dose was assessed in the cortex, 
while other brain regions, particularly the basal ganglia, are more vulnerable to Mn. 
Still lower doses of the contrast agent have been also used. Specifically, 2 and 3 nmol of 
Mn2+ were applied for tracing neuronal projections from the NAc to the VP [125] and from 
the Hb to the VTA [132]. However, neither the direct neurotoxicity nor the possible effect 
on the glial cells was assessed. Additionally, in all the mentioned studies utilizing the Mn2+ 
doses below 10 nmol, the MRI was carried out directly after the tracer administration. If an 
experimental protocol requires an additional time after the injection, the low amount of the 
administered Mn2+ may be partially washed out by the time of scanning. 
In Study 1, 5 nmol of MnCl2 was administered in a bicine solution. Since the formed 
Mn-bicine is a low affinity chelate, 10 % of the molecules (0.5 nmol) are present as free ions 
[150]. These free Mn ions could have induced a degeneration of the dopaminergic neurons, 
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which did not happen. Therefore, the 0.5 nmol dose could be considered non-toxic, 
although several limitations of the study should be taken into account. 
Firstly, only three rats per group were used which is not optimal for a proper toxicity 
evaluation. Secondly, potential short-term effects were not assessed, even though Mn2+ may 
affect the neuronal activity only temporarily [131]. Finally, only one method, the 
TH-staining, was used to investigate the possible side effects. Hence, some other aspects of 
the pharmacological action or toxicity of Mn, like impact on the GABAA receptors or the 
mentioned astrogliosis, might have been undetected. 
Nevertheless, even if 0.5 nmol was safe for a direct intracerebral application in rats, this 
dose was not sufficient for MRI at 24 h post-injection. The T1 values analyzed in the three 
main output regions of the VTA, where neuronal transport of Mn2+ was expected, were not 
changed as compared to the baseline values.  
Thus, based on the results of Study 1, as well as on the available literature, it can be 
concluded that the Mn2+ doses required for MEMRI are either very close to the toxicity 
threshold of the metal, or even above it. This threshold lies possibly within the 1-5 nmol 
range, however, if only a few nmol of Mn2+ are used, MRI needs to be performed directly 
after the injection. Consequently, in order to use Mn2+ concentrations which are further 
away from the toxicity threshold, or to allow more flexible experimental protocols, a more 
sensitive method would be highly desired for tracing neuronal pathways with Mn2+. 
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26 52Mn PET as an Alternative Method for Tracing 
Neuronal Tracts 
26.1 Dosage 
PET is a much more sensitive technique than MRI. While at least nanomols of Mn2+ are 
required for MEMRI, picomols of 52Mn used in the present work were completely sufficient 
for PET. Hence, the dose of the metal could be reduced by three orders of magnitude. It is 
worth noting that the Mn concentrations of the injected solutions were even lower than the 
physiological concentration of the metal in different regions of the rat brain [222]. 
Therefore, the toxicity effects were not expected. Surprisingly, the results of Experiment 1 
in Study 3, in which as little as 38.3 pmol of Mn2+ were present in the injected volume of the 
52Mn  solution, were contrary to this expectation. 
Four weeks after the injections into the VTA or the STR, approximately half of the animals 
exhibited an increased ratio of the ipsilateral vs contralateral rotations in the rotameter 
test, which indicated an imbalance of the motor control system. A similar effect had been 
observed previously, but it was always induced by hundreds of nmol of Mn2+ [223-225]. In 
one another study, an 8 nmol dose, but of Mn3+, led to a significant impairment of a 
spontaneous motor activity and a conditioned avoidance response 2 weeks after an 
intranigral injection in rats [226]. However, that dose was still more than 200 times higher 
than the dose applied in Experiment 1. Moreover, toxicity of Mn3+ results from the relatively 
high reduction potential of the ion which causes oxidation of DA [226]. This effect would me 
much weaker for Mn2+ based on its lower reduction potential. 
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Additionally to the behavioral effect, the TH-staining performed on the brain tissue sections 
also suggested that the dopaminergic system was affected. A reduced staining intensity 
indicated that the level of TH in the neurons within the injected VTA (or in the SN ipsilateral 
to the injected STR) was lower compared to the level in the respective contralateral regions. 
However, the staining was only reduced, and not completely absent, suggesting that the 
neurons did not degenerate, but only their functionality (TH expression) was affected. This 
speculative claim may be supported by the shape of the neurons observed in the 
microscopic images. While necrotic cells would be characterized by cytoplasmic shrinkage, 
vacuolization, or mineralization in case of an advanced process [227], the neurons 
appeared completely normal. 
As discussed above, changes in the neuronal morphology have been observed following the 
treatment with 20-40 nmol of Mn2+ [146], while lower doses (8-20 nmol) have been 
associated with functional effects [131, 147]. However, investigations of the consequences 
of a direct intracerebral administration of Mn2+ at the dose level lower than 1 nmol have not 
been reported. Thus, a direct comparison of the outcomes of the present results is not 
possible. 
Nevertheless, as mentioned above, the physiological doses of the metal in different areas of 
the rat brain range from 50 to 600 nmol per 1 g of tissue, which corresponds to the 
50-600 µM concentrations [222]. The 38.3 pmol dose used in Experiment 1 was 
administered in 1 µL volume and thus, the concentration of the solution was 38.3 µM. 
Therefore, it is rather unlikely that the toxicity effects observed in Experiment 1 resulted 
from the metal dose. The radioactivity dose of 52Mn seems to be a more probable 
explanation. 
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In fact, the described behavioral as well as histological adverse effects were completely 
absent in the group of rats treated with the decayed solution. Although only four animals 
were used in that group, a total of eighteen rats were injected into the VTA with the reduced 
radioactivity dose (~20 kBq) of 52Mn in Experiment 3. The rotameter test was performed at 
3, 14, and 28 days post-injection and the ipsilateral/contralateral rotations ratio was not 
different from the control group at any of the time points, suggesting no impact on the 
motor control system. Similarly, no differences in the staining intensity between the right 
and left VTAs were found in any of the evaluated tissue senm,2ctions. 
Experiment 2 of Study 3 was carried out to investigate further consequences of using 
different radioactivity doses for a direct intracerebral injection. DNA damage is one of the 
best known effects of ionizing radiation on biological tissues [228] and hence, it was chosen 
to evaluate this aspect.  
Following a single or double DNA strand break caused by the radiation, the histone protein 
H2AX at the damage site is phosphorylated on the 139th serine residue [229]. This is an 
important molecular signal for the initiation of the DNA repair processes. The γH2AX 
staining, which was used for the evaluation, detects the locations where the specific 
reaction has taken place. Therefore, what is actually imaged with this technique is the 
activation of the DNA repair machinery [230].  
It was found that 90 min after the injection of ~150 kBq of 52Mn into the VTA, the DNA 
repair processes had been initiated at numerous foci. The ratio of the cells with foci vs the 
total number of cells was approximately seven times higher as compared to the control 
group within the injected VTA. The fact that the result of the 30 kBq group was hardly 
distinguishable from the controls strongly suggests that the radioactivity dose played a 
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crucial role. Interestingly, the “cells with foci/cells total” ratio was also elevated in the 
contralateral VTA of the 150 kBq group. This could be due to the possible transport or 
diffusion of the tracer along the VTA decussation. Since the VTAs are situated close to the 
midline of the brain, 90 min might have been sufficient for the transport of the tracer along 
this short distance. 
At the second investigated time point, i.e. 24 h post-injection, the results of the three 
experimental groups were more homogenous. The “cells with foci” fraction in the ipsilateral 
VTA of the 150 kBq group had dropped as compared to the first time point, although it still 
remained the highest among the three groups. Why this reduction had occurred is not 
completely clear.  
Due to the relatively long half-life of 52Mn (5.6 days) and the low clearance rate of the metal 
from the brain (7-8 days to wash out half of the intranasally-administered dose from 
trigeminal ganglia and spinal trigeminal nucleus [231]), the radiation level at 24 h post-
injection was not much lower than at the 90 min time point. Therefore, a similar level of 
induction of the DNA damage would be expected. A possible explanation would be an 
adaptation of the cells to the ionizing radiation [232]. Alternatively, the phosphorylation 
processes initiating the DNA repair, which are visualized with the γH2AX staining, might 
have become saturated. 
However, to better understand the effects of radiation, the radiation doses should be taken 
into consideration. This aspect was investigated with the dosimetry analysis in Study 5. The 
results showed that 90 min after the administration of 30 kBq of 52Mn into the VTAR-PBP, 
the accumulated dose in this region was 0.2 Gy and that it was five times higher following 
the injection of 150 kBq. Interestingly, while the former value falls within the range of “low” 
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radiation doses, 1 Gy is often considered the border value between the “low” and “high” 
doses [233]. 
It is well documented that the responses of neural and glial cells to the low and high 
radiation doses are very distinct. For instance, an acute exposure of the hippocampal cells 
to the irradiation of 1 Gy or higher induces oxidative/nitrosative stress, increases DNA 
damage, promotes cell cycle arrest, and reduces the cells differentiation [234, 235]. The 
inhibition of the neurogenesis in the hippocampus, observed following an irradiation with 
2-10 Gy doses, depends on the microglial activation which induces neuroinflammation 
[235]. Other cellular impairments, collectively referred to as the “radiation-induced injury”, 
include lipids peroxidation and microvascular damage and they can be induced by 2-6 Gy 
doses [236, 237]. Moreover, when a dose as high as 10 Gy was applied to different 
populations of the CNS cells in culture, an increased apoptosis and decreased cell survival 
were observed [238]. Finally, all these cellular and molecular effects may be manifested 
also at the cognitive level [235, 239]. 
As mentioned above, very different reactions of neurons and glia have been reported 
following an exposure to the low radiation doses, defined usually as < 1.0 Gy, although less 
data are available regarding this dose range [233]. Specifically, it has been shown that 
0.1 Gy may not affect gene expression, neither behavioral capabilities associated with 
learning and memory [240]. Furthermore, doses in the range of 0.05 to 0.5 Gy have been 
found to suppress the release of pro-inflammatory cytokines and reactive oxygen species 
leading to the attenuation of the inflammatory responses [241]. Finally, radioresistance and 
adaptation may occur after a treatment with doses below 0.3 Gy [232]. 
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In summary, despite the difference in the experimental protocols, species of the 
experimental animals, and the applied doses, the available literature strongly suggests a 
distinction between the effects of the low and high radiation doses on the CNS [233]. The 
results of the dosimetry analysis from Study 5 seem to match this pattern very well. 
However, one methodological aspect should be emphasized. Namely, in the vast majority of 
the reported studies a single, acute radiation dose was followed by a period without the 
irradiation, before the effects were tested. In contrast, due to the long half-life of 52Mn, the 
exposure of the VTA in the present work continued undisrupted from the moment of the 
tracer injection until the moment of the effects evaluation.  
On one hand, under this condition of a constant irradiation, the cells may potentially not 
have sufficient time to properly initiate and maintain the repair processes. On the other 
hand, the dose rate is significantly lower than in other studies which may make the 
performance of the molecular repairs easier. Since these two factors act in opposite 
directions, possibly, they may cancel each other out.  
However, in one study, the effects of a chronic radiation exposure of human neural 
progenitor cells to a low dose rate, have been examined in vitro. The cumulative doses 
ranged from 0.031 to 0.496 Gy but the radiation was delivered continuously over 72 h. The 
lowest dose resulted in alterations in the inflammatory pathways, the 0.124 Gy dose 
affected the DNA repair and cell adhesion molecules, while the highest dose affected DNA 
synthesis, cell metabolism, and neural differentiation [242]. Therefore, some of the effects 
known from the exposure to doses higher than 1 Gy have been observed. This might have 
been related to the relatively high sensitivity of the progenitor cells, as compared to the 
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matured cells, to radiation, but the chronic character of the irradiation could have played a 
role as well.  
Although the continuous exposure of the VTA to 52Mn resembles this situation, the dose rate 
following the injection of approximately 30 kBq in Study 5 was only 0.141 Gy/h, which is 
three times lower than the lowest dose rate used in the study referenced above (0.42 Gy/h) 
[242]. Moreover, the 0.141 Gy/h dose rate was slowly, but continuously, decreasing, due to 
the 52Mn decay. Additionally, the accumulated doses calculated based on this dose rate were 
actually overestimated because of the assumption of no biological clearance of 52Mn. In fact, 
as already mentioned before, the time required for the clearance of the half of the 
intranasally administered Mn dose from the trigeminal system was 7-8 days [231]. 
Therefore, although the computed cumulative doses in the VTAR-PBP were: 0.2 Gy 90 min 
after the injection of 28 kBq (Experiment 2) and 17.10 Gy 4 weeks after the injection with 
the 20 kBq dose (Experiment 3) in Study 3, the true values were certainly lower. 
Consequently, the applied doses might have been low enough for the VTA cells to fully deal 
with. This conclusion would be supported by no increase in the DNA damage, no reduction 
in the TH expression, and no effect on the rotation behavior found in these experiments. 
The dose rate calculated for the entire brain VOI in Study 5 was extremely low 
(0.001 Gy/h), resulting in very low accumulated doses of 0.03 Gy and 0.20 Gy at 24 h and at 
4 weeks after the application of 30 kBq of 52Mn, respectively. Thus, the radiation-induced 
injury would be also unexpected in other parts of the brain. Nevertheless, possible 
bystander effects, i.e. the effects experienced by the cells not directly exposed to the 
radiation but receiving molecular signals from the neighboring irradiated cells [232], 
should be further verified. 
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26.2 Advantages of the method and potential applications 
Tracing neuronal pathways with MEMRI has already proven to be a useful technique in the 
field of neuroscience and neurology, but the sensitivity of MRI systems poses limitations for 
some studies. Also using the method in primates is more restricted than in rodents due to 
their greater vulnerability to the Mn toxicity [243]. Hence, the present work proposes 25Mn 
as an alternative approach and demonstrates for the first time that tracing neuronal tracts 
with PET is feasible.  
Specifically, following a unilateral 52Mn injection into the VTA, the mesolimbic and 
mesostriatal pathways were clearly visible in the images obtained 24 h later (Experiments 
1 and 3 in Study 3). Together with the mesocortical pathway, these are the main rostral 
projections of the dopaminergic midbrain [9]. Although the mesocortical tract was not 
directly recognizable in the images, the quantitative analysis revealed a higher 
concentration of 52Mn in the ipsilateral than in the contralateral PFC, indicating that the 
tracer had reached that region. Moreover, a significantly higher concentration of 52Mn was 
found also in the ipsilateral NAc, OT, STR and AMG, which receive direct neuronal input 
from the injected VTA, as compared to the respective contralateral areas. Only the CER, 
used as a control region, showed no difference in the tracer accumulation between the right 
and the left side.  
Similarly, after the injections into the STR, the ipsilateral GP, THL and SN accumulated 
significantly greater amounts of 52Mn compared to the respective contralateral areas, 
confirming the transport to the expected target regions of the STR. Once again, only the 
concentrations in both the hemispheres of the CER did not differ. In summary, these results 
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indicate that, similarly to non-radioactive Mn2+, 52Mn can be taken up and transported by 
neurons. 
Also the results of Study 5 showed that the 52Mn transport visualized in, and quantified 
based on, the PET images, is in accordance with the known rat brain anatomy. Particularly 
grouping the experimental animals based on the injected subnucleus of the VTA allowed 
identification of the expected directions of the neuronal transport. Specifically, it was 
observed that when the tracer was injected into the VTAR-PBP region, its concentration 
was gradually rising in the ipsilateral dorsal and ventral striatal areas, including the STR 
NAc, OT, VP, and HLDB & MPN. These regions are known to receive the neuronal 
projections from the main nucleus of the VTA, the PBP [41].  
In contrast, the 52Mn concentration in these areas was lower in the RN group. In fact, it is 
well established that the main output of the red nucleus in rodents is the rubrospinal tract 
which projects caudally and on the contralateral side into the spinal cord [244]. 
Accordingly, the MO was the only region analyzed in Study 5 in which the concentration of 
the tracer was higher on the contralateral side than on the ipsilateral side, and this was true 
only for the RN group. It is worth noting that the rubrospinal tract is a relatively thin bundle 
within the medulla oblongata, which was used as the VOI, and since the average 
concertation of the entire VOI was evaluated, the obtained value was most probably 
underestimated.  
Interestingly, although smaller than in the rats injected into the RN, a gradual increase in 
the 52Mn content in the contralateral MO was also observed in the VTAR-PBP group. This 
could have possibly resulted from a partial diffusion of the tracer from the injections site to 
the RN. Similarly, a gradual increase in the 52Mn level in the regions which do not receive 
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the neuronal input from the RN (e.g. the NAc, the VP, or the STR) has been observed in these 
areas in the RN group. This was potentially due to the diffusion of a portion of the injected 
volume from the RN to the PBP. In fact, in all these VOIs, the mean values of the RN group 
were lower than in the VTAR-PBP group. Therefore, although it seems that depending on 
the exact location of the injection site a characteristic distribution pattern of 52Mn can be 
recognized, the distribution patterns could have potentially differed even more between the 
groups provided a smaller injection volume had been used.  
Nevertheless, a very distinctive 52Mn distribution pattern could be recognized in the PN-PIF 
group. The mean concentration of the tracer in all the analyzed ipsilateral VOIs was highest 
among the three groups, and the differences from the VTAR-PBP and the RN groups were 
particularly apparent in the HLDB & MPN, AON, OT, and OB areas. In fact, these regions 
receive the neuronal input from the medial aspects of the VTA, including the PN, PIF, and 
the Li [41]. Since these subnuclei of the VTA are also situated rather ventrally, the distance 
to the RN, which is located in the dorsal portion of the midbrain, could be too large for a 
simple diffusion process. Consequently, the 52Mn transport along the contralateral 
rubrospinal tract would not be likely. In fact, the concentration of the tracer in the MO was 
approximately the same on both sides in the PN-PIF group and clearly lower than in the 
other two groups. Thus, the distribution of 52Mn observed in the PN-PIF group was, 
similarly to the first two groups, in agreement with the known neuronal connectivity of the 
rat brain. 
Furthermore, the PET images of the PN-PIF group have provided perhaps the most 
intriguing result of Study 5. A clear signal of 52Mn was visible along the ipsilateral tract 
leading from the injection site, through the HLDB & MPN, AON, and up to the OB in the 
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images of almost all the rats from this group. The HLDB & MPN complex is recognized as the 
intermediate portion of the basal forebrain which, among other regions, prominently 
innervates the OB [11] (Figure 26.1). The direct neuronal projections from the VTA to the 
OB are rather sparse (compare Figure 1.2). Hence, the observed trace of 52Mn might be a 
reflection of the neuronal transport along two pathways: from the VTA to the basal 
forebrain and from the basal forebrain to the OB. Provided this is true, it could be concluded 
that 52Mn had crossed a synapse, which have been reported many times for Mn2+ [123, 127-
130]. Unfortunately, the present study lacks a histological validation, and thus, an ultimate 
conclusion should not be drawn. 
Another interesting characteristic of the images from the PN-PIF group was that the 
prominent transport of 52Mn to the OB had occurred within an hour from the injection of 
the tracer into the VTA. This indicates a rather fast transport rate and possibly reflects 
Figure 26.1. The main neuronal projections of the rat basal forebrain 
The basal forebrain is composed of several, mostly cholinerigic, nuclei: ms – medial septal nucleus, vertical 
and horizontal limbs of the diagonal band (vdb and hdb, respectively), substantia innominate (si), and nucleus 
basalis (bas), which project to many cortical areas, to the hippocampus, amygdala, and to the olfactory bulbs. 
BLA – basolateral amygdala, EC – entorhinal cortex. Adapted from [11]. 
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some physiological properties of the neurons, apparently different from the properties of 
other neuronal pathways imaged in this study. For instance, 52Mn in the NAc was first 
observed approximately 2 h after the injection into the VTAR-PBP (Figure 23.3), although 
the distance from the injection site to the NAc is shorter than the distance to the OB. 
Additional experiments, potentially employing electrophysiological recording, should be 
conducted to verify whether the observed quick transport reflects an increased neuronal 
activity. Currently, this notion remains speculative. 
One aspect of the 52Mn transport which the present work has not investigated in detail is 
the neuronal specificity. Since Mn divalent ion is taken up into the cells mostly by ion 
channels, ion exchangers or antiporters [114-117], which may be present on the cell surface 
of different neuronal types, the uptake should depend on the availability of the channels 
and the frequency as well as the duration with which they open. In fact, non-radioactive 
Mn2+ has been used to trace very different neuronal pathways, consisting of dopaminergic, 
noradrenergic, and other neurons [146, 159]. As long as the chemical form of the tracer is 
preserved (i.e. the oxidation state of +2), it should be possible to image the same pathways 
with 52Mn PET. The present work focused on the VTA, and thus, the imaged pathways were 
mostly dopaminergic. However, the rubrospinal tract originating from the RN is almost 
entirely glutamatergic [244], while the basal forebrain projection to the OB is composed 
mostly of cholinergic neurons [11]. Hence, 52Mn PET can be useful for imaging a verity of 
neuronal connections in the brain. 
Assuming activity-dependence of the 52Mn transport, which has been already demonstrated 
for non-radioactive Mn2+ [119], it would be particularly interesting to use 52Mn PET for 
imaging the tracer distribution in the brain in relation to the animal’s behavior. For 
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example, if the tracer is injected via a guide cannula previously fixed on the skull, the 
experimental animal may be engaged in a behavioral task while 52Mn is being taken up and 
transported by the involved neuronal circuits. Only after completing the task, the animal is 
anesthetized and the scanning procedure takes place to read out the distribution of the 
tracer. 
This approach has been already used in one MEMRI study [125] and the main idea behind it 
is to remove the impact of anesthesia on the brain during the behavioral performance, 
when the involved brain pathways or areas are being “labeled”.  This issue is currently the 
main drawback of other neuroimaging modalities, such as BOLD fMRI or DTI. Even though a 
few fMRI studies using the awake animal protocol have been reported [98, 245], a physical 
restraining had to be applied. This is not optimal not only because of a possible stress effect 
on the neural activity [246], but also because the restrained animal cannot perform active 
tasks, involving interactions with the environment (for example, pressing a lever or 
exploring a new territory), which are commonly used especially in rodent studies to assess 
the brain function. 
Another possible application of 52Mn PET could be imaging of neurodegenerative processes 
in different animal models. For instance, an investigation of axonal transport in a mouse 
model of AD has been performed using MEMRI [172]. However, carrying it out with 52Mn 
PET would be burdened with a lower risk of metal intoxication. Furthermore, a reduced 
transport rate or total amount of the transported tracer would be expected in the affected 
neuronal pathways of the PD models or models of amyotrophic lateral sclerosis (ALS). 52Mn 
could be useful for monitoring the development and progression of these diseases as well 
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as the effects of experimental treatment strategies. This cannot be readily conducted with 
MEMRI since Mn2+ itself may evoke symptoms resembling parkinsonism [133]. 
Future applications could possibly also include imaging of visual, olfactory or peripheral 
neuronal pathways, where the stereotactic injection procedure might not be necessary. In 
fact, the usefulness of MEMRI in monitoring a sciatic nerve after a traumatic injury has been 
already tested in rats [214]. Due to the lower metal dose required, 52Mn PET could be more 
appropriate for this application. 
Finally, it is worth mentioning that 52Mn production and separation methods have been 
largely advanced over the recent years [186-188, 191, 204], which is a prerequisite for any 
application. The relatively long half-life of 52Mn allows sufficient time for radiochemistry, as 
well as for a shipment of the tracer from a far situated production unit. Moreover, 
experiments with a complicated protocol can be easily conducted and a single injection 
might be sufficient for multiple measurements. Thus, first application studies have been 
already conducted [8, 189] and there is a potential for many further developments. 
26.3 Activity-dependence of the 52Mn neuronal transport 
One concern arising from the results of this work is that the tested pharmacological agents 
were not able to enhance or reduce the neuronal transport of 52Mn (Study 5). The only 
exception was non-radioactive Mn2+ whose effect was robust. AMPA, NMDA, AP-5 and TTX 
did not have any effect, despite the relatively high doses applied. Out of these substances, 
AMPA and TTX have been previously used to modulate the transport of Mn2+ from the 
injection site in the Hb to the interpeduncular nucleus (IPN) [132]. 
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The authors found a significant increase in the longitudinal relaxation rate (R1, an inverse 
of the T1) in the group treated with 100 µM AMPA, starting from approximately 2.5 h after 
the Mn2+/AMPA injection. The difference from the R1 of the control group, injected with the 
Mn2+ solution alone, remained significant until the end of the measurement, 9.5 h post-
injection. Thus, it was very surprising to find no difference between the CTRL and the AMPA 
groups in the 52Mn PET study. However, several factors in the experimental protocols used 
in the present work and in the referred study, might have influenced the results. 
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26.4 Limitations and technical considerations 
Besides the considerations raised in the previous section, several other limitations of 52Mn 
PET exist. Firstly, the relatively long half-life of the isotope, which allows sufficient time for 
the radiochemistry, shipment of the tracer, and convenient performance of complicated 
experiments, as already discussed, results in the relatively high radiation exposure for the 
experimental subject as well as for the researcher. The effects of different radioactivity 
doses on the brain tissue have been extensively discussed in Section 26.1. In regard to the 
scientific personnel, the dose exposure should be strictly monitored. Additionally, 
a prolonged storage of the radioactive waste would be necessary [180]. 
Another characteristic of 52Mn is the presence of numerous prompt γ rays in the decay 
scheme. These γ rays contribute to the issue of the radiation exposure discussed above, but 
additionally, they may have an effect on the PET images. As described in the Introduction 
(section 5.1), three types of the γ rays occur with a high probability and, if scattered, may be 
potentially captured by the detector system. In fact, a small artificial signal caused by this γ 
radiation has been reported in a phantom study utilizing the acquisition energy window of 
450-600 keV [185]. The deviation from the true value of the image was in the 2 % range but 
could be reduced to -0.5 % by applying a cascade background correction. 
The impact of the cascade γ rays on the PET images was investigated in Study 2. Without 
applying the cascade correction, the normalized profiles of the images of two phantoms did 
not differ depending on the energy window used for the acquisition (energy windows from 
450-600 keV to 350-650 keV were tested). This apparently improved, as compared to the 
results obtained by Topping et at. [185], image quality might have resulted from a different 
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algorithm used for the image reconstruction. While the FBP algorithm was used in the cited 
work, the OSEM3D-MAP algorithm was applied in Study 2. Additionally, different PET 
scanners were used in both studies which might have also played a role. 
Finally, the main drawback of 52Mn PET is its limited spatial resolution. In the image of the 
resolution phantom (Study 2), the smallest rod volumes which could be resolved had the 
diameter of 1.35 mm. Accordingly, it was possible to identify the brain regions as small as 
the rat SN in the images from the in vivo studies. Thus, currently, imaging of the neuronal 
pathways at the regional level is feasible in rats, but would be probably more challenging in 
mice. Nevertheless, possible improvements in the spatial resolution of PET scanners are 
currently under investigation. Results of simulation and experimental studies indicate that 
the resolution of 0.5-0.6 mm of the full width at half maximum (FWHM) may be achieved 
[247, 248]. If scanners with this high spatial resolution are available, the intrinsic limitation 
of 52Mn PET will be the positron range of the isotope, i.e. 0.63 mm [184]. 
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27 Small Animal PET with Online Recording of the 
Blood Radioactivity using a Blood Sampler 
As the final part of this PhD project, an experimental protocol for PET with online recording 
of the blood radioactivity level with a BS was established. The time course of the 
concentration of a PET tracer in the blood is required for full kinetic modeling, and the 
kinetic modeling, in turn, is very important for a detailed evaluation of pharmacokinetics of 
every novel tracer. Although the present work proposes 52Mn for tracing neuronal 
projections following a direct intracerebral administration, this isotope may be also used 
for labeling compounds which would be administered systemically. Therefore, the 
established experimental protocol may be potentially used for kinetic modeling of different 
PET tracers, including possible future 52Mn-labeled compounds. 
The advantages of using a BS, rather than manual blood sampling, in small experimental 
animals include: (1) limiting the loss of the blood volume which may affect physiological 
parameters in rats [202] and be potentially lethal for mice; (2) accurate measurement of 
the peak activity after a bolus injection [249] which may be missed during MS due to the 
lower sampling rate; and (3) maintaining the entire amount of the tracer being under 
investigation in the body. Moreover, the MR-compatibility of the device used in this study 
provides additional benefits, as it potentially enables simultaneous PET-MRI 
measurements. This type of studies allows an acquisition of complementary structural and 
functional information in a reduced time [250, 251]. Additionally, the exceptionally high 
sensitivity of the BS (23 %) may be possibly sufficient also for human studies. In this case, 
the translation of research from the preclinical to the clinical level could be facilitated. 
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In the present study, there was a good agreement of the wb TACs measured with the BS and 
the MS, especially in the beginning of the experiments. Consequently, the mean K1 and k2 
obtained with the BS-based approaches were very close to the reference values. However, 
the BS TACs were slightly overestimated in the second half of the recording. This was 
possibly due to an adhesion of the blood to the inner walls of the shunt tube and resulted in 
the underestimation of the mean k3. In order to solve the problem, one manually collected 
blood sample was combined with the first 10 min of the BS recording. This approach, 
together with the used fitting procedure and the dispersion correction, allowed a full 
recovery of the k3 value and can be used in future studies. Alternatively, a different type of 
tubing may be used to reduce the adhesion of the blood and of the tracer itself, which will 
be particularly relevant for more lipophilic compounds. One possibility could be a Teflon® 
tube which has been recently proposed [252]. 
The main limitation of the BS recording technique is the necessity of applying the 
population-based approach to calculate the p values from the wb data. In the present study, 
using the mean coefficients of the ௣
௪௕
 ratio, rather than the measured p samples, to obtain 
the AIF in the same group of animals resulted in the 8 % difference of the k3 from the 
reference. If this ௣
௪௕
 ratio is used in a separate group, potentially even higher deviations may 
be expected. Hence, the differences in the KPs lower than 10 % should be interpreted 
carefully.  
Finally, although the ID-AIF was not the main focus of the present work, this approach was 
also evaluated for comparison. The wb TACs obtained from the PET images largely 
overestimated the MS as well as the BS TACs, which resulted in the substantial 
underestimation of the k3. This was most probably due to the gradual accumulation of 
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[18F]FDG in the myocardium which resulted in the spillover effect in the left ventricle [253] 
and led to the substantial underestimation (above 48 %) of the k3. Therefore, if the AIF is 
derived from a PET image, it is critical to apply a correction for the spillover effect, but also 
for the partial volume effect [254, 255].  
 
 
 
  
CONCLUSIONS AND OUTLOOK 
  
C o n c l u s i o n s  &  O u t l o o k   | 195 
 
The present work demonstrates the feasibility of tracing neuronal pathways with 52Mn PET 
as an alternative method to MEMRI. The main advantage of 52Mn PET is the possibility to 
reduce the dose of the metal to the physiological level. This is important since doses of non-
radioactive Mn2+ commonly used in MEMRI experiments may have pharmacological or even 
toxic consequences.  
In fact, 50 nmol of Mn2+ administered into the rat striatum in Study 4 resulted in a reduced 
BPnd of [11C]flumazenil in the ipsilateral cortex, indicating that the contrast agent interacts 
with the GABAergic system. This effect is unacceptable if MEMRI shall be used for functional 
neuroimaging. Furthermore, although there was no effect of the intrastriatally injected Mn2+ 
on the BPnd of [11C]methylphenidate, suggesting no impact on the DAT, the 45 nmol dose 
administered into the VTA did induce a dopaminergic lesion. This was manifested as a 
reduced intensity in the TH-stained brain tissue sections.  
These data collectively indicate that Mn2+ interacts with the GABAergic as well as 
dopaminergic system, which is in agreement with the available literature. Since the 
neurotransmitter systems affected by Mn may influence each other, it will be important in 
future studies to investigate these interactions, and especially how they evolve in the course 
of Mn intoxication. The outcomes of such investigations should facilitate the development of 
treatment strategies for manganism.  
Contrary to the Mn2+ doses required for MEMRI, the doses of the metal used in 52Mn PET 
were not harmful. Even with the nano-molar concertation and despite a lower spatial 
resolution of PET, known neuronal projections could be identified in PET images following 
a direct intracerebral administration of the tracer. Moreover, the reduced transport of 52Mn 
after its co-injection with Mn2+ showed that both isotopes use the same transport 
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mechanisms. Although the activity-dependence of the neuronal transport could not be 
confirmed in this work, these measurements should be repeated, possibly with a different 
anesthetic.  
Additionally, the present results suggest that some physiological properties of different 
neuronal populations might be potentially observed with 52Mn, since the transport rate of 
the tracer appeared to depend on the specific sub-nucleus of the VTA into which the tracer 
was injected. Further studies, possibly utilizing electrophysiological recording or 
optogenetic methods, will be useful in untangling which specific mechanisms are 
responsible for the activity-dependent uptake and transport of 52Mn. 
Although defining the most suitable applications of 52Mn PET will require further research, 
including the mentioned investigations of the exact molecular mechanisms, the present 
findings already provide a ground for many future developments. Besides employing the 
technique in animal neurological and neuroscientific studies, 52Mn may become 
an interesting PET isotope potentially applicable in the fields of oncology or infectious 
diseases. Given its long half-life, 52Mn may be particularly suitable for long-term studies.  
However, the long half-life also implies that the exposure to the ionizing radiation will be 
prolonged compared to more traditional PET isotopes. Hence, although injecting 20-30 kBq 
of the tracer into the rat brain allowed avoiding the dopaminergic lesion, the effect on the 
motor control system, as well as inducing DNA breaks, monitoring of the possible 
consequences of the applied radioactivity doses will be very important. In addition, 
a possible impact of 52Mn on other cellular and molecular processes susceptible to 
irradiation should be assessed. 
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Finally, if 52Mn is used to label new PET tracers, the pharmacokinetics of these compounds 
in small animals may be examined using the experimental protocol established herein. 
Although the first measurement with a novel tracer always requires manual blood sampling 
for the collection of the plasma and evaluation of metabolites, subsequent studies may be 
based on the blood sampler recording, the estimated ௣
௪௕
 activity ratio, and the previously 
measured metabolite content. This approach ensures an accurate characterization of the 
peak activity and allows avoiding a blood loss which is critical in small animals. Thanks to 
the very high sensitivity, the blood sampler tested in the present work will be also suitable 
for studies with short-lived isotopes, such as 11C or 15O. 
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